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ABSTRACT 
The work presented in this thesis examines the 
in vitro characteristics, and the in vivo role of antigen-
triggered lymphokine release from activated T cells. 
Analysis of cell dose response curves revealed that 
release of two lymphokines, interleukin 2 (IL2) and 
interleukin 3 (IL3) can be triggered solely by antigen 
stimulation. Thus, either lymphokine can be used to study 
antigen exposure of the T cell. 
A closer examination of cell dose curves for 113 release 
revealed the cellular requirements for T cell stimulation 
by the 'polyclonal' T cell mitogens, concanavalin A (Con A) 
and Naro4 . These agents do not signal T cells following 
direct contact but must be 'presented' on the surface of 
another cell before the antigen-equivalent signal is 
triggered. 
A steady state binding model of T cell-target cell 
interaction was derived and could successfully describe the 
observed cell dose response curves for lymphokine release if 
the assumption was made that the reaction, triggering of 
lymphokine release, is an all or none event. 
An analysis of the site of action of cyclosporine (CsA) 
(viii) 
revealed a specific inhibitory a ction on transmission of the 
antigen signal. This drug was used in vivo to show the 
importance of lymphokine release in T cell-dependent 
reactions. 
The possible application of these results to the 
development of quantitative methods of assaying activated T 
lymphocytes as well as the more general implications of how 
the results might relate to the development of immune 
response heterogeneity are discussed in the final chapter. 
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CHAPTER 1 
THE CELLULAR BASIS OF IMMUNE REACTIONS 
. . 
1 . 1 
1.1 THE CENTRAL PROBLEM 
An important step in the scientific study of the immune 
system was taken by Pasteur in the late 19th century. As a 
consequence of his 'germ' theory of disease and the success 
of vaccination in preventing smallpox, it occurred to 
Pasteur that all 'germ'-related diseases could be prevented 
if attenuated 'germs' could be developed and used for 
immunisation (reported by Parish, 1965). 
In the subsequent hundred years the art of vaccination 
has given way to the science of immunology. In fact, 
prevention of disease through vaccination need never impinge 
on the work of a modern day immunologist who can find 
convenient experimental systems in a number of diverse 
fields which are not necessarily related to disease control . 
A great deal is now known about the components and 
characteristics of the immune response. However , Pasteur 's 
grand vision of protection against all infectious disease , 
has not been realised. One problem has been the 
difficulties associated with growing sufficient quantities 
of the organisms concerned, such as the causative agents of 
malaria and shistosomiasis . Future vaccines , therefore , 
depend on the development of alternative methods for 
preparing antigen suitable for i mm unization . Experience has 
already shown , however , that some antigen preparations can 
induce an immune response without providing significant 
protection against disease . One reason for this is that a 
response may proceed through a number of different pathways 
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which have diverse abilities in protection against certain 
diseases. This heterogeneity probably evolved to cope with 
infectious organisms which dis'play different modes of 
pathogenesis. The basic features of this heterogeneity and 
some of the implications both for vaccination and as a 
scientific problem for analysis will be discussed below . 
Adaptive immune responses (those that mount a faster 
and more effective response to secondary antigen challen g e) 
fall naturally into two cate gories : immunity which c a n be 
transferred with serum (humoral) and immunity which is 
transferred with cells (cell-mediated immunity, CMI) . 
Humoral immunity is a property of immunoglobulins , which in 
th e mouse , exist in eight different forms or isotypes, seven 
of which are secreted and play a role in mediating humoral 
protection. Each isotype has a different capacity to 
interact with immune cell types and serum components . CMI, 
ch aracterised by tissue graft rejection, virus clearance and 
delayed type hypersensitivity (DTH) reactions , is also 
het e ro genous ; the cells involved exist in at least two 
classes, each capable of at least two different effector 
functions. 
To prepare an effective vaccine to a given infectious 
agent requir es both a knowledge of the most effective immune 
response and the means by which that response can be 
induced. In many cases neither piece of informati on is 
available . Stimulating the appropriate immune respon se to 
prevent a given disease by immunization is the "central 
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problem" faced by vaccinators. A solution to this probl em 
could be achieved entirely through experience with different 
antigen preparations, or, it could be solved through the 
development of a theory which would define the 
characteristics of antigen/i mm une system/immunization-
protocol necessary to produce a nominated immune status. 
The viewpoint adopted in this thesis is that future 
empirical vaccine development will be inferior to that based 
on a theoretical construction. Furthermore, one likel y 
framework or paradigm within which a theoretical descript ion 
could be formulated is the 'cellular' approach adopted by 
biologists to describe the working of a multicell ul a r 
organism. Thus the work to be described he re bear s in no 
direct way on vaccination, but does explore one arm of the 
immune response in the theoretical ter ms defined by the 
cellular paradigm . 
In the next section some gene ral properties of cellular 
signalling will be described. Later sections will revie w 
some of the known features of the cells which con tri bu te to 
the observed hetero gene it y of the immune response . 
1.2 CELLS, SIG ALS A, D THE BIOLOGICAL RESPO SE 
A philosophy which under lies mos t current work in 
immunology is the 'c ellular paradigm' . It is by now 
unnecessary to point out that all animals are composed of 
individual units (cells) each carryin g a full complement of 
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genetic material and each one "programmed" through a series 
of differentiative steps to respond in a particular way to 
its environment. An important principle of this paradigm is 
that many of the signals that alter the behaviour of each 
cell are received from the cell surface through a receptor. 
Within any multicellular organism each cell can be 
defined in terms of this paradigm. The two basic 
components, receptor and programmed response, can be quite 
plastic: the same receptor does not necessarily trigger the 
same response in different cells, and quite different 
receptors on different cells may trigger a similar response. 
This simple yet powerful principle is a dominant force in 
attempts to explore and describe the workings of a 
multicellular organism. The success it will achieve is 
unknown. What is clear is that the methods of analysis it 
provokes are many years from being exhausted. Its 
application to the study of the immune system 
infancy. 
. . 
is in its 
Before treating in detail the cells engaged in the 
immune system, it is necessary to discuss some general 
characteristics of cell si g nalling via membrane receptors. 
The relationship between the molecule that binds to the 
receptor (ie . pharmacon, li gand, dru g ), the receptor itself 
and the resulting biological response is given by the 
following scheme . 
L + 
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Lis the ligand, R the receptor and Eis the biological 
effect. The rate constants K1 and K2 determine the strength 
with which Land R bind. K3 , called the 'intrinsic 
activity' by Ariens (1954) and the 'efficacy' by Stephenson 
(1956) relates the number of L-R complexes present on the 
cell surface to the strength of the biological effect. It 
is possible to proceed and prepare quantitative expressions 
for each term. The exercise however is not necessarily 
general and will vary for different systems. However, a 
qualitative observation is relevant. That is, that receptor 
binding alone does not necessarily lead to cell triggering. 
This has been amply demonstrated with competitive inhibitors 
of drugs. These agents bind with high affinity and yet do 
not signal any biological effect. Thus, the second 
reaction, defined by K3 , must always be considered when 
describing the triggering requirements of a cell. 
1.3 THE LYMPHOCYTE 
The cell type responsible for both immunoglobulin 
production and CMI is the lymphocyte. To apply the cellular 
paradigm to the generation of response heterogeneity 
requires a restatement of the nature-nurture debate which 
occurs in the study of human behaviour: 
How much of the heterogeneity is a function of separate 
"ground-state" lymphocytes (that is lymphocytes which 
have not been exposed to antigen) and how much depends 
on changes to the cellular program resulting from 
signals received during or after antigen trig ge ring? 
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One aspect of this question which can be adequately 
answered is how the lymphocyte can respond to so many 
different antigens - including molecules synthesized de nova 
in the laboratory. Is the information for such a diverse 
response coded in the germline (nature) or is it learned 
after antigen challenge (nuture) ? The answer in the case 
of immunoglobulin production has both a cellular and 
molecular component. 
The cellular basis was proposed as the clonal selection 
theory by Burnet (1957). This theory holds that each 
lymphocyte expresses and makes antibody of only one 
specificity. This cell is "stimulated" following antigen 
exposure and proliferates and differentiates into a pool of 
cells each secreting antibody identical to that which was 
expressed by the original cell. This enlarged cell pool 
ensures a greater response to subsequent challenge with the 
same antigen. The explanation of how lymphocytes achieve 
sufficient diversity to respond to so many antigenic 
determinants has been provided by analysis of immunoglobulin 
genes. 
The molecular genetics of antibody formation has been 
recently reviewed by Tonegawa (1983) and Honjo (1983). The 
immunoglobulin molecule is a peptide composed of two 
identical light chains and two identical heavy chains joined 
by disulphide bonds. The carboxy (C) terminal end of the 
light chain is relatively invariant within a species. The 
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C-terminal end of the heavy chain varies within a species 
along the lines of immunoglobulin class. That is, for 
example, all IgM molecules express the same C-terminal 
segment . The amino terminal portion of both light and heavy 
chains is highly variable. It is this variability that 
gives rise to the large number of available antibody 
specificities . Four mechanisms have been described which 
adequately explain the generation of diversity of the 
immunoglobulin variable (V) regions. 
The first mechanism occurs via recombination. The 
immunoglobulin gene in lymphocytes contains a number of 
genetic building blocks many of which exist in a number of 
copies. For example, a light chain gene, Kappa, is put 
together by joining one of 300 possible germ-line encoded VK 
genes with one of 4 germline JK genes. The heavy chain is 
constructed from 1 of 200 germline VH genes, 1 of 12 D gene s 
and 1 of 4 JH genes. The second mechanism of diversity 
occurs in the joining region between the building blocks. 
So called "junctional site" diversity occurs at the V1-J1, 
VH-D and D-JH junctions as the joining ends are imprecise. 
A third mechanism depends on the insertion of several 
nucleolides in the VH-D and D-JH junction. A high frequency 
of somatic mutation of bases throughout the variable region 
is the fourth mechanism for the generation of diversity. It 
is estimated by Honjo (1983) that 5 x 107 different variable 
regions could be created by the first three mechanisms 
alone . 
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1.4 LYMPHOCYTE GROUND STATES 
Different ground state lymphocytes are assumed to be 
cells which are programmed to respond in different ways to 
their first antigenic exposure. 
The first distinction which can be drawn is that 
between "T" and "B" lymphocytes. Miller (1961) and Martinez 
et al (1962) showed that removal of the thymus from neonates 
considerably weakened their ability as adults to reject skin 
grafts. Subsequent work demonstrated a role for thymus 
derived lymphocytes in other cell-mediated reactions such as 
DTH (Arnason et al, 1962) and recovery from virus infection 
(Blanden, 1971; Yap and Ada, 1978). It was shown by Davies 
et al, (1967) that thymus-dependent lymphocytes do not make 
antibody. A complementary experiment by Glick et al (1956) 
showed that removal of the avian Bursa of Fabricus from 
chickens within two weeks of birth severely compromised 
their ability to produce antibodies to_§_.=._ typhimurium. It 
was later found that bursectomized chickens were fully 
competent to effect CMI reactions (Aspinal et al 1963). 
Lymphocytes which mature in the thymus and mediate CMI 
reactions have been named "T" lymphocytes. Although mammals 
do not have a bursa, the lymphocytes which produce 
immunoglobulin are referred to as "B" lymphocytes. Their 
site of differentiation (which is presently unresolved) will 
be called the mammalian "bursa" equivalent. 
TABLE 1.1 
Biological activities of murine imrnunoglobulinsa 
Reaction IgM IgGl IgG2a IgG2b IgG3 IgA IgE 
Complement 
fixation + - + 
Cutaneous 
anaphylaxis -
- + + - - + 
Macrophage 
binding 
- + 
Placental 
transfer 
- + + + + 
a Adapted from Spiegelberg (1978) Adv. Irnrnunol. 19: 259-294 
' 
1 . 9 
Thus, CMI-inducing and immunoglobulin-secreting 
lymphocytes are physically distinct cell types with 
different "cell programs" laid down prior to antigen 
exposure as a result of differentiation in separate 
anatomical sites. The B cell antigen receptor is 
immunoglobulin. At least one component of the T cell 
receptor is an immunoglobulin-like heterodimer composed of 
an~ and~ chain. 
constant regions. 
Both chains exhibit variable and 
The basic properties described previously 
for the generation of immunoglobulin diversity, such as 
clonal selection and gene rearrangement (Section 1.3) also 
apply to the T cell receptor (reviewed by Hood et al, 1985). 
1.5 LYMPHOCYTE FUNCTION 
The effector function of B lymphocytes is mediated by 
secreted immunoglobulins. The seven secreted 
murine immunoglobulin isotypes important in immunity are 
listed in Table 1.1 along with their functional 
characteristics. As different immunoglobulin isotypes have 
different functional capacities the ability to generate a 
given isotype is clearly important. This isotype variation is 
not a ground-state property of B cells (reviewed by Cebra et 
al, 1984). Treatment of mice from birth with anti-µ ( the IgM 
heavy chain antigenic determinant) prevented the appearance 
of not only IgM but all Ig isotypes (Manning and Jutila, 
1972). This occurs despite the observation that B cells 
usually only express one surface isotype. This experiment 
suggested that B cells must first express IgM before making 
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IgG, IgE or IgA. The molecular biology of this B cell 
isotype switching has been described by Shimizu et al, 1982, 
but the antigenic and cellular requirements which lead to 
the switch are poorly understood. T lymphocyte involvement 
is important for the initation of secretion of particular 
isotypes from B cells, ie. IgG 1 (Taylor and Wortis, 1968; 
Torrigiani, 1972), IgE (Harnaoka et al, 1973; Ishizaka and 
Okudaira, 1973) and IgA (Torrigiani, 1972; Cebra et al, 
1976) . 
The irnmunoglobulin isotype produced following antigen 
exposure is not predetermined but is influenced by a number 
of parameters. The first described is the effect of 
reimmunization, which for many antigens induces a switch 
from IgM production to IgG. The presentation of antigen 
associated with a particular adjuvant can also affect the 
developing isotype response. The clearest example of this 
phenomenon is the ability of alum precipit.ated antigen to 
induce an IgE response (Revoltella and Ovary, 1969). The 
physical characteristics of the antigen itself can play a 
role, for example potent B cell mitogens when injected into 
mice induce quite different patterns of immunoglobulin 
isotype production (McKearn et al, 1982). Another important 
variable is the route of administration. Rats primed to 
cholera toxoid by an intraperitoneal (i.p.) injection of 
antigen produce very few cells which release IgA if 
rechallenged i.p., however large numbers of IgA secreting 
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cells are detected if the second anti g en dose is gi v en 
intragastrically (Pierce and Gowans, 1975). 
Possible mechanisms by which T lymphocytes initiate CMI 
reactions were discovered following the development of in 
vitro techniques for culturing lymphocytes. Bloom and 
Bennett (1966) described the release from sensitized 
lymphocytes of a molecule which inhibited the in vitro 
migration of macrophages. Other factors were described such 
as mitogenic factor, which triggered lymphocyte 
proliferation (Gordon and MacLean, 1965) and chemot ac t ic 
factors which directed the in vitro move ment o f c ells such 
as eosinophils (Cohen and Ward, 1971), macr ophag e s (Ward, 
Renold and David, 1970) and basophils ( Kay a nd Austen , 
1972). The obvious parallels that the s e in vitro activities 
have with the cellular infiltratio n whi c h characterises the 
DTH reaction, implied that th i s re a ction occurred in 
response to the release o f these f acto r s. Injection of 
cell-free supernatants cont ai n ing l ym phocyte - derived facto rs 
produced a t y p i c al DTH lesion (Bennett and Bloom , 1 968 ) . 
The g eneric t e r m " lymphokine" was coined by Dumonde et al , 
(19 6 9 ) t o inc lude all immunologically active l ym phoc y te -
derived facto r s other than i mmunoglobulin . 
Anot he r T cell function , cell mediated cytotoxicity , 
was f ir s t des cr ibed by Bru nne r e t al , (1970) . Lymphocytes 
from the s pleen, lymph nodes and b lood f r om a n an i mal 
inoculated with a f orei g n tu mour, were f ound t o s pecifically 
lyse homologous tu mour cells in vitro. Cell- me d iat ed 
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cytotoxicity is also active against virus-infected cells 
(Blanden et al, 1976) and cells carrying foreign minor 
hist o comp at i bi 1 it y antigens (section 1. 6) (Bevan, 19 7 6 a) • 
The parameters which affect immunoglobulin isotype 
production described above for B cells, probably also affect 
T cell heterogeneity. Two examples are the immunization 
protocol for inducing DTH reactions and the infectious 
status of an immunising virus. Guinea pigs innoculated 
intradermally with vaccinia virus in saline develop on 
rechallenge, a DTH reaction where the predominant 
infiltrating cell type is the basophil. By contrast animals 
sensitized with the same dose of virus in complete Freunds 
adjuvant develop 'true' DTH, characterised histologically by 
the presence of numerous mononuclear cells and only rare 
basophils (Dvorak and Hirsch, 1971). The distinction in 
cell infiltrate probably reflects the elaboration of 
different lymphokines by the antigen-reactive lymphocytes. 
The second example is the greater effectiveness of live 
virus vaccines over killed virus preparations in providing 
protection against natural virus infection. A more detailed 
discussion of this phenomenon is included in section 1.8. 
1.6 GRAFT REJECTION AND THE MAJOR HISTOCOMPATABILITY COMPLEX 
Studies by Gorer et al, (1948) and Snell (1948) 
recognised that the fate of tumour grafts between non-
identical mouse strains was controlled by at least 7 and 
possibly 14 genetic loci. These genes controlling 
1 . 1 3 
histocompatibility were designated "H" and numbered serially 
(Snell, 1948). Tissue rejection across the genetic 
disparity, "H-2" was particularly rapid. Thus the rnurine H-
2 became known as the major histocompatibility complex 
( MHC) • All other "H" loci were collectively referred to as 
minor or non-H-2 histocompatibility genes. 
Today the protein products and organization of the MHC 
gene region are well described (Reviewed by Hood et al, 
1983; Klein, et al, 1983). Three subregions of the MHC, K, 
D and I code for glycoproteins expressed at the cell 
surface. The Kand D region products display a marked 
homology in both sequence and structure. Each molecule 
consists of a single polypeptide chain of molecular weight 
45 000 daltons non-covalently associated on the cell surface 
with a small polypeptide called {3 -2-microglobulin ( 12 000 
daltons). Cell surface molecules with these basic features 
were termed "class l" MHC antigens by Klein (1979). 
Two cell surface molecules have been identified as 
being coded for in the MHC I region. Both products are 
similar in structure and sequence and are known as class 2 
MHC antigens (Klein, 1979). These molecules consist of 2 
non-covalently linked chains called a and {3. The a chains 
range in molecular weight from 30 000 to 33 000 daltons. 
The{3chain has a molecular weight of 28 000 daltons. 
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Class 1 and class 2 MHC products exist in many 
different allelic forms. The allelic composition of the MHC 
is termed the MHC haplotype and is designated by an 
alphabetical superscript, eg the DBA mouse strain is called 
H-2d (made up of Kd, Dd and Id). Recombinant mouse strains 
are available with haplotypes containing H-2 alleles from 
different strains. 
Class 1 and class 2 MHC products display a different 
pattern of expression in tissues. In general, class 1 
antigens can be found on all mammalian cells whereas the 
class 2 antigens are much more restricted, being present on 
B lymphocytes and other lymphopoietic cell types such as 
macrophages, dendritic cells (Steinman and Witner, 1978) 
and T cells (Hammerling, 1976). Class 2 antigens are also 
expressed at the cell surface of a number of cell types 
during an immune reaction (Mason et al, 1981). 
One clue as to why the MH C products are particularly 
strong transplantation antigens was provided by the 
discovery of the mixed lymphocyte reaction (MLR). 
Incubating lymphoid cells from two strains with a disparity 
at the MHC, in in vitro culture results in a rapid 
proliferative response (Bain et al, 1964). It was estimated 
by Simonsen (1967) and Wilson, et al (1968) that 1-3% of all 
T lymphocytes are reactive to cells bearing foreign MHC 
antigens . No generally agreed explanation for this 
remarkable preoccupation of T lymphocytes with foreign MHC 
has yet been supplied, although a number of competing 
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theories based on the discovery of MHC restriction (next 
section) have been proposed. The high frequency of reactive 
cells does explain why these antigens are particularly 
important in triggering tissue graft rejection. 
1.7 T CELL RESTRICTION 
Although the H-2 loci were defined for their role in 
tissue graft rejection, subsequent studies have revealed a 
much broader influence of the MHC on T cell function. Two 
examples to be discussed below are MHC restriction of T cell 
killing and the control of the immune response to simple 
antigens. 
T lymphocytes whch were cytotoxic for lymphocytic 
choriomeningitis virus - infected cells were found to kill 
only infected cells which shared the MHC region with the 
reacting lymphocytes (Zinkernagel and Doherty, 1974). This 
MHC "restriction" of effector function has been shown for 
many other viruses (reviewed by Zinkernagel and Doherty, 
1979) as well as for cytotoxic cells which recognise minor 
histocompatibility antigens (Bevan, 1976b) and chemically 
altered target cells (Shearer, 1974). Other studies found 
that the amount of antibody produced by different mouse 
strains following priming with simple antigens such as poly-
L-lysine and T(GAL) was controlled by the H-2 gene complex 
(McDevitt and Chinitz, 1969). Later mapping studies 
isolated this "immune response" (Ir) locus to the I region 
of the H-2 (McDevitt et al, 1972). 
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The currently accepted view of MHC-dependent immune 
phenomena is that they all occur as a result of the 
requirement for T cells to be restricted by one or other 
cell surface expressed MHC product (Blanden et al, 1975; 
Klein et al, 1981). This theory maintains that MHC gene 
products serve to guide T lymphocytes in distinguishing 
between self and non-self. The Ir - gene control of 
antibody levels is explained by the role of I region (or 
class 2) restricted T cells in helping B lymphocytes produce 
antibody. Evidence for this assertion is the observation 
that T cell proliferation in vitro to a given antigen 
correlates well with the level of antibody formed in vivo 
(Klein and Nagy, 1982). 
It is not yet determined how the T cell antigen 
receptor detects MHC and antigen, nor is it clear how T 
cells become "restricted"; whether by a learning process in 
the thymus (ie. pre-antigen as suggested by Zinkernagel 
(1978) )or as a result of the T cell's particular activation 
require ments (i.e. during antigen stimulation as suggested 
by Lafferty et al, 1983). It is clear however, that MHC 
restriction limits T cell function to cell-associated 
antigen. 
Matzinger and Bevan (1977) have shown how MHC 
restriction provides an explanation for the high proportion 
of T cells reactive to foreign MHC-bearing cells. Their 
hypothesis holds that T cells recognize an 'interaction' 
antigen, formed by the close association of MHC and a cell 
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surface antigen. T cells reactive to self antigen-self MHC 
association are assumed to be in some way unresponsive. 
Incorporation of a foreign MHC molecule in to the cell 
membrane will allow interaction antigens to form with each 
'self' cell surface component, which, by the rule of MHC 
restriction, will no longer resemble self and be potentially 
antigenic . As the number of non-MHC products on a cell 
surface is likely to be large, many new antigens will be 
generated . In contrast, incorporation of a single non-MHC 
antigen into the cell surface will create a smaller number 
of interaction antigens. This number will be related to the 
number of new antigens created by a foreign MHC product by a 
factor proportional to the number of different cell surface 
molecules. 
1.8 T CELL ACTIVATION 
Implicit in this discussion so far has been the 
assumption that T lymphocytes exist in at least two states: 
a " resting" form which will not contribute to an immune 
response , and an "active" form. It is the active form of 
the T cell which is cytotoxic and releases lymphokines. 
Clearly T cell "activation" is a necessary step before any 
CMI reaction can be generated. 
Most information on T cell activation has come from 
studies in vitro using either alloantigenic cells to trigger 
an MLR or T cell mitogens (section 1.9) to stimulate large 
numbers of lymphocytes. Early studies showed that treating 
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lymphoid cells with ultraviolet (UV) radiation or heating 
the cells to 45° for 60 minutes destroyed the cells' 
ability to initiate a MLR, without affecting the levels of 
serologically detectable MHC antigens (Lindahl-Keissling and 
Safwenburg 1972; Lafferty et al, 1974; Schendel and Bach 
1975). These studies indicated that antigen alone was an 
insufficient stimulus to drive the proliferative and 
differentiative reaction which occur in an MLR. Further 
studies have shown that antigenic cell viability is not the 
sole requirement, as stimulating ability is restricted to 
only a few cell types, all of which are haemopoeitic in 
origin, and most of which carry class 2 MHC antigens 
(Sunshine et al, 1982; Minami et al, 1980). The correlation 
between stimulation ability and class 2 antigen expression 
is interesting although not absolute. A number of tumour 
cells will stimulate and are class 2 MHC negative (Lafferty 
et al, 1980) while B cell lymphomas express class 2 antigens 
and are unable to stimulate an MLR (Glirncher et al, 1982). 
Cells capable of triggering a primary MLR were designated s+ 
(for positive stimulation) by Lafferty and Cunningham 
(1975). s- cells can induce a positive reaction if the 
cultures are supplemented with cell-free supernatants from 
mitogen stimulated T lymphocytes (Talmage et al, 1977). 
These supernatants without antigen will not stimulate T cell 
activation. This result suggests thats+ cells produce a 
factor ·which 'costimulates' the T cell response to antigen. 
One such costimulating factor, interleukin 1 (IL 1) is 
released by lipopolysaccharide (LPS) or activated T cell-
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triggered macrophages and macrophage-derived tumour cell 
lines (Mizel et al, 1978; Farrar et al, 1980). 
The concept that a special cell type is required to 
activate T cells suggested that these stimulator cells in 
tissue grafts represent the major barrier to successful 
transplantation. Lafferty et al, (1975), and Bowen et al, 
(1980) found that long-term culture of thyroid or pancreatic 
islet tissues in 95% o2 and 5% CO 2 indefinitely prolonged 
survival of this tissue in allogenic hosts. If engrafted 
animals received an injection of donor-type spleen cells 
rapid rejection followed (Lafferty et al, 1980). The 
explanation proposed by Lafferty et al (1981) is that 
cultured tissue is free of s+ cells and therefore 
stimulation of host graft-specific T cells cannot occur 
(antigen presented on hosts+ cells would trigger a host-MHC 
restricted response which would not be graft specific). 
Further evidence implicating s+ cells in this 
phenomenon has been provided by Faustman et al, (1981) who 
treated uncultured islets with anti-class 2 MHC antibody and 
complement and achieved a significant increase in g raft 
survival. 
The mode of antigen presentation plays a role in 
activation of different classes of T cell. A study by Ertl 
(1981) examined the properties of viruses which were 
important in generating class 1 or class 2 - MHC restricted 
T cell responses. T cells primed in vivo with infectious 
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sendai virus were restimulated for 5 days in vitro with 
different preparations of virus and different antigen 
presenting cell types. The resulting cells were tested for 
their ability to induce DTH. Class 1 - MHC restricted DTH 
occurred only if the virus preparation was infectious or 
could fuse with the cell membrane. Class 2 restricted DTH -
inducing T cells were only stimulated by macrophages from 
the spleen or peritoneal cavity. In this case virus 
infectivity was not required. The general conclusion to be 
drawn from this work is that class 1 restricted T cells are 
only triggered by antigen which can incorporate as part of 
the cell membrane. Conversely, antigen which cannot be 
incorporated into the cell membrane must be 'processed' by a 
specialized cell type (see section 1.11). This mechanism 
leads to class 2 - MHC restricted T cell responses. The 
reason for this division, in cellular or molecular terms, 
is unknown. 
Studies by Leung and Ada (1981) have shown that class 1 
restricted T cells are much more effective in clearing 
influenza virus from infected mouse lung than are class 2 
restricted T cells. In fact these latter cells contribute 
to the observed lung pathology. Clearly in considering 
anti-viral vaccines it would be advantageous to understand 
the mechanism by which a class 1 - MHC restricted response 
can be generated to the exclusion of a class 2 restricted 
response . 
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1.9 T CELL ACTIVATION: MITOGENS 
Nowell (1960) first showed that plant lectins 
(multivalent sugar-binding glycoproteins), could initiate 
lymphocyte proliferation. This "mitogenic" response could 
be either T lymphocyte or B lymphocyte specific depending on 
the lectin used (Jannossy and Greaves, 1971). This ability 
of plant lectins to distinguish between T and B lymphocytes 
suggests that the triggering mechanism used by the two cell 
types are different. A number of mitogenic lectins have now 
been described. The differences between rnitogenic lectins 
and non-mitogenic lectins is assumed to reflect the binding 
of different cell surface glycoproteins (Dillner-Centerlind 
et al, 1980). 
In 1971 Novogrodsky and Katchalski reported that mild 
oxidation of lymphocytes with NaI04 induces extensive 
proliferation of T lymphocytes. A major cell surface change 
caused by this agent is the conversion of sialic acid to an 
aldehyde (Van Lentan and Ashwell, 1971). These aldehydes 
were implicated in the triggering process following the 
demonstration that the aldehyde blocking agents KBH 4 and 
NH20H markedly reduced the response (Novogrodsky and 
Katchalski, 1972; Zatz et al, 1972). Sequential treatment 
of lymphocytes with neuraminadase and galactose oxidase, 
which also generates aldehyde moieties is also rnitogenic 
(Novogrodsky and Katachalski, 1973). 
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T cell activation by lectins was found to require the 
participation of class 2 MHC bearing accessory cells (Habu 
and Raff, 1977 ; Ahmann et al, 1978). Thus "mitogenic" 
lectins are not directly mitogenic for lymphocytes. 
Larsson and Coutinho (1980) showed that accessory cell 
requirement could be replaced by cell-free supernatants from 
lectin stimulated spleen cells. Similarly NaI04 stimulation 
was found to require "accessory cells" which can be replaced 
with soluble factors (Greineder and Rosenthal, 1975). 
These experiments showed that mitogen stimulation 
displayed requirements identical to those found for 
alloantigen stimulation. Apparently a number of steps are 
involved in T lymphocyte activation. Curiously, stimuli as 
diverse as lectins, cell oxidation and cells carrying 
foreign MHC fulfill these requirements for a large 
percentage of T lymphocytes. 
1.10 PROPERTIES OF ACTIVATED T CELLS 
Once activated by antigen or mitogen, T cells express 
receptors for a lymphokine which triggers growth of these 
cells. This lymphokine, T cell growth factor (TCGF), has 
been used to maintain activated T cells in culture 
indefinitely and to clone T cells of a particular 
specificity (Shreier et al, 1980; Nabholz et al, 1978; 
Gillis and Smith, 1977). TCGF was given the "neutral" term 
interleukin 2 (Aarden et al, 1979) (IL2) when it was found 
to possess other biological activities such as the ability 
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to influence B cell differentiation (Watson et al, 1979) as 
well as costimulating the response of thymocytes to mitogens 
(Mills et al, 1976). Another method found for 
immortalising a T cell is to fuse activated T cells with a 
tumour cell. The resulting hybridomas grow independently of 
IL2, yet display a number of T cell functions, such as 
lymphokine release (Kappler et al, 1981). The requirements 
for triggering lymphokine release from IL2-dependent T cells 
or T cell hybridomas are much simpler than those found for T 
cell activation. Alloreactive T cells are triggered by any 
cell bearing the appropriate antigen, including cells 
rendered metabolically inactive by UV irradiation (Andrus 
and Lafferty, 1981). Also, cloned T cells can be triggered 
to lymphokine production by T cell mitogens, in the absence 
of the accessory cells found to be obligatory for activation 
by these agents (Ely et al, 1981). 
The number of different lymphokines which can be 
released by T cells is unknown. Waksman (1979) documented 
100 different activities characterized by an assay and an 
acronym. This number is probably an order of magnitude too 
high as many different assays have been found to measure the 
same activity. For example, macrophage activation factor 
(MAF), which increases the ability of macrophages to kill 
tumour cells, and Y -interferon ( r -IFN), which inhibits 
virus replication, are probably the same lymphokine (Pace et 
al, 1983). Also, interleukin-3 (IL3), originally defined by 
its ability to induce an enzyme 20 a hydroxysteroid 
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dehydrogenase in spleen cells of nude mice (Ihle, et al, 
1981) was found to be an active growth factor for mast cells 
as well as causing growth of bone-marrow cells in agar (Ihle 
et al, 1983). 
Potentially, lymphokine producing and cytotoxic T cells 
could reflect separate ground states or mutually exclusive 
cell programs. However, both possibilities are ruled out by 
the demonstration that T cell clones can exhibit both 
functions (Kelso and Glasebrook, 1984; Morris et al, 1982; 
Dennert et al, 1981). 
Cytotoxicity is generally associated with class 1 MHC 
restricted cells, although sufficient numbers of cytotoxic 
class 2 restricted cells have been described to prevent a 
generalization (Wagner et al 1975; 
et al, 1983; Kaplan et al, 1984). 
Klein et al, 1977; Spits 
One non-functional 
phenotypic characteristic, which does appear to be 
"absolute" is that class 1 MHC restricted T cells express 
the lyt 2 marker - defined initially by Cantor and Boyse 
(1975) as a marker for the cytotoxic function. Recently a 
mur1ne marker for class 2 restricted T cells, called L3T4, 
has been described (Dialynas et al, 1983). 
A number of authors have examined T cell clones for 
their lymphokine release and cytotoxic potential. Kelso et 
al, (1982) found from a study of 72 individual clones, 
reactive to either Moloney leukaemia virus, minor 
histocompatability antigens or MHC antigens, that MAF was 
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released by 68 clones and that release of this activity did 
not correlate with their cytolytic activity or with 
production of other lymphokines such as IL2 or a colony 
stimulating factor (CSF) for granulocyte-macrophages (GM-
CSF) . Most IL2 releasing cells were found to be non-
cytolytic but there were exceptions. All lymphokines 
a c hieved a maximum activity within 24 hours of antigen 
stimulation. In a later report Kelso and MacDonald (1982) 
looked at the precursor frequency of cytolytic and 
lymphokine releasing cells. As a starting point these 
authors used a MLR with limiting numbers of responder cells 
selected on the basis of lyt 2+ or lyt2- phenotype and 
incubated for 7-9 days. The resulting clones were split and 
restimulated for lymphokine production and tested for 
cytotoxicity. All cytotoxic cells were found to be derived 
from lyt2+ precursors. This result may be meaningless as 
the target cell used, P815, carries only class 1 MHC 
antigen , and therefore would not be recognized by the class 
2 reactive (Lyt2- population). Precursors of cells 
secreting MAF and GM-CSF were present in both lyt2+ and 2-
populations. IL2 release was found predominantly in the 
lyt2- non-cytotoxic population. A similar study using the 
mitogenic lectin conconavalin A (Con A) to provide the 
primary stimulus reached similar conclusions; ie. T cells 
are heterogenous in their ability to secrete a variety of 
lymphokines irrespective of their lyt phenotype (Guerne et 
al, 1984) . In this work 50% of lyt 2+ clones produced IL2 -
a much higher percentage than that reported by Kelso and 
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MacDonald, ( 1982). A further characteristic of lyrnphokine 
release revealed from analysis of clones is that the range 
and amount of lymphokine produced per clone is constant 
(Kelso and Glasebrook, 1984). An exception to this rule is 
IL2 release which was see·n to decrease with time in an 
unpredictable manner. 
These studies highlight the potential heterogeneity of 
T cell effector function. There appears to be little 
correlation between the "repertoire" of lymphokines a T cell 
clone will produce, the cytotoxic capacity of the cell and 
the cell surface phenotype and MHC restriction class. 
1.11 ANTIGEN PRESENTING CELLS , 
CELLS. 
STIMULATING CELLS, ACCESSORY 
The need for "costirnulation" of a primary T cell 
response and the MHC restriction of T cells gives rise to a 
requirement for accessory cells in culture. These cells 
could be defined as non-responding cells which must be 
included with T cells before a response can be generated. 
From the discussion in the previous sections of this chapter 
some features of this accessory cell requirement can be 
deduced. 
For a MHC-restricted T cell to respond to a soluble 
protein then that protein must be "presented" on the surface 
of a cell bearing the appropriate MHC antigen. Studies by 
Ziegler and Unanue (1981) have shown that this presentation 
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is the function of macrophages and requires an active 
internal processing step which is inhibited by chloroquine. 
Glimcher et al, (1982) have reported that B cell 
tumours can process soluble antigen for recognition by T 
cells but cannot stimulate a primary response to 
alloantigen. Thus "processing" cells can be divided into 
two classes, those that ares+ and could therefore stimulate 
a primary response to soluble or processed antigens, and 
those that ares-. s- antigen presenting cells would be 
capable of triggering lymphokine release from an activated T 
cell. 
If the antigen is not soluble and is present as a cell-
surface component (as follows infection with virus) then any 
cell expressing the antigen plus MHC could presumably 
present the antigen. That is, in this case there is no 
requirement for a specialized antigen processing function. 
Presumably this class of antigen must be present on the 
surface of ans+ cell to activate reactive T cells. 
categories of accessory cell, stimulating and non-
These 
stimulating, processing and non-processing, are often 
confused in the literature and require a more formal 
universal nomenclature. 
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1.12 CONCLUSIONS 
The intention of this introduction was to review 
briefly the cellular foundation for the heterogenous nature 
of the immune response. This heterogeneity is a function of 
different lymphocyte classes which have the potential for 
alternative effector programs. B lymphocytes may secrete 
any one of seven immunoglobulins, whereas T lymphocytes 
secrete a range of lymphokines selected from a large set of 
possible activities. T lymphocytes may also kill antigen 
bearing target cells. The features which control this 
diversity in cell function are poorly understood, however, 
parameters such as route of administration, dose, and 
frequency of antigen exposure all appear to play some role. 
The ability of these external factors to influence the class 
of an immune reaction imply that a reaction is not 
predetermined or preprogrammed to respond in a particular 
way to a given antigen determinant. Rather these 
observations suggest a general view that the ground state 
lymphocyte program and those programs which unfold during 
the immune response are patterned to fit not the antigen, 
but the nature of the antigen, its mode of presentation and 
the site of exposure. The conclusion is inescapable that, 
under normal circumstances, a response appears to fit the 
antigen challenge. For example, the lymphocyte generated 
during live virus (but not killed virus) infection, is 
cytotoxic, a response which appears "appropriate" to cope 
with a virus infection. It seems likely that similar 
'appropriate' responses have evolved to counter other 
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antigen classes. To avoid arguing from final causes this 
concept can be rephrased into the more practical formulation 
of the vaccinator: what are the properties of each 'antigen 
class' which are perceived by lymphocytes and which 
ultimately influence the generation of different immune 
reactions? 
The cellular paradigm can identify three broad 
mechanisms which would allow the lymphocyte to detect 
different antigen classes: 
1 Lymphocytes could exist which have different antigenic 
triggering requirements. This parameter is difficult 
to quantitate, but relates to the efficacy of ligand-
receptor interaction described in section 1.2. The 
number of possible mechanisms and the vagueness of the 
concept when applied to lymphocytes (for instance the 
term "cross-linking" is used by immunologists to 
describe a triggering requirement) suggests that the 
pharmacological term "efficacy" in general use for 
drugs is inadequate for the use of immunologists. An 
early now abandoned term "intrinsic activity" coined by 
Ariens (1954) could be used in this context. 
2 Lymphocytes could be influenced by extra 'hormonal' 
signals received during antigen stimulation. This 
mechanism has been shown to be important for the 
activation of T cells. It could also carry information 
regarding the site of antigen exposure. For instance 
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the s+ cell found in the skin, the langerhans cell, 
could "costimulate" a T cell in a different manner than 
others+ cells. This information could potentially 
then be expressed as a separate lymphokine repertoire 
in the activated T cell. 
3 Lymphocytes could receive differentiative signals 
through cell surface molecules following contact with 
other cells. A documented case is the "cognate" signal 
received by B cells via their cell surface class 2 
antigens following interaction with a class 2-
restricted T cell (Howard and Paul, 1983). Clearly, 
this mechanism could transfer extra information to the 
B cell (ie. that a class 2-restricted T cell response 
can be mounted against the antigen which the B cell 
recognizes). 
These parameters represent the "solution" to the 
central problem outlined in section 1.1, in the sense that 
they could be shuffled into m algorithm for each class of 
immune response. It is important to recognize that this 
solution relies upon a philosophy, the cellular paradigm, 
which may or may not be appropriate for this problem. 
However, as mentioned previously, the success this method 
will achieve is unknown, while the experimentation it 
suggests is many years from being exhausted. 
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1 . 13 AIMS AND OUTLI NE OF THIS TH ESIS 
One problem which arises when studyin g the T l ympho c y te 
antigen signal is the complex behaviour of conventional in 
vitro assay systems such as the MLR and mito g en sti mula tion. 
These systems do depend on lymphocyte signalling, however, 
other reactions involving cell interaction and rele a s e o f 
soluble factors are also required . In this thesis we h ave 
attempted to ' isolate' the T cell antigen signal by 
measuring the induction of lymphokine release from acti va t e d 
T cell . 
Chapter 3 establ i s h es conditions wh e r e b y lymphok i ne 
release can be assumed to be dependent so l el y on antigen 
signalling . This chapter provides evi d ence t ha t r elease of 
IL2 and IL3 are un d er id entical contr ol and therefore either 
lymphokine coul d b e used to dete ct an t igen signalling . IL3 
is more generall y useful as t h e assay is more sensitive and 
not subject to an i nhibi tor whic h c an comple t ely mask the 
presence of IL2. 
Chapter 4 expl o r es t he effect of an immunosuppressive 
drug , cyclosporine (CsA) , on the activity of activated T 
cells . This stud y i s ol a t e s th e dr u g's inhibitory action to 
a site after anti g e n b ind in g an d before mobilization of 
lymphokine-incodin g g enes - a si te o perationally defined as 
the T cell anti g en si gnal . The speci f ic site of action 
suggests CsA can be used to exa mine t h e r o l e of t he T cell 
antigen si g nal and l ym phokine release both in vi tr o and in 
vivo . This potenti a l is exploited in Ch a pt e r 5 , whe r e the 
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release function of activated T cells is found to be 
important for a number of lyt 2+ cell dependent immune 
reactions. 
Chapters 6 and 7 use the technique of dose response 
curve analysis to define the cellular requirements for 
signalling by antigenic cells and by T cell mitogens. These 
cellular requirements are complex and suggest; 1) that 
mitogens do not trigger the antigen signal by a direct 
action on the T cell; and 2) that the T cell antigen signal 
is an all or none event. 
In the final chapter these findings are discussed for 
their relevance to the development of assays for activated T 
cells, and to the implications for the development of T cell 
response heterogeneity. 
CHAPTER 2 
MATERIALS AND METHODS 
2. 1 
2. 1 ANIMALS 
The inbred mouse strains listed in Table 2.1, and a 
Canberra outbred strain were maintained in the Animal 
Breeding Establishment of the John Curtin School of Medical 
Research. Donors of lymph node and spleen cells were used 
between 6 and 14 weeks of age. 
2.2 TISSUE CULTURE MEDIA AND BUFFER SOLUTIONS 
Eagle's Minimal Essential Medium (EMEM) was prepared by 
dissolving 10 g of medium powder (GIBCO, 410-1500) in 1 
litre of double distilled deionized water containing 2.2 g 
of sodium bicarbonate. 
Dulbecco's Modified Eagle's Medium (DMEM) was prepared 
by dissolving 10 g of medium powder (GIBCO, 430-1600) in 1 
litre of double distilled deionized water containing 3.7 g 
of sodium bicarbonate. 
RPMI 1640 (RPMI) was prepared by dissolving 10.4 g of 
medium powder (GIBCO) in 1 litre of double distilled 
deionized water containing 0.02% w/v sodium bicarbonate. 
Hanks Balanced Salt Solution (HBSS) was prepared 
according to the procedure described by Hanks and Wallace 
(1949) and buffered with sodium bicarbonate at 0.013 g per 
100 ml. 
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EMEM, DMEM and RPMI were supplemented with antibiotics 
(penicillin, 100 u/ml. streptomycin, 100 µg/ml, neomycin, 
100 µg/ml) and sterilised by filtration through a 0.22 µm 
membrane (Millipore Corporation). HBSS was sterilized by 
autoclaving and antibiotics were added immediately before 
use. 2-mercaptoethanol (2-ME; KODAK) was stored at -2ooc 
as a 0.1M solution in water. This stock was diluted 1/1000 
to yield a final concentration in media of 10- 4 M. 
Heat inactivated foetal calf serum (HIFCS) was prepared 
by incubating selected serum batches (Flow Laboratories, 
Stanmore, Australia, and Commonwealth Serum Laboratories, 
Melbourne, Australia) at 560C for 30 mins. 
Phosphate Buffered Saline (PBS) was prepared according 
to the following formula: sodium chloride, 8.0 g; potassium 
chloride, 0.4 g; disodium hydrogen phosphate, 1 .2 g; sodium 
dihydrogen phosphate, 0.39 g; double distilled deionized 
water, 1 litre. 
Citrate buffer, pH 5.0 was prepared by mixing 205 ml 
0.1M citric acid with 295 ml 0.1M sodium citrate and adding 
500 ml distilled water. 
Glycine buffer, pH 10.4 was prepared by mixing 250 ml 
0.2M glycine with 193 ml 0.2M NaOH and adding 557 ml 
distilled water. 
2.3 DETERMINATION OF CELL VIABILITY BY TRYPAN BLUE 
EXCLUSION 
2.3 
To determine viable cell numbers in preparations of 
normal or transformed cells, 0.1 ml of cell suspension was 
mixed with a known volume of a 0.5% w/v solution of Trypan 
Blue in PBS. An aliquot was then counted using a 
haemocytometer. 
2.4 TRANSFORMED CELL LINES 
Six tumour cell lines were used in this study. The 
strain of origin and characteristics of each, as well as the 
standard culture medium used in their maintenance, are given 
in Table 2.2. 5 x 10 4 viable cells were subcultured every 
3-4 days into 25 cm2 tissue culture flasks (Falcon, 3013 or 
Corning, 25100) containing 5 ml of culture medium . The 
flasks were then incubated at 370c in a humidified 
atmosphere of 10% co 2 in air. 
2.5 PREPARATION OF LYMPHOID CELL POPULATIONS 
Mouse spleen and lymph node cell suspensions were 
prepared by removing the organs aseptically, trimming away 
excess fat, and pressing them through a fine stainless steel 
grid into HBSS. The resultant cell suspension was 
transferred to a sterile centrifuge tube and allowed to 
settle on ice for 2 mins to remove clumps. The supernatant 
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was transferred to a fresh sterile centrifuge tube, 
centrifuged at 300g for 5 mins and the cell pellet was 
resuspended in EMEM containing 10% v/v HIFCS and 10- 4 M 2-ME. 
The viability of the resultant single cell suspensions as 
assessed by Trypan Blue exclusion, ranged between 75 and 
90%. 
2.6 PREPARATION OF CONCANAVALIN A-ACTIVATED SPLEEN CELL 
SUPERNATANTS (CS) 
CS was prepared using a modification of the method 
described by Talmage et al (1977). Spleen cells were 
cultured in serum-free EMEM containing 10- 4 M 2-ME and 5 
µg/ml concanavalin A (Con A)(Sigma, grade IV). Cultures 
were set up in 75 cm 2 tissue culture flasks (Falcon, 3024) 
with each flask containing 15 mls of medium and 3 x 10 8 
spleen cells. These cultures were gassed with a 7% o2 , 10% 
CO 2 and 83% N2 gas mixture, and incubated at 37°C for 2 
hours. By this time, the cells formed a rnonolayer on the 
plastic surface. The original medium was discarded, and the 
adherent cells were washed gently 3 times with 15 ml of HBSS 
to remove unbound Con A. The cultures were then refed with 
30 ml of serum-free EMEM containing 10- 4 M 2-ME. The flasks 
were regassed and incubated at 37°C for a further 16-20 
hours. The resulting supernatant was centrifuged for 10 
minutes at 1800g to remove cell debris. The cell free 
supernatant was then concentrated 10-fold over a PM-10 
membrane (Amicon), sterilized by filtration through a 0.22 
µm Millipore membrane and stored at -2ooc. 
2.5 
2.7 IRRADIATION OF CELLS 
Normal splenocytes used as stimulators in mixed 
lymphocyte cultures were y-irradiated with 750 rads from a 
60co source. UV-irradiation of tumour cells or lymphocytes 
was carried out in 4 inch plastic petri dishes (Kayline, 
Adelaide) with the cell suspension (,106 cells/ml) covering 
a depth of 1mm. Exposure was for 4 mins from a Sylvania 
G30TS Germicidal lamp at an intensity of 960µW/cm 2 in the 
230-270 nm range. 
2.8 MIXED LYMPHOCYTE CULTURES 
The conditions for obtaining optimal responses in these 
cultures were taken from Talmage et al (1977). 
The responding cell population was prepared from a 
number of pooled mesenteric lymph nodes. Suspended in EMEM 
containing 10% HIFCS and 10- 4 M 2ME, 2 x 106 responding cells 
were added to each well of a 24 well tissue culture tray 
(LINERO, 76-033-05). To these cells was added another 1 ml 
of medium containing 3.16 x 10 6 y-irradiated spleen cells of 
the appropriate stimulating strain. Culture trays were 
incubated at 370c for 4 days in a humidified atmosphere of 
2.9 PREPARATION OF EXPANDED POPULATIONS OF ACTIVATED T-
CELLS (SEVEN DAY ACTIVATED T CELLS) 
Cells harvested from 4-day old mixed lymphocyte cultures 
2.6 
were diluted to 5 x 10 4 /ml in EMEM with 10% HIFCS, 10- 4 M 2-
ME and 3-10% v/v CS. Cultures were incubated for 3 days at 
370c in 75 cm 2 tissue culture flasks (Falcon, 3024) in a 
humidified atmosphere of 7% o2 : 10% CO 2 : 83% N2 . 
Cells prepared in this manner are )99% Thy 1 positive 
and contain less than 1 .5% immunoglobulin positive cells 
(Woolnough and Lafferty, 1979). 
2.10 IL2 ASSAY 
The ability of IL2 to maintain the proliferation of 
Con A activated lymphocytes forms the basis of this assay. 
Con A activated lymphocytes were prepared by incubating 
10 6 C57Bl/6J (B6) spleen cells with 1 µg/ml Con A in 1 ml 
EMEM containing 10% v/v HIFCS and 10- 4 M 2-ME. Cultures 
were set up in 24 well tissue culture plates (Falcon, 
3008). On the third day of culture, the activated cells 
were harvested, washed once, and resuspended at 4 x 10 5 
viable cells/ml in EMEM containing 10% v/v HI FCS and 10- 4 M 
2-ME. 
Assays were prepared in flat bottomed 96 well trays 
(NUNC; 1-67008). Serial two-fold dilutions of the lyrnphokine 
preparation were made in 50 µl of EMEM containing 10% v/v 
HIFCS and 10- 4 M 2-ME. All titrations were carried out in 
duplicate. Each well received 50 µl of the Con A activated 
2.7 
lymphocyte suspension. Control cultures consisted of 24 
replicate wells containing 50 µl of cell suspension and 50 
µl of medium. The cultures were then incubated at 370c 1n 
a humidified atmosphere of 10% CO2: 7% 02: 83% N2. 
After 16 hours, 1 .25 µCi of 3 H-methyl thymidine (Amersham 
Intl. Ltd, TRK.418) were added to each well in 50 µl of 
HBSS, and the cultures were incubated for a further 5 hours. 
The cultures were harvested onto glass fibre filter paper 
discs (Whatman, Grade GF/A) using a Titertek Cell Harvester. 
The amount of thymidine incorporated by the cells in the 
culture was determined by placing the discs into a xylene 
based scintillation fluid and counting on a Packard liquid 
scintillation spectrophotometer. Figure 2.1 shows a typical 
dose response curve obtained from plotting log 10 counts per 
minute (c.p.m.) per culture against the log 10 lymphokine 
reciprocal dilution. Although sigmoid in shape, the curve 
approximates a straight line over its central region. The 
endpoint titre is obtained from this plot by measuring the 
dilution at which the straight line portion of the curve 
intersects the background level, set arbitrarily at 3 
standard deviations (S.D.) above the mean (X) c.p.m. of 24 
control cultures. This assay is highly reproducible; the 
mean titre of duplicate titrations has a 95% confidence 
interval of+ 0.13 log 10 units (Lafferty et al, 1980). Where 
IL2 titres are to be compared between different lymphokine 
preparations, all assays are performed on the same day. 
2.8 
2.11 MAINTENANCE OF 113-DEPENDENT CELL LINES 
113 is a haemopoietic growth factor which can be used to 
establish cell lines whose continued proliferation depends 
upon the presence of the lymphokine. These cells form the 
basis of a sensitive method for detecting and quantitating 
1L3 activity. 
Two cell lines, 32D-cl (32D)(Greenberrer et al, 1983) 
and FDC-P1 (FD)(Dexter et al, 1980) were used in these 
studies. 
A convenient source of 1L3 for maintenance of these cells is 
the 24 hour supernatant obtained from the WEHl 3 tumour cell 
line. Both FD and 32D cells were routinely passaged in RPMl 
containing 5% HlFCS and 10% WEHl 3 supernatant. 
2.12 113 ASSAY 
Twelve serial two-fold dilutions of the test supernatant 
were prepared in 96 well microtitre trays (NUNC) using RPMI 
plus 5% HIFCS as diluent and yielding a final volume per 
well of 50 µl. Each well then received 2 x 10 4 FD (or 32D) 
cells in 50 µl RPMI plus 5% HlFCS. Trays were incubated at 
37°c in a humidified atmosphere containing 10% co 2 
. . in air. 
One of two methods was then used to measure the extent of 
proliferation of the 1L3 sensitive cell line. 
A) Tritiated thymidine incorporation: An aliquot of 1 .25 µCi 
3 H-methyl thymidine was added to each well after 16 hours of 
2.9 
culture and following a further 6 hour incubation, the 
thymidine uptake by the cells in each well was determined 
using the procedure described in section 2.10 for IL2 
assays. 
A typical plot of log 10 c.p.m. versus log 10 reciprocal 
supernatant dilution is shown in Figure 2.2. Endpoint 
titres were determined by fitting a line to the linear 
portion of the curve and reading the dilution where this 
line intersects with the background, defined arbitrarily as 
the mean plus 3 x S.D. of 24 control wells. 
An estimate of the variability of this assay using 
analysis of variance was performed by assaying a standard 
preparation of IL3 activity in 6 replicates on 3 separate 
days. 
The result of this study is presented in Table 2.3. 
Between day variation is sufficiently great to prevent 
comparisons to be made on assays performed on separate days. 
Removing the day to day variation illustrates the highly 
reproducible nature of this assay. The expected standard 
error (S.E.) on a duplicate assay 1s 0.074 providing a 95% 
confidence interval of± 0.148 log 10 units. 
B) Measurement of hexosaminidase levels: To simplify the 
estimation of IL3 activity when large numbers of assays were 
required, the method of Landegren (1984) was employed. In 
2.10 
this procedure levels of the ubiquitous cell lysosomal 
enzyme, hexosaminidase, are determined to indicate the 
extent of cell proliferation per well. 
The substrate p-nitrophenol-N-acetyl-S-D-glucosaminide 
(Sigma, N-9376) was dissolved at 7.5 mM in 0.1M citrate 
buffer, pH 5.0. The solution was then mixed with an equal 
volume of 0.5% Triton X-100 in water, and stored at -2QOC 
Each culture tray containing an IL3 assay was incubated 
for 48 hours and then centrifuged at 800g for 5 mins. The 
supernatant was removed by rapidly inverting the plate. 
Each well was then washed by adding 200 µl PBS, centifuging 
at 800g and again flicking off the supernatant. Washing was 
essential to remove traces of HIFCS which contain high 
levels of hexosaminidase. Each well then received 60 µl of 
substrate solution and the reaction was allowed to proceed 
for 1 hour at 370c in a humidified atmosphere. The 
reaction was blocked and the colour developed by the 
addition to each well of 90 µl of a 50 µM glycine buffer, pH 
10.4, containing 5 mM EDTA. 
The absorbance of each well at 410 nm was measured in a 
Dynatech MR 600 microplate reader. Plots of log 10 of optical 
density (O.D.) versus log 10 supernatant dilution produced 
curves similar to that depicted in Figure 2.3. The 
intersection between a line drawn through the linear portion 
of the curve and the background O.D., defined arbitrarily as 
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the mean plus 3 x S.D. of 24 control wells containing medium 
and cells only, was taken as the endpoint titre. 
The reproducibility of this assay was measured 1n a 
manner similar to that for the 3 H-methyl thyrnidine 
incorporation assay (section 2.12B). 
The within day variation, shown in Table 2.4 is greater 
than that obtained for the thyrnidine uptake method. Thus 
duplicate determinations provide a 95% confidence interval 
of 0.193 log 10 units. However the ease of this assay means 
that a greater number of replicates can be performed. Four 
replicates for example have a 95% confidence interval of 
0.14, equivalent to duplicate samples in the thymidine 
assay. 
2.13 ASSAY OF CYTOTOXIC ACTIVITY 
R1(TL+) or P815 tumour cells at 5 x 10 6 /ml in EMEM plus 
5% HIFCS were incubated with 100 µCi/ml Na 5 lcro4 (Amersham 
Intl. Ltd) for 1 hour at 37°C. The labelled cells were 
then washed with 3 changes of EMEM plus 5% HIFCS and 
resuspensed to a final concentration of 10 6 viable cells per 
ml in EMEM plus 10% HIFCS. 
Cell populations to be tested for cytotoxic activity 
were prepared in EMEM containing 10% HIFCS and a number of 
2-fold dilutions in quadruplicate were prepared in flat 
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bottom microtitre trays (NUNC, 1-60078) 1n a final volume of 
0.1 ml EMEM plus 10% HIFCS. Each well then received 0.1 ml 
labelled target cell suspension. Spontaneous 5 1Cr release 
was determined by mixing 0.1 ml medium and 0.1 ml target 
cell suspension in quadruplicate cultures. Total releasable 
chromium was determined by mixing 0.1 ml target cell 
suspension with 0.9 ml distilled water in quadruplicate 5 ml 
plastic centrifuge tubes. All cell mixtures were incubated 
for 4 hours at 37°C in a humidified atmosphere of 10% co 2 in 
air. At the end of this period 0.1 ml supernatant was 
decanted from each well without disturbing the cells. Water 
lysis tubes were vortexed, centrifuged at 1200g for 5 m1ns 
and 0.5 ml supernatant removed. Supernatants were counted 
for 1 minute in a gamma scintillation spectrophotometer. 
Cytotoxic activity is expresed in terms of cytotoxic 
units (C.U.), where one C.U. is the activity required to 
lyse one target cell under the conditions of the assay: 
where 
C.U. - -Y .ln(1-y) 
0 
Y
0 
- number of targets per asay well 
y - the fraction of targets specificlly lysed 
during the assay 
(test lysis - spontaneous lysis) 
(water lysis - spontaneous lysis) 
The derivation of the cytotoxic unit has been described in 
detail (Woolnough and Lafferty, 1979). 
2. 1 3 
2.14 STATISTICAL METHODS 
Analysis of variance 1s used to gain an estimate of the 
variation of lymphokine release assays within and between 
days. This information is also used to ascribe confidence 
intervals on small mumbers of replicates (1 or 2). To do 
this, the "within day" variance is taken as an estimate of 
the assay variance. Thus the S.E. of the mean of 2 samples 
is given by: 
S. E. -
1 
(within day variance) 2 
./ 2 
• 
The t-distribution is then used to determine 95% 
confidence intervals, although, at the number of degrees of 
freedom used, this distribution is essentially normal and 
the 95% confidence limits are given approximately by the 
sample mean± 2 x S.E. 
It should be noted that this procedure assumes that the 
distribution of log 10 endpoint titres is normal about the 
mean, that the standard deviation is independent of the size 
of the titre and that the variation observed on the original 
days of assay is preserved in subsequent assays. 
2.14 
2.15 ISOLATION OF ADULT MOUSE PANCREATIC ISLETS 
Groups of 8-12 donor BALB/c mice were anaethetized with 
ether and sacrificed by cervical dislocation. The pancreas 
was removed, finely diced with scissors and washed in 
isolation medium - HBSS buffered with 0.5 g N-2-hydroxyethyl 
piperazine-N-2-ethanesulfonic acid (HEPES)(Sigma)/100 ml and 
supplemented with Bovine Serum Albumin (0.15%), DNase (Sigma 
Type 1, 0.01 mg/ml) and antibiotics (penicillin, 100 
units/ml, streptomycin, 100 µg/ml and neomycin, 100 µg/ml). 
The minced tissue was allowed to settle at 4°C for 4 mins 
and debris remaining in suspension was removed with a 
Pasteur pipette. After three 30 second-dicings and 
subsequent washings, the minced tissue was transferred to a 
siliconized 15 ml graduated glass centrifuge tube and 
allowed to settle for an additional 4 mins. The volume of 
tissue was noted and the tissue was then transferred to a 
siliconized 20 ml glass vial. Collagenase (Boehringer 
Mannheim) was freshly prepared in PBS at a concentration of 
10 mg/ml, and then filtered through a 0.20 µm filter 
(Millipore Corporation). One ml of this solution was added 
to each 1 ml volume of minced pancreatic tissue and the 
volume was made up to 5 ml with isolation medium. The 
pancreatic tissue was then digested at 370c for 17 mins in 
a shaking water bath. The digest was vigorously shaken by 
hand for an additional 15-20 seconds, in order to disperse 
any residual clumps of tissue. The enzymatic digestion was 
arrested by the addition of 15 ml of chilled isolation 
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medium and the digest was then allowed to settle for 4 
minutes at 40c. The supernatant was removed, and the 
digested tissue was washed twice with isolation medium. 
Individual islets were identified using a stereomicroscope 
set at 15 x magnification and then removed from the digest 
with a fine siliconized pipette. The isolated islets were 
placed on ice in a petri dish containing RPMI culture medium 
supplemented with HIFCS. The isolated islets were kept on 
ice prior to preparation for organ culture. 
2.16 ORGAN CULTURE OF ADULT MOUSE PANCREATIC ISLETS 
Adult islets were cultured as islet clusters. Groups of 
approximately 50 islets were transferred to 35 mm 
hydrophobic petri dishes (Falcon, 1008) containing 2 ml of 
RPMI culture medium supplemented with 10% HIFCS. To promote 
islet aggregation, initially each group of islets was gently 
rotated on an orbital platform (gallenkamp SGM-300, ENGLAND) 
at 50-60 cycles per minute, for 18-24 hours. The cultures 
were maintained at 370c in a humidified gas phase of 95% 
o2 , 5% CO 2 . The islet aggregates were then maintained as 
stationary cultures for 7 days in the same gas phase. The 
culture medium was changed 3 times per week; on the first 
and subsequent changes, the culture medium was removed using 
a Pasteur pipette and 0.75 ml fresh culture medium was 
replaced in each dish. During the culture period each 
aggregate condensed into a tight cluster suitable for 
transplantation. 
2.16 
2.17 PREPARATION OF AVERTIN ANAESTHETIC 
Avertin was prepared by dissolving 1 .0 g of 2,2,2 
tribromoethanol (Fluka AG, Switzerland). The solution was 
diluted to a final volume of 50 ml with hot tap water 
(SOOC) and shaken vigorously to mix. The v/w dose of 
avertin used to anaethetize mice was 0.010 - 0.013 ml/gm 
body weight, administered intraperitoneally (i.p.). 
2.18 TRANSPLANTATION UNDER THE KIDNEY CAPSULE 
Recipient mice were anaesthetized with avertin (section 
2.17) and shaved on the left flank with electric animal 
clippers to remove hair from the incision site. Instruments 
were sterilized by boiling immediately prior to use. The 
left flank was swabbed with 70% ethanol and a vertical 
midline incision was made in the skin using a scalpel blade. 
The abdominal wall was cut with scissors and the kidney 
exposed and held in position with a cotton swab. A small 
incision was made in the kidney capsule using a 19 gauge 
needle (Terumo, Australia) and a space was made between the 
capsule and kidney parenchyrna, using a rounded 27 gauge Luer 
lock needle. The transplant tissue was then inserted under 
the capsule using the modified Luer lock needle as a probe. 
During the procedure the kidney was swabbed regularly with 
HEPES-buffered HBSS to prevent dehydration. The kidney was 
then replaced in the abdominal cavity and the incised skin 
was sutured together with autoclips (9 mm; Clay Adams, 
USA). The transplanted mice were placed under an 
incandescent lamp until they recovered from anaesthesia. 
TABLE 2. 1 
H-2 haplotypes of mouse strains used in this study 
K I-A 
C57Bl/6J (B6) b b 
BALB/c d d 
CBA/H (CBA) k k 
B10.AQR q k 
B10.A k k 
B 10. T ( 6R) k q 
I-E 
b 
d 
k 
k 
k 
q 
D 
b 
d 
k 
d 
d 
d 
Background 
strain 
type 
type 
type 
C57Bl/10J 
C57Bl/10J 
C57Bl/10J 
TABLE 2.2 
Characteristics of the tumour cell lines used in this study 
Name 
P815 
EL4 
R1(TL+) 
WEHI 3 
MLA 144 
K562 
Strain of 
origin 
DBA/2 
B6 
C58 
BALB/c 
Gibbon 
Human 
Cell type 
Mastocytoma 
T cell lymphoma 
T cell lymphoma 
Myelomonocyte 
T cell lymphoma 
Erythroid leukaemia 
Culture media 
DMEM + 10% HIFCS 
DMEM + 10% HIFCS 
DMEM + 1 0% HIFCS 
RPMI + 5% HIFCS 
RPMI + 5% HIFCS 
RPMI + 5% HIFCS 
TABLE 2.3 
Estimation of the reproducibility of IL3 determination 
using 3H-thymidine incorporation 
IL3 activity determined from replicate titrations on day: 
A 
B 
C 
D 
E 
F 
X 
S.D. 
Source of 
variation 
Between days 
Within days 
Day 1 
1 • 60 
1 • 65 
1 • 86 
1 • 65 
1 • 60 
1 • 65 
1 • 6 7 
0.09 
Day 2 
1 • 60 
1 • 50 
1 . 50 
1 • 43 
1 • 53 
1 • 40 
1 • 50 
0.07 
Analysis of variance table 
Sum of 
squares 
0.3675 
0.1052 
Degrees of 
freedom 
2 
15 
Day 3 
1 . 8 0 
1 • 80 
1 • 80 
1 • 80 
1 • 86 
2.00 
1 • 84 
0.08 
Estimate 
of variance 
0. 184 
0.007 
TABLE 2.4 
Estimation of the reproducibility of IL3 assays employing 
measurement of hexosaminidase levels 
I13 activity determined from replicate titrations on day: 
A 
B 
C 
D 
E 
F 
X 
S.D 
Source of 
variation 
Between days 
Within days 
Day 1 
2.58 
2.45 
2.50 
2.58 
2.85 
2.70 
2.61 
0. 15 
Day 2 
2.55 
2.46 
2. 46 
2.67 
2.55 
2.55 
2.54 
0.08 
Analysis of variance table 
Sum of 
squares 
1 • 202 
0.2792 
Degrees of 
freedom 
2 
15 
Day 3 
3.06 
3.00 
3. 1 0 
3.30 
3.06 
3. 1 5 
3. 1 2 
0. 10 
Estimate 
of variance 
0.601 
0.0186 
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Figure 2.1. Assay for IL2 activity. CS was prepared as 
described in section 2.6 and titrated in the IL2 assay 
(section 2.10). Each point is the arithmetic mean of 
duplicate cultures. The thin line is the mean background 
incorporation determined in the absence of CS. The dotted 
line is the arbitrary endpoint level (Xx 3.S.D. ). 
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Figure 2.2. Assay for IL3 activity: Thymidine incorporation. 
A 1:10 dilution of a WEHI 3 tumour cell supernatant was 
titrated in the IL3 assay (section 2.12). Proliferation of 
the FD IL3 indicator cell was measured using 3H thymidine 
incorporation (section 2.l2B). Log 10 c.p.m. is plotted 
against log 10 recipro
cal dilution of supernatant. Lines 
indicating the mean background incorporation in the absence 
of WEHI 3 supernatant and the arbitrary endpoint 
-(X + 3 x S.D.) are shown. 
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Figure 2.3. Assay for IL3 activity; Measurement of enzyme 
levels. A WEHI 3 supernatant was titrated 1n an IL3 assay 
using the FD cell line. Proliferation was measured by the 
hexosaminidase level per well (section 2. 128). Log 10 O. D. 1s 
plotted against log 10 reciprocal dilution of supernatant. 
Lines indicating the mean background incorporation in the 
absence of WEHI 3 supernatant and the arbitrary endpoint (X 
+ 3 x S.D.) are shown. 
CHAPTER 3 
CHARACTERISTICS OF LYMPHOKINE RELEASE 
3. 1 
3.1 INTRODUCTION 
The release of biologically active molecules, 
generically termed "lymphokines" from T lymphocytes is an 
important feature in generating an immune response. 
Lymphokine activities have been described which affect 
macrophage migration and activation (Fowles et al, 1973; 
Bloom and Bennett, 1966), which are chemotactic for a number 
of cell types such as eosinophils (Cohen and Ward, 1971) and 
monocytes (Ward et al,1970) and which influence cell 
differentiation, most notably of B lymphocytes (Swain et al, 
1981, Andersson et al, 1980). The release of one of these 
factors, the T cell growth factor or IL2, was the subject of 
a study by Andrus and Lafferty (1981). The major finding of 
this work was that activation of IL2-secreting cells 
required antigen presented on specialized stimulator cells 
in a way which is analagous to the activation of cytotoxic T 
cells. Once activated, however, T cells would initiate IL2 
release following exposure to any cell bearing the 
appropriate antigen, including cells rendered metabolically 
inactive by UV-irradiation. This observation lead to the 
conclusion that an antigen signal only controlled IL2 
release from activated T cells. Lafferty et al, (1983) have 
extrapolated from this to suggest that all lymphokines 
released from activated T cells are controlled solely by the 
antigen signal. If this is the case lymphokine release from 
activated T cells could serve as a simple means of studying 
the necessary physical characteristics of antigens in 
providing the antigen signal. 
3.2 
The purpose of the work described in this chapter was to 
examine the reproducibility of lyrnphokine release assays and 
test the assertion that lyrnphokines are under identical 
cellular control by comparing 112 release to that of IL3. 
IL3 is a haemopoietic growth factor with physical 
characteristics distinct from 112 (Ihle et al, 1983). 
3.3 
3.2 MATERIALS AND METHODS 
3.2.1 Preparation of seven day-activated T cells 
Seven day-activated T lymphocytes were prepared from a 
B6 anti-BALB/c MLR as described in section 2.9. Cells 
prepared in this manner are 99% Thy 1+ (Woolnough and 
Lafferty, 1979). 
3.2.2 Triggering of lymphokine activity from seven-day 
activated T cells 
A) 3 ml assay: Seven day-activated T cells were suspended 
at 2 x 106/ml in EMEM containing 10- 4 M 2-ME. P815 target 
cells were UV-irradiated at 960 µW/cm 2 for 4 mins and 
suspended in EMEM plus 10- 4 M 2-ME at 8 x 106 cells/ml. An 
aliquot of 1.5 ml of each suspension was mixed in a Falcon 
3002 culture tube (Falcon, California). These cultures were 
gassed with a 7% o2 ; 10% CO 2 ; 83% N2 for 6 hours at 37°c. 
At the end of culture each tube was centrifuged at 1000g for 
I 
10 min to sediment cells and cell debris. The supernatants 
were then decanted and stored at 40c. 
B) Micro-release assay: Cells used for this assay were 
prepared as described for the 3 ml release assay. To 
initiate the reaction 100 µl of T cell suspension was added 
to 100 µl of target cell preparation in individual wells of 
a 96 well microtitre tray (NUNC, Denmark). These plates were 
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then incubated at 37°C in a humidified atmosphere of 7% o2 ; 
10% CO 2 ; 83% N2 , for the appropriate time. At the end of 
culture 100 µl was removed from each well and transferred in 
two aliquots of 50 µl to the first wells of a new microtitre 
tray in preparation for a lymphokine assay. Prior to assay, 
50 µl of media was added to each supernatant aliquot to take 
the final volume to 100 µl. Thus each lymphokine containing 
supernatant was assayed in duplicate. 
3.2.3 Treatment of supernatants for inhibitor removal 
To remove the IL2 inhibitor (Andrus and Lafferty, 1981), 
2 of the 3 mls from one lymphokine release experiment were 
removed and diluted to 10 ml with fresh EMEM plus 10- 4 M 2-
ME. This diluted supernatant was then supplemented with 0.2 
mls HIFCS and concentrated to less than 2 mls using a B15 
Minicon concentrator fitted with a PM 10 ultrafiltration 
membrane (Amicon Corp, Lexington, Mass). The concentrated 
supernatant was removed and reconstituted with fresh medium 
to its initial volume of 2 ml. This supernatant was then 
sterilised by filtration through a 0.22 µm disposable 
filter (Millipore Corporation) and stored at -2ooc until 
assayed. 
3.2.4 Lymphokine assays 
Estimates of IL2 and IL3 activity in cell supernatants 
3.5 
were determined according to the methods described in 
sections 2.10 and 2.12 respectively. 
3.2.5 Preparation of mRNA from activated T cells 
Total mRNA was prepared from an aliquot of 10s seven day 
activated T cells suspended in 0.1 ml serum-free EMEM using 
the method of Maniatis (1982). The RNA preparations were 
electrophoresed on a 2.2M formaldehyde-10% agarose gel 
(Lehrach et al, 1977) and transferred to nitrocellulose 
(Maniatis, 1982). The gel was prehybridized for 5 hours at 
420c in a buffer containing 50% formamide, 1 x Denhardts 
solution (Denhardt, 1966), 100 µg/ml salmon sperm DNA, 0.1% 
sodium dodecylsulphate and 5 x SSPE solution (SSPE = 0.15M 
NaCl, 10mM NaPhosphate, 1mM EDTA, pH 7.7). The nitrocellulose 
membranes were then hybridized for 20 hours at 420c in the 
same buffer containing 6 x 106 c.p.m./ml of mur1ne 113 cDNA 
probe (Fung et al, 1984) labelled with 32 P-dATP by random 
priming (Taylor et al, 1976). Autoradiography was performed 
using an intensifying screen and preflashed film (Laskey, 
1980). 
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3.3 RESULTS 
3.3.1 The reproducibility of the 3ml lymphokine release 
assay 
Stimulation of 112 from activated T cells is effected 
equally by UV-irradiated and live target cells (Andrus and 
Lafferty, 1981). In this study, therefore, all target cells 
are UV-irradiated to eliminate any metabolic contribution 
from these cells. Andrus and Lafferty (1981) also 
described an inhibitory activity which was found in T cell 
supernatants and which could completely mask the presence of 
112. This inhibitor appeared to bind to Amicon PM 10 ultra 
filtration membranes, thus offering a simple means for its 
removal. 
In developing an assay for 112 release, 3 ml was the 
minimum supernatant volume which could satisfactorily 
be treated for inhibitor removal. 
An experiment was performed to gain some estimate of the 
error involved in obtaining 112 using 3 ml supernatant 
volumes and PM 10 treatment for removal of the inhibitor. 
Eight replicate cultures containing 1 .5 x 106 seven-day 
activated T cells and 6 x 10 6 UV-irradiated P815 were 
prepared and cultured as described in section 3.2.2. The 
results of an 112 assay of both untreated and treated (as 
described in section 3.2.3) supernatants are shown in Table 
3 • 1 • 
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Two points arise from this data. Firstly, there is no 
evidence of the IL2 inhibitor which can be present in 
supernatants prepared in this manner and, secondly, that the 
standard deviation of treated and untreated samples are 
similar, indicating that the bulk of the error inherent in 
this procedure lies in the IL2 assay and not in the 
preparation of each replicate. As the inhibitor did not 
appear to be produced, the above procedure was repeated on a 
further two days without the PM10 treatment. The data and 
an analysis of variance table are depicted in Table 3.2. 
Between day variation precludes the effective comparison of 
IL2 titres obtained on different days. Within days however, 
the assay is highly reproducible. 
The expected standard error (S.E.) about the mean of 2 
replicates would be 0.04 and on one r e plicate, 0.08. These 
figures yield 95% confidence intervals of 0.08 and 0.16 
respectively. 
3.3.3 Reproducibility of a micro-release assay 
Many experiments require at least 3 ml of lymphokine 
supernatant, either for PM10 treatment or for assay of a 
number of different lymphokine activities. The estimation of 
dose response curves, relating antigen, T cell dose and 
lymphokine titre, requires only a single assay and can, 
therefore, be achieved with a supernatant volume of 200 µl. 
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The previous study showed no evidence of an IL2 
inhibitor which was present in supernatants produced in a 
very similar way by Andrus and Lafferty (1981). The removal 
of this constraint allowed the assay volume to be reduced to 
200 µl. 
The reproducibility of a "micro-assay" was determined by 
repeating the procedure described in section 3.2.2B on four 
occasions over a four week period and employing eight 
replicates per day. 
The results and an analysis of variance table are 
presented in Table 3.3. As with the 3 ml release assay, 
significant day to day variation in titre is present, most 
probably due to variation in the separate T cell 
preparations. Removing the between day variation reveals an 
extremely reproducible determination when taken on a single 
day. Duplicate samples taken on the same day would be 
expected to have a S.E. about the mean of 0.037 and a 95% 
confidence interval of 0.074. 
The standard error expected on a single determination is 
no greater than that found for the IL2 assay itself (0.13, 
as assessed by Lafferty et al, 1980). Thus, the bulk of the 
sample variation occurs not in the release step but in the 
subsequent lymphokine assay. 
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3.3.4 The time course of IL2 and IL3 release are similar 
The relationship between the time of release of IL2 and 
IL3 from activated T cells was examined. The 3 ml assay as 
described in section 3.2.2A was used. Supernatants were 
harvested at varying times up to 27 hours. Assays for IL2 
and IL3 were performed on both untreated and PM10 treated 
supernatants. The 32D IL3 responsive cell was employed in 
the IL3 assay. The results are shown in Figure 3.1. T cells 
alone did not release detectable lymphokine at any time. 
IL2 activity rises to a peak at 8 hours before rapidly 
falling to undetectable levels. This apparent decrease in 
titre can largely be accounted for by an inhibitor, the 
presence of which masks the IL2 assay. Thus, when treated 
for inhibitor removal using the PM 10 method of Andrus and 
Lafferty (1981), a major portion of the maximum titre is 
restored. Following this treatment a further twofold 
decrease in titre between 10 and 27 hours is observed. Thi s 
additional effect is probably due to the consumption of IL2 
from the media by the T cells themselves. The ability of 
activated T cells to remove IL2 from culture supernatants 
has been described previously (Watson and Mochizuki, 1981). 
IL3 activity also reaches its peak titre at 8 hours and 
remains at this level until the completion of the 
experiment. Thus, the IL3 assay is not affected by the IL2 
inhibitor, nor is IL3 activity absorbed from the cultures by 
the T cells. It is also worth noting that the IL3 titres 
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obtained are substantially greater than the 1L2 titres 
obtained from the same supernatant. The 113 assay is either 
more sensitive than the 1L2 assay, or greater quantities of 
113 are produced by this cell population. 
When plotted as a percentage of the maximum response a 
close parallel 1n the time course of 1L2 and 113 production 
over the first 10 hours is observed (Figure 3.2). 
In Figure 3.3 a time course of 113 production by cells 
taken from an M1R at 4 days is presented. The four-day cells 
release some 113 in the absence of antigen stimulation 
although this level rises when antigen is supplied. This 
contrasts with the seven-day activated T cells which give no 
detectable release in the absence of antigen stimulation. 
This background release is probably due to the presence of 
cells which were triggered by antigen just prior to removal 
from the M1R, or to the residual presence of antigenic 
cells. This result emphasises the importance of the 3 day 
expansion step after the initial M1R. During this period the 
specifity for H-2 bearing target cells is maintained but the 
spontaneous background seen at 4 days is eliminated. 
3.3.5 A comparison of 32D and FD 113 responsive cell 
lines 
The cell 32D was used to measure 113 in the above 
section. However, the titration curves obtained from these 
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assays were not always linear when plotted as log 10 cpm 
versus log 10 supernatant dilution. An example of this is 
shown in Figure 3.4. Such non-linearity is never observed 1n 
112 assays and when it occurs in the 32D assay an accurate 
determination of the endpoint is difficult. 
Another 113 sensitive cell line, FD, became available 
and a comparison between it and 32D was performed. Table 
3.4 indicates that 32D was consistently more sensitive than 
FD, yielding endpoint titres higher by 0.2 to 0.65 log 10 
units. However, the consistency of both the slope and the 
linear section of the curve obtained from the FD assay was 
generally superior to 32D. For these reasons FD was adopted 
as a standard 113 indicator cell. 
The standard error of the FD assay as determined in 
section 2.11A is 0.07. This is similar to the 112 assay. As 
this error represents the major part of the error associated 
with the lymphokine release procedure, it can be used to 
estimate the error of 113 determinations in lymphokine 
release assays. 
3.3.6 Measurement of antigen dose responses: 112 versus 113 
Figure 3.5 shows the result of performing a micro-
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release assay holding the number of activated T cells 
constant at 10 5 cells/well and varying the number of P815 
targets through 2-fold dilutions from 103 to 2 x 106/well. 
Four replicate supernatants per dilution were generated, two 
being used for an 112 assay and two for an 113 assay. 
Clearly, there is a very close relationship between the 
amount of 112 and 113 produced in response to changes in 
antigen dose. A more detailed analysis of this dose response 
curve is given in chapter 7. 
3.3.7 The T cell dose response curve 
The result of measuring the levels of 112 and I13 
produced in cultures where the number of antigenic cells is 
held constant and the number of T cells is varied in 2-fold 
steps from 103 to 10 5 ·7 is shown in Figure 3.6. Both 112 
and 113 determinations lie on a straight line for most of 
the T cell doses used. The gradients of these two lines are 
not significantly different (p < 0.05); for 112 the slope 
and 95% confidence interval is 1 .03 ± 0.1, and for 113, 1 .16 
± 0.06. The closeness of this gradient to 1 .0 suggests an 
empirical relationship of the form; 
(3.1) or, 
(1K) - kNT (3.2) 
where (1K) is the lyrnphokine titre, NT 1s the number of T 
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cells/well and k is a constant related to the average titre 
attributable to one lymphokine releasing cell over the 
period of assay. 
3.3.8 The antigen dose response curve using live and UV-
irradiated P815 as target cells 
The antigen dose response relationships between 113 
titre and target cell dose, for both live and UV-irradiated 
target cells are shown in Figure 3.7. The two curves are 
similar, the most notable distinction being a sharp decrease 
in 113 production when live P815 were added at 10 6 ·0/well. 
This decrease may have been caused by the depletion of 
culture media components by such a large number of 
metabolically active tumour cells. 
3.3.9 Stimulation by mitogen involves synthesis of new 
lymphokine-encoding mRNA 
An aliquot of 10 8 seven day-activated T cells was 
incubated with or without 5 µg/rnl Con A for 2 hours in 50 ml 
EMEM containing 10- 4 M 2-ME. The cells were then washed and 
recultured with fresh medium for a further 4 hours. 
The method for detection of 113 encoding mRNA in these cell 
preparations is described in section 3.2.5. 
Con A was used to trigger lyrnphokine production in these 
experiments to eliminate the problem of increased total mRNA 
which would be created by using P815 target cells. 
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Figure 3.8 shows that I13 encoding mRNA was undetectable 
in unstimulated cells but could be measured in cells exposed 
to Con A. Thus, triggering of I13 release requires 
transcription of specific mRNA. 
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3.4 DISCUSSION 
The measurement of IL2 release from activated T cells 
can be used to indicate exposure of these cells to an 
appropriate antigenic source (Andrus & Lafferty, 1981). Data 
presented in sections 3.3.1 and 3.3.2 demonstrates that the 
quantity of IL2 released in replicates is extremely 
reproducible and that the bulk of the variation observed can 
be attributed to the IL2 assay itself. The release of IL3, 
like IL2 follows exposure of activated T cells to 
an antigenic target cell. The assay of this lymphokine has 
an advantage over IL2 measurement, 1n that it is not 
affected by an inhibitor, produced in culture, which can 
completely mask IL2 activity. In this study the IL2 
inhibitory activity was detected in T cell supernatants 
after 20 hours of culture. However, a similar study by 
Andrus and Lafferty (1981) found that IL2 activity was 
inhibited at any time following antigen exposure. 
The existence of this inhibitor may cast some light 
upon a dispute concerning the release of IL2 from class 1 
MHC-reactive T cells. Studies by Andrus et al (1981) and 
Swain (1981), have reported IL2 production from class 1 MHC-
reactive T cells. Other reports describe IL2 release by T 
cells carrying the lyt 2 marker (Guerne et al, 1984; Kern e t 
al, 1981). This cell surface antigen is a phenotypic 
characteristic of class 1 MHC-reactive T cells (Swain, 
1983). In contrast, work by Miller and Stutman (1982) and 
Kelso and MacDonald (1982) has failed to find evidence for 
IL2 release from lyt 2+ T cells. 
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In the latter study, the number of T cell precursors which 
gave rise to 112 secreting T cell clones was found to be one 
fiftieth of that found for lyt 2- T cells. 
In a more recent report, Kelso et al (1984), divides 
class 1 MHC-reactive T cells into cytolytic and non 
cytolytic, and the cytolytic group into 112 dependent and 
112 independent groups. 112 releasing cells were never 
observed in the 112 dependent cytolytic group but were found 
amongst the other subdivisions. It is interesting to note 
that these authors found 112 production to be a variable 
property of an individual clone whereas the rates of release 
of other activities, such as MAF or CSF were very stable. 
Also 112 was often observed at 24 hours but had disappeared 
by 48 hours, a phenomenon attributed by these authors to 
consumption by the T cells. 
A possible alternative explanation of these findings is 
that in a number of clones an inhibitor of 112 activity is 
produced at various times following initiation of culture. 
This would account for the variability associated with 112 
detection, and for the apparent disappearance of 112 with 
time. It would also explain why Andrus et al (1981) who 
routinely treated supernatants to remove the inhibitor, 
consistently found 112 released in equivalent amounts by lyt 
2+ and lyt 2- T cell populations. That this inhibitor exists 
and that it can affect the time course of 112 production in 
the manner described by Kelso et al (1984) is demonstrated 
in Figure 3.2. 
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Although this explanation implies lyt 2+ cells 
preferentially release this inhibitor, a hypothesis for 
which there is no evidence, it would nevertheless appear to 
be good practise to anticipate the presence of this 
inhibitor when testing for 112 production. 
The time course, antigen dose response curves and T 
cell dose response curves for 112 and 113 production 
following antigen triggering are similar. These 
observations suggest that in fact these two physically 
distinct lymhokines are under the control of the same 
cellular mechanism. In section 3.3.9 it was found that 
triggering of 113 production involves transcription of new 
mRNA. If, as is suggested above, 112 and I13 are under 
. similar control, then the release of I12 should also require 
de novo synthesis of 112 encoding mRNA. A study by 
Granelli-Piperno et al. (1984) of 112 secreting Con A 
activated T cells found this to be the case. 
It is not possible, without knowledge of the rates of 
I12 and I13 production from a single cell, to determine 
whether both lymphokines are produced within the same cell. 
However, numerous studies of cloned T cells have 
demonstrated that multiple lymhokines can be produced by a 
single T cell clone (Kelso and Glasebrook, 1984; Guerne et 
al, 1984; Wilde et al, 1984). It seems reasonable to 
conclude that at least a proportion, if not all, cells in 
the seven day-activated T cell population release both I12 
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and IL3 following antigen exposure. However, even if 
produced in different cells, the above observations suggest 
that the same triggering requirements hold for all IL2, IL3 
and IL2/IL3 releasing cells. 
The addition of antigenic cells was used to initiate 
the lymphokine release reaction. It is not clear whether 
antigen is the sole requirement in triggering lymphokine 
from activated T cells. It has been reported that the 
tumour promoter PMA can enhance the lymphokine release 
capacity of activated T cells suggesting the possibility 
that more than one signal is involved (Wiscocil et al., 
1985). In this study the possibility of the target cell 
producing a factor, such as IL1, which could modify the T 
cell response is eliminated by the routine UV-irradiation of 
any cells used as a source of antigen. In fact this 
treatment has little effect upon the antigen dose response 
curve (Figure 3.7). 
It is also possible that the T cells themselves produce 
some factors which might enhance their own rate of 
lymphokine release. This is reportedly true of y-interferon 
production, which according to Kelso et al. (1984) is 
enhanced and prolonged in the presence of IL2. This cannot 
be true however for the release of IL2 and IL3 described in 
this study, as the T cell dose response curve indicates a 
simple linear relationship between T cell dose and 
lymphokine titre. Any arrangement whereby T cells produce a 
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modifying factor would complicate the T cell dose response 
by placing an additional constraint upon the number of T 
cells. Thus, the rate of lymphokine release would depend 
upon both the number of T cells and the concentration of 
modifying factor. The latter variable is itself dependent 
upon the number of T cells, giving rise to a higher order 
relationship between T cell number and lymphokine titre. The 
difference between this conclusion and the results of Kelso 
et al (1984) may be due to our relatively short lymphokine 
release period (6 hours versus 24 hours) or that IL3 
synthesis, unlike y-interferon, is not affected by the IL2 
concentration. 
From the above discussion a simple model of lymphokine 
release emerges. A single signal initiated at the cell 
surface by either antigen or mitogen binding, mobilizes a 
range of lymphokine encoding mRNA. In Figure 3.9 this model 
is divided into four stages; antigen binding, transmission 
of the antigen signal, transcription of lymphokine encoding 
mRNA and translation and secretion of the active molecule. 
This model is used in the next chapter to analyse the site 
of action of _CsA. In later chapters the model is important 
in a more detailed analysis of antigen and T cell dose 
response curves. 
TABLE 3. 1 
Estimation of the error involved in the 3 ml lymphokine 
release ass~y following treatment for 
IL2-inhibitor removal. 
Sample IL2 activity (log 10 titration endpoint) 
untreated PM-10 membrane treated 
A 2.00 1 . 65 
B 2. 10 1 . 80 
C 1 . 9 5 1 . 80 
D 2.05 1 . 80 
E 1 . 9 5 1 . 70 
F 2. 10 1 . 9 5 
G 2.20 1 . 80 
H 1 . 9 5 1 . 80 
X 2.04 1 • 7 9 
S.D. 0.09 0.088 
Cultures contained 1 .5 x 10 6 seven day-activated T 
cells plus 6 x 10 6 UV-irradiated P815 in 3 ml EMEM. Each 
supernatant was harvested after 6 hours incubation at 
370c. PM10 treatment for inhibitor removal is 
described in section 3.2.3. 
TABLE 3.2 
The reproducibility of the 3 ml lymphokine release assay 
112 activity (log 10 titration endpoint) 
Day 1 Day 2 
A 2.00 1 . 85 
B 2. 10 1 . 9 5 
C 1 . 9 5 1 • 95 
D 2.05 1 . 9 5 
E 1 . 9 5 1 . 90 
F 2. 10 1 . 90 
G 2.20 1 . 90 
H 2. 1 0 1 . 90 
X 2.04 1 . 91 
S.D. 0.09 0.035 
Analysis of variance table 
Source of Sums of 
variation squares 
Between days 1 .3 
Within days 0.135 
Degrees of 
Freedom 
2 
21 
Day 3 
1 . 35 
1 . 40 
1 . 60 
1 . 50 
1 . 65 
1 . 50 
1 • 60 
1 . 50 
1 • 5 1 
0. 103 
Estimate of 
variance 
0.65 
0.006 
TABLE 3.3 
Reproducibility of the micro-release assay 
IL2 activity (log 10 titration endpoint) 
Day 1 Day 2 Day 3 Day 4 
2.92 2.55 2.88 2.85 
2.97 2.56 2.76 2.77 
2.88 2.61 2.74 2.73 
2.94 2.55 2.73 2.73 
2.82 2.49 2.80 2.71 
2.92 2.47 2.75 2.73 
3.01 2. 51 2.82 2.73 
2.89 2.58 2.85 2.73 
X 2.92 2.5 2.79 2.74 
S.D. 0.06 0.05 0.055 0.045 
Source of 
variation 
Between days 
Within days 
Analysis of variance table 
Sums of 
squares 
3 
28 
Degrees of 
Freedom 
0.6045 
0.0766 
Estimation 
of variance 
0.2015 
0.0027 
TABLE 3.4 
A comparison of 32D and FD as 113 indicator cells 
Test 
supernatant 
WEHI 3 (1 :10)C 
Batch 1 
Batch 2 
Con A stimulated 
Titrea 
3.45 
2.90 
T cell supernatantd 
Sample 1 
Sample 2 
3.0 
3.4 
32D 
Slopeb 
0.77 
0.75 
0.5 
0.5-o.1e 
a Log 10 endpoint titre. 
Titre 
2.90 
2.70 
2.60 
2.90 
FD 
Slope 
0.77 
0.74 
0.77 
0.82 
b Slope of linear section of plot of log 10 c.p.m. versus 
log 10 supernatant dilution. 
c 1 :10 dilution of 24 hour supernatant from WEHI 3 
culture. 
d Seven day-activated T cells were incubated with 5 
µg/ml Con A for 2 hours in 3 ml EMEM plus 10-4M 2-ME. 
The cells were then washed and 3 ml fresh medium 
added. The cultures were then incubated a further 6 
hours. 
e Slope of this line appeared to have 2 straight 
sections one of slope 0.5 and the other of 0.7 (see 
Figure 3.4). 
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Figure 3.1. Time course of IL2 and IL3 production from s e ven 
day-activated T cells. 1 .5 x 10 6 T cells were stimulated 
with 6 x 106 UV-irradiated P815 tumour cells in Lhe 3 ml 
stimulation procedure described in section 3.2.2. Triangles 
represent the IL2 titre obtained before (open) and after 
(closed) treatment for inhibitor removal. The open and 
closed squares represent untreated and treated IL3 
determinations. T cells incubated alone produced no 
detectable IL2 or IL3 at any time. Each point is the 
arithmetic mean of two cultures. Expected 95% confidence 
intervals are; for IL2, ± 0.08, and for IL3, ± 0.14 log 10 
units. 
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Figure 3.1 are plotted as the percentage of the maximum 
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Figure 3.3. Time course of IL3 production from cells taken 
at day 4 of a B6 anti-BALB/c MLR. 1 .5 x 106 cells were 
incubated either alone ( o) or with 6 x 106 UV-irradiated 
P815 cell (e) for 6 hours according to the method described 
in section 3.2.2A. 
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Figure 3.4. An example of a non linear dose response curve 
obtained with the 32D 113 indicator cell line. The assay was 
performed as described in section 2.12A. Each point is the 
arithmetic mean of duplicate cultures. The titrated I13 
containing supernatant was obtained from Con A stimulated 
seven day-activated B6 anti-BALB/c T cells. 
3.6 
" w 
a: 3.3 
I-
-I-
I- 3.0 
z 
-0 
a.. 
0 
z 
w 
0 
~ 
2.7 
2.4 
8 2.1 
_J 
~ 
>- 1.8 
I-
-> 
-I-
(.) 
<t: 
w 
z 
-
1.5 
1.2 
~ 0.9 
0 
I 
a.. 
~ 
>-
_J 
0.6 
0.3 
D 
4.2 4.5 4.8 5.1 5.4 5.7 6.0 6.3 
LOG 10 UV-P815/WELL 
Figure 3.5. Antigen dose response. Varying numbers of UV-
irradiated P815 were incubated with 10 5 B6 anti-BALB/c 
activated T cells for 6 hours in a final volume of 200 µl. 
Supernatants were assayed for 112 ( •) and 113 ( o ) 
activity. The estimated 95% confidence interval of each 
point is; for 112 ± 0.08 and for 1L3 ± 0.14 log 10 unit5. 
4.8 
,..... 
4.5 w 
a: 
I- 4.2 
-I-
1--- 3.9 0~ z 
- DI 0 3.6 a_ 
0 3.3 z 
w 
0 3.0 
T"" D C, 
0 2.7 / ...J 
""' 2.4 >- 0/ I- 2.1 -> 
-I- 1.8 (.) 
<( 
w 1.5 
z /D 
- 1.2 ~ 
0 0 
a_ 0.9 
~ 0.6 >-
...J 
0.3 
3.0 3.6 4.2 4.8 5.4 
LOG10 T CELLS/WELL 
Figure 3.6. The T cell dose response curve for lyrnphokine 
release. Varying numbers of seven day activated T cells were 
incubated with 10s UV-irradiated P815 tumour cells in a 
final volume of 200 µl (section 3.2.2B). Supernatants were 
assayed for 112 ( •) and for IL3 ( o). Estimated 95% 
confidence interval for 112 determinations is± 0.08, and 
for 113, ± 0.14 log 10 units. 
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Figure 3.7. The P815 dose response curve for 113 release 
using both live and UV-irradiated targets. Varying numbers 
of live or UV-irradiated P815 were incubated with 10 5 seven 
day-activated B6 anti-BA1B/c T cells for 6 hours in the 
lymphokine release assay described in section 3.2.2B. Each 
supernatant was assayed for 113 activity. The · estimated 95% 
confidence interval for each point is± 0.14 log 10 units. 
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Figure 3.8. IL3 encoding mRNA in activated T cells. 108 
seven day-activated B6 anti-BALB/c T cells were incubated 
alone (lane 1) or with 5 µg/ml Con A (lane 2) for 2 hours at 
37°c in EMEM plus 10-4M 2-ME. These cultures were then 
washed with fresh medium and reincubated for 4 hours. At the 
end of this culture total mRNA was prepared and 
electrophoresed on formaldehyde-agarose gels, blotted to 
nitrocellulose and hybridized with a murine IL3 cDNA probe 
to detect IL3 encoding mRNA in the manner described in 
section 3.2.5. 
* This figure is also included in chapter 4 where lane 3 is 
relevant. The figure is included here as the first two lanes 
are important to this chapter. 
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Figure 3.9. Model of lymphokine release from activated T 
cells depicting four steps in triggering lymphokine 
release; antigen (or mitogen) hinding, transmission of the 
antigen signal, transcription of lymphokine encoding mRNA 
and translation and release. 
CHAPTER 4 
THE SITE OF ACTION OF CYCLOSPORINE 
4. 1 
4.1 INTRODUCTION 
Cyclosporine (CsA) is the first of a new generation of 
immunosuppressive agents with a specific site of action 
within the immune system (Borel, 1981). The agent is 
primarily lymphocyte specific and acts at an early phase of 
the cell's activation. A very low degree of myelotoxicity 
has allowed its use in clinical bone marrow transplantation. 
CsA appears to suppress lymphocyte function without damaging 
the activity of the reticuloendothelial system: animals 
treated with CsA show a normal capacity to clear colloidal 
particles or heterologous erythrocytes from the circulation 
(McIntosh and Thomson, 1980), and stem cell granulopoiesis 
is unimpaired (Hellmann and Goldman, 1980). Thus CsA 
provides a means of regulating the lymphocytic response to a 
tissue graft without completely laying waste the 
antibacterial defenses of the recipient. A greater 
understanding of the drug's site of action would be 
beneficial because of its clinical application and its 
potentially valuable use as a tool for dissecting the 
immune response. 
Studies examining the effects of CsA in vitro have 
revealed an inhibitory effect on T cell activation, and 
lymphokine release, while having little or no effect on 112-
mediated T cell proliferation or the cytotoxic activity of 
activated T cells. This pattern of effects led Andrus and 
Lafferty (1982) to suggest that CsA blocks T cell behaviour 
by interfering with the antigen signal. The model of 
lymphokine release established in the previous chapter 1s 
used here to test this proposition. 
4.2 
4.2 MATERIALS AND METHODS 
4.2.1 Activation of lymphocytes by H-2 alloantigens 
Mixed lymphocyte cultures were prepared as described in 
section 2.8. Three mouse strain combinations were used: 
B6 anti-BALB/c, which represents a whole MHC haplotype 
disparity, B10.AQR anti-B10.A, a reaction against the Kk 
alloantigen and B10.AQR anti-B10.T(6R) an anti-Iq reaction. 
4.2.2 Expanded populations of alloantigen activated T cells 
Seven day activated T lymphoctyes were prepared from the 
above MLCs using the method described in section 2.9. 
4.2.3 Triggering of lymphokine activity from seven-day 
activated T cells 
A) Antigen stimulus. Activated T cells from CS-expanded 
populations were harvested, washed, and suspended at 2 x 
10 6 /ml in EMEM plus 10- 4 M 2-ME. Cells to be used as a source 
of antigen were UV irradiated (section 2.7) for 4 mins and 
suspended in EMEM plus 2-ME at 8 x 10-6 cell/ml. Equal 1 .5 
ml volumes of target and effector cell suspensions wer e 
combined in a 5 ml plastic culture tube (Falcon, 2003) and 
4.3 
gassed with a 7% o2 : 10% CO 2 : 83% N2 gas mixture. These 
cultures were incubated at 37°C for 5 hours. At the end of 
culture, the tubes were spun at 700g for 10 minutes and the 
supernatant removed and stored at -2ooc. 
B) Con A stimulus. Activated T cells were suspended at 106 
cells/ml in EMEM with 10- 4 M 2-ME and 5 µg/ml Con A. An 
aliquot of 3 ml of this suspension was placed in a 5 ml 
culture tube (Falcon, 2003) and incubated at 37°c for 2 
hours. The cultures were then spun at 200g for 5 m1ns, 
washed once, and refed with 3 ml of fresh medium. The 
cultures were then reincubated for 5 hours . . The supernatant 
was harvested as described for antigen triggering (section 
4.2.3A). 
4.2.4 Lymphokine assays 
Estimates of the IL2 and IL3 activity in cell 
supernatants were determined according to the methods 
described in section 2.10 and 2.12B respectively. All IL3 
assays employed the FD indicator cell and were performed in 
duplicate. 
4.2.5 Preparation storage and use of CsA 
CsA was prepared by Sandoz Ltd. (Basel, Switzerland) and 
was a gift from Dr. Jean Borel of that company. As CsA is 
water insoluble a stock solution of 1 mg/ml was prepared in 
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dimethylsulphoxide (DMSO) and stored at -20°C until 
required. The stock solution was added directly to cell 
cultures or culture medium, usually diluted 1/1000 to 
provide a final concentration of 1 µg/ml. This procedure 
maintains CsA in a soluble form. 
4.2.6 Preparation and detection of 113 encoding mRNA from 
activated T cells 
The procedure for detecting 113-encoding rnRNA in 
activated T cells has been described (section 3.2.5). 
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4.3 RESULTS 
4.3.1 The effect of CsA on 113 assays 
The influence of CsA on the 113 assay was tested by 
adding CsA at four different concentrations to a standard 
preparation of 113 and estimating the 113 content using the 
assay described in section 4.2.4. The results are shown 1n 
Table 4.1. Neither CsA concentrations as high as 3 µg/ml 
nor the solvent DMSO alone had any effect on the 
determination of the 113 titre. It has been established that 
CsA has no inhibitory effect on 112 assays (Andrus and 
Lafferty, 1982; Larsson, 1980; Bunjes et al, 1981; DosReis 
and Shevach, 1982). For these reasons no attempt was made 
to remove DMSO or CsA from cell supernatants required for 
lyrnphokine assays. 
4.3.2 CsA blocks 112 and 113 release from antigen and 
Con A triggered, activated T cells 
In Chapter 3 it was shown that antigen could be used to 
induce the release of the lymphokines 112 and 113. In this 
experiment CsA was added to the lyrnphokine release procedure 
at a final concentration of 1 µg/ml to test its effects on 
this reaction. 
Antigen and Con A induced 112 and 113 release was 
achieved following the procedure described in section 4.2.3, 
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using, as the source of seven day-activated T cells, the B6 
anti-BALB/c MLR combination. The effects of CsA on the 
lymphokine release reaction are shown in Table 4.2. CsA 
prevents detectable release of both IL2 and IL3 from 
activated T-cells when induced by antigen or rnitogen. 
The cells used for this experiment were derived from an 
MLR between strains that displayed a whole H-2 haplotype 
difference. It was of interest to determine the relative 
sensitivity to CsA of class 1 and class 2-MHC-reactive T-
cells. Seven day activated T cells which were reactive to 
defined alloantigens were prepared using MLRs between 
congenic mouse strains as described in section 4.2.1. Cells 
prepared in this manner have been previously shown to 
release IL2 upon antigen or mitogen exposure, and that anti-
class 1 MHC and not the anti-class 2 MHC reactive T cells 
were sensitive to treatment with anti-lyt 2 sera and 
complement (Andrus et al, 1980). For these experiments cells 
of each subclass were incubated with 5 µg/ml Con A using the 
lyrnphokine release procedure of section 4.2.3B. Table 4.3 
shows that CsA inhibits release of IL2 and IL3 from each 
subclass. 
4.3.3 CsA has no effect upon constitutive lyrnphokine release 
from tumour cell lines 
To determine whether CsA can block the secretion of 
preformed lymphokine, the effect of the drug on tumour cells 
which constitutively release lympokine was studied. 
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The tumour cell lines used were: M1A 144, a gibbon cell 
line which produces 112, and WEHl 3B which produces 113. 
Tumour cells at 1 x 10 6 /cm 2 /ml cells were incubated with 
1 ug/ml CsA for 24 hours at 370c. At the completion of the 
culture the supernatants were harvested and tested for 
lymphokine activity. Control cultures were incubated 
without the drug. The results, presented in Figure 4.1 show 
that lymhokine release from either M1A 144 or WEHl 3 was not 
affected by CsA in that time period. 
4.3.4 CsA has little effect on lymphokine release from 
activated T cells in the 2 hour period following 
antigen or Con A exposure 
In section 4.3.3 it was established that CsA does not 
affect lymphokine release from tumour cells which produce 
112 or 113 constitutively. One implication of this is that 
CsA has no effect upon release of already synthesised 
lymphokine. To confirm this result, and to ensure that it 
was not peculiar to tumour cells, an experiment was designed 
to test the ability of CsA to inhibit lyrnphokine release 
from activated T cells for the 2 hour period after an 
initial triggering stimulus from either Con A or antigen. 
T cells were seven day-activated B6 anti-BA1B/c prepared 
as described in section 4.2.1 and 4.2.2. The cells were 
suspended at 1 x 106 cells/ml in EMEM containing 1Q-4M 2-ME 
and incubated in 3 ml volumes 1n culture tubes (Falcon, 
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2003). Control tubes were incubated for 2 hours with 5 
µg/rnl Con A, washed and 3 mls of fresh medium added before a 
further 2 hour incubation at 370c. A CsA control received 
. 
1 µg/ml CsA for both 2 hour culture periods and the test 
sample was stimulated with Con A in the first 2 hour period 
and received 1 ug/ml CsA for the second 2 hour culture. The 
supernatants harvested from the second two hour culture 1n 
each group were assayed for 112 and 113. 
Results of two such experiments are shown in Table 4.4 
These results indicate that CsA has little effect upon 
lymphokine release by activated T-cells for the 2 hour 
after the reaction has started. 
Identical experiments were also performed using P815 as 
the lymphokine trigger. These results (Table 5) show the 
same pattern of inhibition as that observed for Con A 
triggering. 
4.3.5 CsA acts before the transcription of 113-encoding 
mRNA 
Having established that CsA does not inhibit the release 
of synthesized lymphokine from the cell, it was of interest 
to determine whether the drug acted before lymphokine 
encoding mRNA was produced. To examine this question 
hybridization experiments were performed using the I13 rnRNA 
probe developed by Fung et al (1984). 
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In a typical experiment 1 x 10 8 seven day B6 anti-BALB/c 
activated T cells were used in each of three groups; 
1) T cells without stimulation 
2) T cells plus 5 µg/ml Con A 
3) T cells plus Con A plus 1 µg/ml CsA 
Each group of 10 8 cells was incubated in 50 mls of 
medium in a test tube. The cells were gassed in a 7% 02 ,10% 
co 2 and 83% N2 gas mixture and incubated for 2 hours in a 
370c waterbath. At the end of 2 hours the cells were 
washed twice and fresh medium without Con A was added to 
each group. CsA was present in the medium added to the cells 
in group 3. Following a further 3-4 hour incubation period, 
the cells were washed twice in PBS and total mRNA prepared 
by the procedure described in section 3.2.5. 
The RNA preparations were electrophoresed on 
formaldehyde-agarose gels, blotted to nitrocellulose and 
hybridized with a murine IL3 c-DNA probe to detect IL3 mRNA. 
The results, which are typical of three separate experiments 
are shown in Fig 4.2. The only detectable region of 
complementary RNA was found in lane 2, which contained mRNA 
from the Con A triggered cells. The position of the band 
indicated a molecular weight of 1 .1 kb, similar to that 
described by Fung et al, (1984) for the IL3 message. This 
result indicates that CsA acts prior to synthesis of 
lymphokine encoding mRNA. 
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4.3.6 CsA added to activated T cells after exposure to 
antigen significantly alters the time course of 
lymphokine release 
In the time course of lymphokine production described in 
section 3.3.4 lymphokine accumulated for approximately 10 
hours before tapering off to a plateau. It was possible 
given the information from the preceding sections of this 
chapter, to test whether the production of lymphokine over 
this period required repeated stimulation of the T cells via 
the CsA-sensitive step or whether one exposure to antigen, 
stimulated lymphokine secretion for a 10 hour period. 
To examine this question lymphokine release was 
initiated in seven day activated-B6 anti-BALB/c T cells 
using the procedure described in section 4.2.3.A. After two 
hours incubation, each culture was washed twice with medium 
and supplemented with either fresh medium or medium 
containing 1 µg/ml CsA. The time course of IL3 release was 
then followed in each group. From Figure 4.3 it can be seen 
that IL3 release in the cultures which received CsA 
continues for a further 3-4 hours before reaching a plateau. 
However, the control cultures continue to produce IL3 for a 
further 8 hours. This indicates that continued lymphokine 
production from activated T cells requires repeated 
stimulation through a CsA sensitive step. 
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4.3.7 1yrnphokine release decreases at a consistent rate 
irrespective of when CsA is added after an initial 
triggering period 
An experiment was performed which examined the effect of 
CsA on the rate of 113 production from T cells which had 
been previously committed to lymphokine production for 2, 4 
or 8 hours. 
Four replicate 3 ml cultures containing 1 .5 x 106 seven 
day-activated T cells and 6 x 106 UV-irradiated P815 were 
incubated at 370c for 2, 4 or 8 hours before being washed 
and divided into two separate cultures. In one group (the 
control), the supernatant was harvested every 2 hours and 
the cell pellet was washed and re-fed with fresh medium. 
This procedure of repetitive supernatant removal and 
addition of fresh medium was performed on 5 consecutive 2 
hour periods. The procedure for the other culture group was 
identical except that medium containing 1 µg/ml CsA was 
added to the cells after each wash. In this way the rate of 
113 production per 2 hour period in the presence and absence 
of CsA was determined. 
The result of assaying each supernatant generated in the 
above experiment for 113 is shown in Figure 4.4. In the 
control cultures 113 is released at the approximate rate of 
3 log 10 units/2 hours for the first 8 hours after the 
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initial wash. From that point the rate of release decreased 
slowly until, by 18 hours, very little 113 was being 
synthesized. When CsA was included in the medium the 113 
titre varied between 50-100% of control values over the 
first 2 hours. Following this, the titre declined 
approximately 10-fold for each ensuing 2 hour period and 
was undetectable 8 hours after drug exposure. This pattern 
of action was identical whether CsA was added at 2, 4 or 8 
hours after antigen stimulation, and therefore suggests that 
the CsA sensitive-step maintains a constant rate of 113 
production throughout the normal period of lymphokine 
release. 
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4.4 DISCUSSION 
CsA inhibits the release of IL2 and IL3 from activated T 
cells responding to Con A or alloantigen (section 4.3.2). In 
the previous chapter, it was suggested that the lymphokine 
release reaction could be divided into a number of stages: 
the binding of antigen; the transmission of an antigen 
signal; the transcription of lymphokine-encoding mRNA, and 
the translation and export of active lymphokine. The 
inhibitory effect of CsA could therefore be expressed at one 
or more of these steps. Experiments presented in sections 
4.3.3. and 4.3.4. demonstrate that constitutive release of 
lymphokine from tumour cell lines was not affected by CsA. 
These findings indicate that CsA does not inhibit the export 
of active lymphokine, has no inhibitory effects upon 
translation of lymphokine and has no direct effects upon the 
lymphokine encoding mRNA. In section 4.3.5 it was found that 
IL3-encoding mRNA was not produced in CsA blocked lymphokine 
releasing cells. IL2 encoding mRNA is also absent 1n CsA 
treated cells (Granelli-Piperno et al, 1984). These 
experiments suggest that CsA affects lymphokine release at a 
site before synthesis of lymphokine coding mRNA, blocking 
either transmission of the antigen signal or the binding of 
the T cell to its target. However, CsA does not inhibit the 
expression of cytotoxic activity displayed by either bulk 
cultures or cytotoxic T cell clones (Andrus and Lafferty, 
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1982; Bunj es et al, 1981 ; Orosz et al 1983). Since 
expression of cytotoxic activity requires the binding of the 
T cell to its target, it follows that the drug cannot 
inhibit antigen binding to the T cell. 
A possible objection to this argument could be that the 
cytotoxic cell and the lymphokine-secreting cell represent 
two distinct cell types: antigen binding by the cytotoxic 
cell would be unaffected by CsA, whereas the drug would 
block antigen binding by lyrnphokine secreting cells. This 
hypothesis cannot satisfactorily explain the observation 
that the cytotoxic and lymphokine release activities of an 
activated T cell population display a common pattern of 
target cell cross reactivity (Andrus and Lafferty, 1981; 
Sinickas et al,submitted for publication), suggesting that 
if they are not the same cell then they at least share a 
common antigen binding receptor. Moreover, the capability 
of single cells to possess both cytotoxic and lymphokine 
release function, has been demonstrated by numerous reports 
of multifunctional T cell clones (Kelso and Glasebrook, 
1984; Andrus et al, 1984). 
An important variation of the above argument is the 
claim of Palacios and Moller (1981) that CsA blocks binding 
of class 2-MHC restricted T cells to the class 2 MHC 
antigen. This postulate is based on the idea that only 
class 2-MHC-restricted T cells produce 112, a growth factor 
essential for activation and growth of class 1-MHC-
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restricted T cells. However, I12 is produced by class-1-MHC 
reactive T cells (Andrus and Lafferty, 1981; Swain, 1983) 
and lymphokine production by these cells is also inhibited 
by CsA (Table 4.3). Indeed Palacios and Moller have based 
their concept on experiments which show that CsA blocks IL2 
production in a system which only involves class 2 MHC 
antigen recognition. These experiments do not contradict the 
conclusion that CsA blocks the reactivity of both class 1 
and class 2 restricted T cells. 
If CsA does not inhibit antigen binding and if it does 
not affect the synthesis or export of lymphokine from the 
activated T cell, then the drug must interfere with the 
transmission of the antigenic signal to the nucleus of the 
cell. Given this conclusion it would be expected that 
release of all lymphokines controlled by this signal would 
be inhibited. Lymphokines other than IL2 and I13 which are 
not released by activated T cells in the presence of CsA 
include, y-interferon (Kalman and Klimpel, 1983), MAF, 
macrophage migration inhibition factor (MIF) (Thomson et 
al, 1983), and CSF (Kaufman et al, 1984). In each case CsA 
has no effect on the assay of the lymphokine activity within 
the same dose range. These studies suggest that lymphokine 
activities which are not released in the presence of CsA 
constitute a set of antigen controlled lymphokines. All 
lymphokines tested so far belong to this set. 
This designation of the site of action of CsA has also 
allowed a closer analysis of the role of antigen in 
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lymphokine release. Lymphokine release from activated T 
cells exposed to antigen will continue for a period of about 
10 hours before subsiding. When CsA is added, the rate of 
lymphokine release remains constant for about 2 hours before 
rapidly decreasing. This suggests that continued antigen 
signals are required to maintain the release of lymphokine 
from the T cell. 
Kronke et al, (1984) examined the effects of CsA on the 
expression of a number of genes induced in the tumour cell 
line Jurkat by Con A plus PMA. 112 release was inhibited 
whereas other non-lymphokine but signal dependent genes such 
as those for HT-3 and the 112 receptor were unaffected. This 
result implies that CsA does not inhibit all the effects of 
antigen signalling. It also suggests that CsA acts at a 
site after the antigen signal has diverged into a number of 
branches. 
Inhibition of the antigen signal could also explain why 
CsA blocks primary T cell activation by alloantigen (Andrus 
and Lafferty, 1982; DosReis and Shevach, 1982; Hess and 
Tutschka, 1980), mitogen (Larsson, 1980; DosReis and 
Shevach, 1982; Weisinger and Borel, 1979; Hess and Tutscha, 
1980), and haptens (DosReis and Shevach, 1982). However this 
theory is mitigated by the observations of Bunjes et al. 
(1981) and Hess (1985) who have found that addition of 
exogenous 112 can restore the proliferative response of T 
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cells although it does not affect the specific block on 
induction of cytotoxic T cells. This result could be 
explained by again assuming a dichotomy in the transmission 
of the T cell antigen signal. One path, which is CsA-
sensitive, controls differentiation in the unprimed cell and 
lymphokine release in the activated cell. The other CsA 
resistant signal, may regulate the proliferative response 1n 
both the unprimed and the primed cell. 
Effects of CsA which cannot be explained by the drugs 
effect on the T cell antigen signal include inhibition of 111 
release from tumour cells (Andrus and Lafferty, 1982), 
competitive binding to T cell 111 receptors (Bendtzen and 
Dinarello, 1984) and inhibitory effects upon antibody 
responses to some T-independent antigens and B cell mitogenic 
responses to anti-µ antibody (Kunkl and Klaus, 1980; Dongworth 
and Klaus, 1982). The latter effects may indicate at least one 
common signalling mechanism between Band T lymphocytes. 
In conclusion, it appears that CsA has effects on T cell 
activation and lymphokine release and no effects on I12 
mediated proliferation, cell mediated cytotoxicity, or the 
activities of any known lymphokine. These characteristics are 
consistent with the observation that CsA acts on the T cell 
antigen signal. Effects on B cell function cannot be so 
explained, but could suggest at least one common signalling 
mechanism between the two lymphocyte subsets. 
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These conclusions allow us to make a certain prediction 
concerning the in vivo function of this agent. At levels of 
100-1000 ng/ml 1n the tissue fluids, the drug should inhibit 
T cell priming and so inhibit primary immune responsiveness. 
The agent will inhibit lymphokine dependent but not 
cytotoxic functions of activated T cells. The possibility of 
using these properties to probe T cell function in vivo is 
explored in the next chapter. 
TABLE 4. 1 
CsA does not affect the assay for IL3 
Additions to IL3 standarda IL3 activity 
(log 10 endpoint titre) 
None 3.2b 
DMSO (3 µl/ml) 3.3 
3 µg/ml CsA (in 3 µl/ml DMSO) 3.2 
1 µg/ml CsA 3 . 1 
0. 1 µg/ml 3 • 1 
a Standard IL3 preparation was a 1 :10 dilution of a 24 hour 
WEHI 3 cell supernatant. 
b Arithmetic mean of duplicate cultures. Expected 95% 
confidence of titres determined in this manner is± 0.15 
log 10 units. 
TABLE 4.2 
Effect of CsA on the release of 112 and 113 from 
activated T cells. 
Culturea 
T only 
T + Con A+ DMSO 
T + Con A+ 1 µg/ml CsA 
T + P815 + DMSO 
T + P815 + 1 µg/ml CsA 
Lymphokine activity 
(log 10 endpoint titre) 
112 
,0.3 
1 • 65 
<0.3 
1 • 65 
<0.3 
113 
~0.3 
3.7 
~0.3 
2.5 
i;;O. 3 
a 1 .sx10 6 B6 anti-BALB/c seven day-activated T cells were 
stimulated with either Con A or 6 x 106 P815 in 3 ml EMEM + 
2-ME as described in section 4.2.3. 
The supernatants were harvested after 5 hours incubation at 
37°C and assayed for both 112 and 113 (section 4.2.4) 
TABLE 4.3 
Release of lyrnphokine from both class 1 and class 2-MHC 
alloreactive T cells is sensitive to CsA 
Specificity of T ceIIs ' ~a CsA 
( 1 µg/ml) 
Anti-Kk 
B10.AQR anti-B10.A 
+ 
Anti-lq 
B10.AQR anti-B10.T(6R) ._ 
+ 
Lymphokine activity 
(log 10 endpoint titre) 
112 
2.0 
~0.3 
2.2 
(0.3 
113 
3. 1 
(0.3 
3.2 
~0.3 
a 1.5x106 seven day-activated T cells which derived 
initially from the specified MLR's were restimulated with 
Con A as described in section 4.2.3B. Cell-free supernatants 
were collected 5 hours after removal of Con A and assayed 
for 112 and 113. 
TABLE 4.4 
CsA has no effect on lyrnphokine release from activated T 
cells pre-exposed to Con A 
Culture mixture 
in first 2 hoursa 
1 ) 
T only 
T + Con A 
T + Con A + CsA 
T + Con A 
2) 
T only 
T + Con A 
T + Con A + CsA 
T + Con A 
Presence of CsA 
in 2nd 2 hours 
+ 
+ 
+ 
+ 
Lyrnphokine activity 
in supernatant from 
2nd 2 hour period 
(Log 10 endpoint titre) 
112 113 
~ 0. 3 N.D.b 
1 . 3 N.D. 
~0.3 N.D. 
1 . 3 N.D. 
~ 0. 3 ~0.3 
1 . 8 2.4 
~ 0. 3 ~0.3 
1 . 6 2.0 
a Seven day-activated T cells were incubated for 2 hours 
in EMEM + 2-ME with Con A (Sµg/rnl) or CsA (1 µg/ml) as 
indicated. At the end of this culture period the cells 
were washed twice and then supplemented with fresh 
medium or medium containing 1 µg/ml CsA where indicated. 
b Not done. 
TABLE 4.5 
CsA has no affect on lymphokine release from activated T 
cells pre-exposed to antigens 
Incubation mixture 
for first 2 hoursa 
T + P815 
T + P815 + CsA 
T + P815 
Presence of CsA 
for 2nd 2 hours 
+ 
+ 
Lymphokine activity 
in supernatant from 
2nd 2 hour period 
Log 10 endpoint titre 
IL2 
1 . 55 
<0.3 
1 • 3 
IL3 
2.7 
<0.3 
2.4 
a 1 .5x106 seven day-activated B6 anti-BALB/c T cells were 
incubated with 6 x 10 6 UV-irradiated P815 in 3 mls EMEM 
using the method described in section 4.2.3A. After 2 hours 
these cells were washed twice in EMEM before addition of 3 
mls of fresh medium with or without 1 µg/ml CsA. The 
supernatant was harvested after a further 2 hour culture 
and assayed for IL2 and IL3 activity. 
IL3 FROM WEHl-3 IL2 FROM MLA 144 
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Figure 4.1. The effect of CsA on constitutive lymphokine 
release from tumour cell lines. The cell lines WEHI 3 and 
MLA 144 were incubated at 106 cells/ml for 24 hours with and 
without 1 µg/ml CsA. The WEHI 3 supernatants were assayed 
for IL3 on the 320 cell line and the MLA 144 derived 
supernatants were tested for IL2. Each point is the mean 
c.p.m. from duplicate cultures. 
1 2 3 
• 
Figure 4.2. The effect of CsA on 113 mRNA levels. 1QB seven 
day-activated T cells were incubated for 2 hours in 50 ml 
EMEM containing 10- 4 M 2-ME at 370c either; alone (lane 1), 
with 5 µg/ml Con A (lane 2), or with 5 µg/ml Con A and 1 
µg/ml CsA (lane 3). These cells were then washed and 
reincubated a further 4 hours. The cells cultured with CsA 
also received 1 µg/ml CsA in this second culture period. At 
the end of culture total mRNA from each group was extracted, 
and hybridized with a murine cDNA probe as described in 
section 4.2.6. 
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Figure 4.3. Time course of 113 release after addition of CsA 
to antigen-triggered activated T cells. Seven day-activated 
T cells were incubated with UV-irradiated P815 for 2 hours 
as described in section 4.2.3A. Following this incubation, 
cells were re supp 1 ied with fresh medium ( • ) or medium 
containing 1 µ g/ml CsA ( .& ) • Samples were harvested at 
various times and assayed for 113 activity. 
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Figure 4.4. CsA blocks IL3 release from lymphokine releasing 
cells in a manner independent of the time of addition. Seven 
day-activated T cells were incubated with UV-irradiated P815 
as described in section 4.2.3A. In the top panel cells were 
incubated for 2 hours, in the middle panel 4 hours, and in 
the lower panel 8 hours, before being washed and 
supplemented with fresh medium (open columns) or medium 
containing 1 µg/ml CsA (hatched columns). The supernatant 
was removed every 2 hours for 113 assay and fresh medium 
added to the same cells to continue culture. The procedure 
of repeated harvest every 2 hours was completed on 5 
occasions. The IL3 titres obtained from each 2 hour 
supernatant are represented as columns in the above figure. 
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CHAPTER 5 
T CELL FUNCTION IN VIVO 
5. 1 
5.1 INTRODUCTION 
A number of immune functions are mediated by T cells 
reactive to class 1 MHC antigens. Such functions include 
graft versus host reactions (GVHR)(Sprent and Korngold, 
1981) graft rejection (Prowse et al, 1983) and DTH reactions 
(Ada et al, 1981). Cells of this specificity have been shown 
in vitro both to be cytotoxic for antigen bearing target 
cells and to release a number of lymphokines in response to 
antigenic or mitogenic stimulation (Andrus et al, 1984; 
Swain, 1981). The relative contributions of these two 
activities to the in vivo function of class 1-MHC reactive T 
cells is unclear. CsA, which inhibits lyrnphokine release 
from activated class 1-MHC reactive T cells but has no 
effect on their cytotoxic activity (Andrus and Lafferty, 
1982. Bunjes et al, 1982), offers the potential for use 1n 
vivo to discriminate between these two functions. 
In this chapter this potential is examined using two 
models; a local inflammatory reaction induced by transfer of 
activated alloreactive T cells to mouse hind footpads, and 
the rejection of cultured islet allografts by transfer of 
sensitized cells to the graft recipient. In both systems 
biological activities of the class 1 MHC-reactive T cells 
were inhibited by CsA and therefore appear to be lyrnphokine 
dependent. 
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5.2 MATERIALS AND METHODS 
5.2.1 Tumour cell lines 
The tumour lines R1(TL+)(H-2k), P815 (H-2d) and EL-4 
(H-2b) were maintained by weekly passage as described in 
section 2.4. 
5.2.2 Preparation of activated T lymphocytes 
Seven day-activated T cells reactive to the Kk 
alloantigen were prepared from an MLR between the congenic 
strains B10.AQR (Kk) and B10.A (Kq) using the methods 
described in sections 2.8 and 2.9. T cells reactive to H-2d 
alloantigens were similarly prepared except that 3.16 x 10s 
y-irradiated (2000 rads) P815 were used as stimulator cells 
in the MLR. 
5.2.3 Assay for cell mediated cytotoxicity 
Measurement of the cytotoxic activity of cell 
preparations using 51 cr release from target cells was 
performed as described in section 2.13. All results are 
expressed as log 10 cytotoxic units. 
5.2.4 Lymphokine release 
Con A was used to induce lymphokine release from seven-
day activated B10.AQR anti-B10.A T cells using the method 
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described in section 4.2.3B. Supernatants were assayed for 
IL2 activity on Con A blasts as described in section 2.10. 
, 
5.2.5 Antiserum treatment of cell populations 
Treatment of cells with monoclonal anti-Thy 1 serum 
(Olac, England) and anti-lyt 2 serum, (ascites fluid from 
H0-2.2 hybridoma, Gottlieb et al, 1980) was as follows. 
Cells at 10 6 /ml were incubated for 1 hour at 40c in 
EMEM containing the optimum antisera concentration. The 
cells were washed once in fresh EMEM and resuspended in a 
1/20 dilution of rabbit complement (C')(Cedarlane, Ontario) 
in EMEM. This suspension was incubated for 1 hour at 370c 
before being washed twice and resuspended in fresh EMEM plus 
10- 4 M 2-ME. 
5.2.6 CsA 
When used in vitro the drug was dissolved at 1 mg/ml in 
DMSO and diluted in medium to a final concentration of 1 
µg/ml. Control cells were treated in an equivalent volume 
of DMSO in medium. For animal treatment the drug was 
dissolved at 25 mg/ml in olive oil and injected 
subcutaneously at a dose rate of 75 mg/kg/day. 
5.2.7 Assay for local GVHR 
Five million seven-day activated T cells in 50 µl EMEM 
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were injected into the left hind footpad of B10.A mice. 
The right footpad received a control injection of medium 
only. Each hind foot pad was measured at a number of time 
intervals using a dial gauge caliper (Mitutoyo, Japan). 
Results are expressed as percent increase over control foot 
and calculated using the following formula: 
thickness (left - right foot) 
X 100 
thickness right foot 
5.2.8 Immunization of mice 
Spleen cell suspensions were prepared from CBA mice 10 
days after the intraperitoneal injection of 2.5 x 10 7 P815. 
The cytotoxic activity of the spleen cells was measured on 
P815 target cells. The cytotoxic activity of the spleen 
cells used in this study varied from 5.4 to 6.1 log 10 
C.U./spleen. 
5.2.9 Preparation, culture and transplantation of islet 
tissue 
The method for preparation of pancreatic islets from 
BALB/c mice pancreas is described in section 2.15. 
CBA mice made diabetic by the intravenous injection of 
streptozotocin (250/mg/kg; Calbiochern-Behring), received 
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transplants of 350-400 islets under the kidney capsule. 
Animals usually became normoglycaemic in less than 7 days. 
Mice in which normoglycaemia was restored and maintained for 
at least 30 days post transplant were used in this study. 
Spontaneous graft rejection was never seen in transplanted 
animals. 
5.2.10 Transplantation of islet clusters and activated T 
cells 
A cultured BALB/c islet cluster was mixed with 4-10 x 
10s activated T cells 1n normal CBA mouse plasma. After 
clotting by the addition of powdered thrombin the clot was 
transplanted under the kidney capsule of CBA mice. In some 
experiments the clot was formed by adding 5 µl of normal CBA 
blood to the mixture of islets and T cells and allowing this 
to clot. Animals were killed 3-4 days after 
transplantation. 
5.2.11 Preparation of CBA T cells devoid of reactivity to 
BALB/c alloantigens 
CBA lymph node cells were injected intravenously into 
gamma-irradiated (850 rads) BALB/c mice. The thoracic ducts 
of the mice were cannulated and 20 hours later the thoracic 
duct lymphocytes collected over the following 24 hour 
period. The cells collected were stimulated with B6 spleen 
cells in an MLR according to the method described in section 
5.2.2. 
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5.3 RESULTS 
5.3.1 Selective in vitro effect of CsA on the function 
of class 1 MHC-reactive T cells 
Seven day activated B10.AQR anti-B10A (anti-Kk) T cells 
are both cytotoxic and capable of releasing IL2 when 
appropriately triggered. In each case function is dependent 
upon a Thy 1+, lyt 2+ cell (Table 5.1). 
The same cell population produces no detectable 112 when 
exposed to Con A in the presence of CsA. In contrast the 
cytotoxic activity measured on R1(TL+) target cells was 
unchanged in the presence of CsA (Table 5.2). 
5.3.2 CsA inhibits the local GVHR 
Seven day-activated T cells induce significant footpad 
swelling 24 hours after transfer to mice bearing the target 
antigen (B10.A)(Figure 5.1 and 5.2A). As with IL2 release 
and cytotoxic activity, this function is also dependent upon 
a Thy 1+, lyt 2+ cell (Figure 5.1). The reaction is antigen 
specific since cells injected into the footpad of syngeneic 
(B10.AQR) mice do not induce a footpad response (Figure 
5.2A). The treatment of the cells with CsA for 1 hour prior 
to injection into the footpad of normal B10.A animals 
delayed the onset of the GVHR, a response becoming evident 
by 10-20 hours after the injection of the cells 
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(Figure 5.3B). Despite the delay the intensity of the 
reaction was the same. Cells in vitro regain their IL2 
release capacity within 3 hours of removal of the drug 
(Table 5.3). The injection of CsA treated cells into the 
footpad of B10.A mice which had been treated with CsA on 
days -1 ,0 and 1 caused no reaction (Figure 5.3.B). 
The complete inhibition of the footpad GVHR in CsA 
treated animals suggests that this immune response is 
dependent upon lymphokine release from class 1 MHC-reactive 
T cells. 
5.3.3 CsA inhibits the rejection of cultured islet 
allografts 
Cultured BALB/c islet allografts, which are accepted 
when transplanted to normal CBA recipient mice, can be 
rejected by the passive transfer to the recipient of 
specifically sensitized spleen cells (Prowse et al, 1983). 
Rejection of the cultured grafts is dependent upon the 
presence of lyt 2 bearing cells in the transferred 
population (Prowse et al, 1983; Warren et al, in press). 
Diabetic CBA mice become normoglycaemic in approximately 
7 days following transplantation with cultured BALB/c islets 
(Figure 5.3A). After a period of normoglycaemia ()30 days) 
half the total group of mice (6) were treated with CsA. One 
day later these mice and 6 grafted but untreated mice 
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received 5 x 10 7 CBA anti-P815 spleen cells. CsA treatment 
was continued daily for one week after the injection of the 
cells. The CsA treated mice remained normoglycaemic during 
this period (Figure 5.3A), whereas all the control mice 
became hyperglycaemic (Figure 5.3A). Reversion to 
hyperglycaemia in this transplant system indicates graft 
rejection. These results therefore, demonstrate that CsA 
inhibits graft rejection triggered by the transfer of 
sensitized cells. 
CsA treatment was terminated in 4 mice, upon which 2/4 
rejected their grafts. A third went through a rejection 
crisis then recovered and the forth remained normoglycaemic 
(Figure 5.3B). The two animals which did not reject their 
grafts were challenged with 5 x 107 BALB/c spleen cells 25 
days after cessation of CsA treatment. In both cases graft 
rejection ensued (data not shown), indicating that a state 
of donor-specific graft tolerance had not developed in these 
animals. 
This finding indicates that the sensitized cells persist 
in the recipient mice and in some cases are able to function 
by rejecting the grafts upon the removal of CsA. 
5.3.4 CsA inhibits graft rejection by sensitized cells 
placed adjacent to the graft 
The experiments outlined above show that the rejection 
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of cultured islet allografts is lymphokine dependent. It is 
unclear whether the lymphokine is required for the 
recirculation of the cells or for mounting an inflammatory 
response at the graft site. To distinguish between these 
possibilities graft rejection was induced in a model where T 
cell recirculation was not required. CBA lymph node cells 
were activated in vitro against P815 and homogeneous 
populations of T cells generated. 
These cells (with or without CsA treatment) were mixed 
in CBA plasma with a single 7 day cultured BALB/c islet 
cluster. The plasma was clotted with thrombin and 
transplanted under the kidney capsule of CBA mice (with or 
without CsA treatment). The grafts were examined 3-4 days 
after transplantation. With one exception, all the grafts 1n 
the CsA treated animals contained islet tissue when examined 
by histology. In contrast none of the grafts in the control 
mice contained islet tissue (Table 5.4). The graft which 
rejected in a CsA treated animal was in an experiment using 
very high levels of cytotoxic activity (6.5 C.U./cluster ). 
CBA lymph node cells activated against a third party 
alloantigen (B6, H-2b) rejected 3/4 cultured BALB/c islet 
allografts. However, where these cells have been 
selectively depleted of reactivity to alloantigens shared 
between B6 and BALB/c, they are unable to destroy the 
cultured BALB/c grafts (Table 5.4). This finding indicates 
that the graft is not destroyed by the non-specific 
interaction of the islet tissue, activated T cells and the 
clot. 
: 
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Thus under conditions where lymphocyte recirculation is 
not required, CsA still inhibits the rejection process 
demonstrating the lymphokine dependence of this immune 
function. 
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5.4 DISCUSSION 
The selective inhibitory effect of CsA upon the function 
of class 1-MHC reactive T cells is apparent from Table 5.2. 
The drug strongly inhibits IL2 release while having no 
affect upon the cells' cytotoxic activity. Release of IL2 
is used here as a general indicator of the effects of CsA on 
lymphokine release. As discussed in previous chapters 
activated T cells release many lymphokine activities 
including factors with an obvious role in inflammation, such 
as phagocyte chemotaxis and macrophage activation. The 
release of these factors, like IL2, 1s inhibited by CsA 
(Kalman and Klimpel, 1983; Thomson et al, 1983; Kaufman et 
al, 1984). 
Class 1-MHC reactive T cells will induce footpad 
swelling (local GVHR) within 24 hours of injection into the 
footpads of mice bearing the priming antigen (Figure 5.2A). 
The reaction was dependent upon a cell of Thy1+, lyt2+ 
phenotype (Figure 5.1). The reaction however is sensitive to 
CsA, as treatment of the cells with the drug prior to 
injection results 1n a delay in the onset of the reaction. 
This suggests that the local GVHR is lymphokine dependent 
and also demonstrates that cells will function in vivo after 
the reversal of the effects of CsA. This is also true 1n 
vitro, as cells treated with CsA and then washed and 
resuspended in medium free of CsA regain their capacity for 
lymphokine production within 3 hours (Table 5.3). 
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Pretreatment of both cells and recipient animals with 
CsA completely inhibits the development of footpad swelling . 
From these results it appears that induction of the local 
GVHR is dependent upon lymphokine release and occurs 
independently of the cells' cytotoxic activity. 
The acute rejection of cultured islets is dependent upon 
a lyt 2+, and therefore presumably class 1-MHC-reactive 
(Swain, 1982), T cell population (Prowse et al, 1983; 
Warren et al, in press). This rejection process is 
inhibited by CsA (Figure 5.3) again demonstrating a 
dependence upon lymphokine release. It could be argued that 
when effector cells are introduced into the systemic 
circulation of CsA treated mice, they cannot recirculate and 
reach the graft site. However, under conditions where 
lymphocyte recirculation is not required, CsA still inhibits 
the rejection process (Table 5.4). The rejection of these 
grafts is the result of antigen specific recognition since 
activated T cells which have been depleted of reactivity to 
graft antigens, are unable to reject grafts. Since 
lymphokine release is CsA sensitive and cytotoxic activity 
is not, these data suggest that graft rejection mediated by 
class 1 MHC-reactive T cells is also a lymphokine dependen t 
process. 
These findings raise an important question concerning 
the process of allograft reactivity: Is cytotoxic activity 
of the effector T cell population irrelevant to the process 
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of tissue damage? This is a possibility, although the 
observation that one graft was damaged when the CsA treat ed 
T cells had a high cytotoxic activity (Table 5.4) indica tes 
a role for direct cell mediated killing in the rejection 
process. It is also possible that lymphokine production is 
required for the expression of cytotoxic activity in vivo. 
112 may be required to maintain the cytotoxic cells in an 
active proliferating state for a sufficient time to cause 
tissue damage. The proliferation of T cells at the graft 
site is a feature of rejecting allografts (Ascher et al, 
1984). Alternatively, y-interferon production may be 
required to raise the antigen density on target cells to the 
level required for efficient killing (Wong et al, 19 84 ; 
Bukowski and Welsh, 1985). 
Another possibility is that the cyto t oxic activ ity o f 
the cell population has little to do with the rejection 
process. According to this hypothesis tissue damage would 
be indirectly controlled by the T cell. That is, lyrnphok i n e 
production (for example 113, y-interferon) by the class 1 
MHC-reactive T cell activates inflammatory cells which 1n 
turn are the proximate mediators of tissue damage. It 
should be possible to analyze this situation furth e r by the 
use of cloned T cell populations that express cy totoxi c 
activity but have lost the capacity to produce one or mor e 
of the lyrnphokines. 
In conclusion, the studies reported here emphasi ze t he 
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potential for using CsA to discriminate between the dual 
biological activities of class 1 MHC-reactive T cells. The 
data indicates that induction of a local GVHR, and graft 
rejection are both dependent upon the lymphokine release 
function of these cells. The exact nature of this 
lymphokine dependence is unknown. 
Other in vivo functions of class 1 MHC-reactive T cells 
in which the relative contributions of cytotoxicity and 
lymphokine release are unknown include, skin graft rejection 
(Loveland and McKenzie, 1983; LeFrancois and Bevan, 1984), 
tumour graft rejection (Engers et al, 1984; North and 
Bursuker, 1984; Eberlin et al, 1982) and virus elimimination 
(Ada et al, 1981). It is anticipated that CsA will be a 
useful tool in assessing this contribution. 
TABLE 5.1 
A Thy 1+, lyt 2+ cell mediates both IL2 
release and cytotoxicity 
Treatment of IL2 activitya 
cell population (log 10 endpoint titre) 
C' only 2.9 
Anti-Thy1 + C' 0.6 
Anti-lyt2 + C' 0.9 
Cytotoxic activityb 
(log 10cu;10 6 cells) 
6.0 
~4.9 
~4.9 
a Seven day-activated B10.AQR anti-B10.A (anti-Kk) T cells 
were triggered to release IL2 following the procedure 
outlined in section 5.2.4. 
b Cytotoxicity was measured on R1(TL+) (H-2k) target cells 
as described in section 5.2.3. 
TABLE 5.2 
CsA inhibits IL2 release from class 1 MHC-reactive T cells 
Treatment of 
cell populationa 
Untreated 
CsA treatedd 
IL2 activityb Cytotoxic activityc 
(log 10 endpoint titre) (log 10cu/1Q6 cells) 
2.0 
<0.3 
6.15 
6.14 
a Seven day-activated B10.AQR anti B10.A T cells prepared 
as described in section 5.2.2. 
b 5 µg/ml Con A was used to trigger IL2 release from 
activated T cells following the method described in section 
5.2.4. 
c Cytotoxic activity of activated T cells was measured on 
R1(TL+) target cells as described in section 5.2.3. 
d 1 µg/ml CsA included 1n IL2 release assay or cytotoxicity 
assay. 
TABLE 5.3 
T cells recover lymphokine release capacity following Cs A 
exposure 
Cell treatmenta 
0 recovery timeb 
No pretreatment 
CsA pretreatment, CsA in culture 
CsA pretreatment 
3 hour recovery time 
No pretreatment 
CsA pretreatment 
6 hour recovery time 
No pretreatment 
CsA pretreatment 
112 activity 
(Log 10 endpoint titre) 
1 • 5 
~0.3 
~0.3 
1 • 85 
1 • 7 0 
1 • 65 
1 • 6 5 
a Cells used were seven day-activated B10.AQR anti-B10.A 
T cells. 
b Cells were pretreated with 1 µg/ml CsA for 1 hour at 
37°C. The cells were then washed twice in EMEM 
containing 10-4M 2-ME and then resuspended in fresh medium 
containing 3% CS. These cultures were incubated at 370c 
for the indicated recovery time before being washed and 
stimulated with 5 µg/ml Con A as described in section 
5.2.4. 
TABLE 5.4 
CsA Prevents Graft rejection mediated by Class 1-MHC-reactive T 
cells 
Specificity 
of cells 
CBA anti-P815a 
CBA anti-P815 
CBA anti-P815 
CBA anti-P815 
CBA anti-B6 
CBA+anti-B6b 
Treatment Cytotoxic activity 
(C.U./cluster) 
P815 EL4 
None 5.5 ND 
None 6.5 ND 
CsA 5.5 ND 
CsA 6.5 ND 
None <4.7 5.3 
None <. 4. 7 6.4 
Grafts with islet 
tissue/no. grafts 
0/2 
0/2 
3/3 
2/3 
1/4 
4/4 
a Seven day-activated T cells prepared as described 1n 
section 5.2.2. 
b CBA+ indicates that the cells stimulated by B6 spleen 
cells had been filtered through a BALB/c mouse to 
selectively deplete reactivity to BALB/c alloantigens 
(Section 5 . 2 . 11 ) . 
.,_ 
50 0 
0 
LL 
_J 
0 40 ~ 
.,_ 
z 
0 
u 30 
~ 
LU 
> 
0 20 
LU 
V) 
4: 
LU 10 ~ 
u 
z 
~ 
0 10 20 30 
TIME (hrs) 
Figure 5.1. The phenotype of alloreactive T cells 
responsible for footpad swelling. B10.A mice received an 
injection of 5 x 10 7 seven day-activated B10.AQR anti-B10.A 
T ~ells into the left hind footpad. Inoculated cells had 
been either, left untreated ( o), incubated with C' only 
( •), incubated with anti-Thy 1 and C' ( ~) or treated with 
anti-lyt 2 and C'(£). Each point is the mean increase of 2 
animals. 
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Figure 5.2A. The mean% increase in footpad swelling in 3 
B10.A mice (top panel) or 3 B10.AQR mice (lower panel) 
following the injection of 5 x 107 seven day-activated 
B10.AQR anti-B10.A T cells into the left hind footpad. The 
bars represent twice the S.E. 
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Figure 5.2B. The mean% increase in footpad swelling in 3 
B10.A mice following the injection of 5 x 10 7 seven day-
activated B10.AQR anti-B10.A T cells pretreated for 1 hour 
with 1 ~g/ml CsA, into the left hind footpad. The lower 
panel shows the mean% increase in footpad swelling when the 
same cells were injected into CsA treated recipients. The 
vertical bars represent twice the S.E. This experiment was 
performed using the same cell preparation used for Figure 
5.2A. Thus, the curves can be directly compared. 
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Figure 5.3A. Non-fasting blood glucose levels in two 
diabetic ~ice. The broken lines indicate the 95% confidence 
limits for normal blood sugar readings. Arrows indicate the 
time of islet transplantation for each mouse. At day O each 
animal received an inoculum of 5 x 10 7 sensitized CBA anti-
P815 spleen cells. The animal indicated by the symbol ( o), 
is representative of six control animals all of which 
returned to the diabetic state within three days post cell 
transfer. The animal shown by the sumbol ( • ) , is 
representative of six animals which received 75 mg/kg CsA on 
days -1 to 6 post cell transfer. All six animals remained 
normoglycaemic through this period. 
Figure 5.3B. Of the six animals, two were killed for 
histological examination and the remaining four were 
monitored for a further twenty days. The blood glucose 
readings of each animal is shown in this panel. Of the four 
animals two rejected their graft following withdrawal of CsA 
treatment. 
CHAPTER 6 
T CELL DOSE RESPONSE CURVES: 
THE TRIGGERING ACTION OFT CELL MITOGENS 
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6.1 INTRODUCTION 
T cell mitogens such as Con A or NaI0 4 are often used 
to activate large numbers of T cells, either to explore the 
potential responsiveness of a lymphocyte population or to 
prepare lymphokine-rich supernatants. The attitude of the 
immunologist to these agents can be summarized into two 
camps. In the first, lectins and oxidizing agents are seen 
as pharmacological agents which act directly on the T cell 
to initiate events leading to activation (Greaves, 1977) 
The alternative view is that these mitogenic responses 
mimic the requirements of antigenic stimulation by 
rendering the cells themselves recognizably antigenic 
(Kimura and Ersson, 1981). Adopting this latter view leads 
to the hypothesis that analysis of the mechanisms by which 
these agents trigger large numbers of lymphocytes can 
supply important information regarding T cell activation 
and its antigenic and cellular requirements. 
Recent evidence suggests that the second view may be 
correct. A number of similarities between alloantigenic 
and mitogenic responses have been described. Alloantigen, 
lectins and oxidizing agents will only stimulate a response 
if a specialized accessory cell is present in the cultures. 
This cell has the adherent properties of macrophages 
(Greineder and Rosenthal, 1975; Mishell and Miller, 1975; 
Schilling et al, 1976; Rosenstreich et al, 1976; 
Novogrodsky et al, 1977). For each stimulating procedure 
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the accessory cell requirement can be circumvented if a 
soluble factor, IL1, is supplied exogenously (Larsson and 
Coutinho, 1980; Lafferty et al, 1980). These observations 
have given rise to a two signal model whereby T cell 
activation requires both an antigenic/mitogenic signal and 
a signal from a soluble co-factor normally delivered by the 
accessory cell (Lafferty et al, 1980; Larsson and Coutinho 
1980). The identical co-factor requirements for each 
method of stimulation can be explained if it is assumed 
that syngeneic accessory cells are recognizable to T cells 
following lectin binding or mild oxidization in a manner 
which mimics a MHC-disparate cell. 
There is, however, indirect evidence that mitogens do 
act directly on the cell. T cell mitogens can trigger 
lymphokine release from populations of activated T cells 
which do not contain accessory cells (Andrus and Lafferty, 
1981; Ely et al, 1981). This result suggests that lectin 
simply binds to the T cell and initiates an antigen 
equivalent signal. Experiments by Chilson et al (1984) 
have also shown that mitogenic lectins can bind to some 
components of the T cell antigen receptor. This 
interpretation appears at odds with the hypothesis given 
above which suggests that triggering must always involve 
presentation of the mitogen on another cell. It is 
possible however, that mitogen stimulation does involve 
cellular presentation, and in the case of pure T cell 
populations these cells cooperate, with one cell presenting 
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the mitogen to another T cell. In chapter 3 it was found 
that triggering lymphokine release from activated T cells 
is dependent solely upon an antigenic signal. Clearly if 
mitogens act directly on the T cell then the lymphokine 
titre which follows a period of mitogen stimulation will be 
directly related to the T cell number. That is, if 
lymphokine release occurs via the following scheme; 
T + mitogen + 113 
then the relationship between T cell dose and 113 titre 
will be of the following form; 
(113) - kNT ( 6 • 1 ) 
where k represents the mean 113 titre attributable to one 
lymphokine releasing cell, NT is the T cell number and 
(113) is the 113 titre. If the T cells co-operate in the 
following way; 
T + T + mitogen + TT + 113 
m 
(6.2) 
where TT is a mitogen induced T cell conjugate, then a 
m 
higher order relation than that shown by equation 6.1 
will be found. 
In this chapter the cellular requirements for mitogenic 
triggering of lymphokine release is explored by examining T 
cell dose response curves. 
6.4 
6.2 MATERIALS AND METHODS 
6.2.1 Lymphokine release assays 
B6 anti-BALB/c seven day-activated T cells were 
stimulated with mitogens in 200 µl B~EM containing 10- 4 M 2-
ME. Each culture was prepared in wells of a 96 well 
microtitre tray (NUNC) and incubated for 6 hours at 370c 
in an atmosphere of 10% CO 2 ; 7% o2 ; 83% N2 . All assays were 
done in quadruplicate and the supernatant IL3 titre measured 
using the hexosaminidase method to measure the extent of 
proliferation of the FD IL3-dependent cell line (section 
2.12B). 
6.2.2 Periodate treatment of cells 
T cells or UV-irradiated (section 2.7) EL4 tumour cells 
were incubated at 107 cells/ml with 10- 4 M Naro4 in PBS for 
10 min at room temperature. Cells were washed twice in EMEM 
before being resuspended at the required cell concentration. 
6.2.3 Pretreatment of cells or plastic wells with Con A 
UV-irradiated (section 2.7) EL4 and K562 tumour cells 
were suspended at 107 cells/ml in EMEM containing 10- 4 M 2-ME 
and 15 µg/ml Con A and incubated for 15 min at 370c. The 
cells were then washed twice in fresh medium and added to 
the lymphokine release procedure. 
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NUNC plastic 96-well microtitre trays were 
preincubated with 100 µl of Con A solution in PBS for 30 min 
at 370c. The solutions were then flicked off by rapid 
inversion of the plate. Each well was then washed twice 
with 200 µl PBS. 
6.2.4 Estimation of cell binding to plastic wells 
Each well received 104 activated T cells in 100 µl EMEM 
supplemented with 10- 4 M 2-ME. These plates were then 
incubated for 1 hour at 370c. The liquid contents were 
then ejected by rapidly inverting the plate. Each plate then 
underwent three cycles of immersion in PBS followed by 
flicking off the contents. To estimate the level of cell 
binding_ the number of remaining cells was assayed by adding 
the hexosaminidase reagent p-nitrophenol-N-acetyl-S-D-
glucosamine. The method for using this reagent to measure 
cell numbers is described in section 2.12B. The O.D. 
obtained for 10 4 T cells was taken as the 100% figure for a 
percentage binding estimation. 
6.3 RESULTS 
6.3.1 Mitogenic tiggering of lymphokine release from 
activated T cells requires T-T interaction 
6.6 
A linear relationship between T cell dose and lymphokine 
titre is expected for mitogenic triggering if these agents 
act directly upon the T cell to trigger lymphokine release. 
If, however, T-T collaboration is required, extra 
constraints will be placed upon the T cell number and the 
reaction order will be higher than one. 
Figures 6.1 and 6.2 present T cell dose response curves 
generated following stimulation with a range of mitogens. 
For the mitogens Con A, leucoagglutinin and Naro 4 the plot 
of log 10 (113) versus log 10 NT produces a curve with the 
slope of the linear section close to 2. This suggests a 
relation of the following form; 
log 10 (113) - 2 log 10 NT+ log 10 k (6.2) or, 
(113) (6.3) 
These equations suggest that some form of cooperation 
between T cells must occur before lymphokine release can 
take place. A possible mechanism for this 
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cooperation is given by the following reaction scheme; 
k1 
T + T + mitogen - 2Tm 
k2 
where Tis a single T cell, and 2T 1s a mitogen induced T-T 
m 
cell conjugate. Equation (6.3) follows if it is assumed 
that only T-T cell conjugates produce IL3. 
One prediction of this model is that presentation of the 
mitogen on another cell will bypass the requirement for T-T 
interaction and produce a T cell dose response curve similar 
to that observed for antigen stimulation. To test this, EL4 
tumour cells, which are syngeneic and therefore non-
stimulatory, were preincubated with Con A or NaI04 prior to 
being added to the reaction wells at 2.5 x 10 5 cells/well. 
Figures 6.3 and 6.4 show that the linear section of the plot 
of log 10 (IL3) versus log NT changed in slope from 2 to 1. 
Thus, incubation of cells with mitogens renders them similar 
to an antigenic cell. 
6.3.2 Con A presented on a solid substrate 1s non-
stimulatory 
One explanation for the requirement for cellular 
presentation of the lectins is that they bind to the T cell 
receptor and that lymphokine triggering requires receptor 
cross linking which is provided in this case by the surface 
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of another cell. To test this, Con A covalently bound to 
Sepharose was used to trigger 113 release. The T cell dose 
response, shown in Figure 6.5, reveals that 113 triggering 
by this agent only occurs at high T cell doses and that the 
relationship between T cell dose and 113 titre is of an even 
higher order than that obtained for soluble Con A. This 
result is inconsistent with the linear relationship expected 
if the T cells simply bound to and were triggered by this 
mitogen. 
To test whether the inability of surface bound Con A to 
trigger 113 production was due to an inappropriate Con A 
density on the surface of the solid matrix, solutions of Con 
A at varying concentrations were preincubated in the wells 
of 96 well rnicrotitre trays for 1 hour prior to addition of 
activated T cells. To eliminate any effect of "leaking" Con 
A, T cells were added at a concentration which does not 
allow sufficient T cell interaction for detectable 113 
triggering in the presence of soluble Con A, but is 
sufficient for high levels of 113 to be produced when the 
lectin is effectively presented on another cell (104 T 
cells/well, as shown in Figure 6.3). Cell binding was 
determined in control wells which, after incubation with T 
cells, were subjected to a vigorous washing procedure. The 
cells which remained were detected using the colorimetric 
reagent for the cell enzyme hexosaminidase. Figure 6.6 
shows that despite significant cell binding there was no 
evidence that Con A presented in this way could trigger 113 
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release. Thus, if cross-linking is required for lectin 
stimulation it was not reproduced on a solid matrix. 
6.3.3 An MHC-negative cell can present Con A to activated T 
cells 
The MHC-negative human tumour cell K562 was used to 
explore the role of MHC encoded glycoproteins in lectin 
induced lymphokine triggering. An aliquot of 2 x 10s K562 
cells, which had been preincubated with Con A (section 
6.2.3) was added to 10 4 activated T cells. Table 6.1 shows 
that Con A coated K562 triggered equivalent quantities of 
113 compared to the control cell EL4. 
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6.4 DISCUSSION 
The T cell dose response curves presented in Figure 6.1 
and 6.2 indicate that some form of T cell cooperation 
occurs between T cells before lymphokine release is 
triggered. Evidence that these dose response 
characteristics are created by a requirement for cell 
interaction was supplied by adding mitogen pretreated cells 
to the T cells. These cells behaved as though they were 
antigenic, yielding a T cell dose response curve with a 
linear section on a log-log plot with a slope of 1. Thus, 1n 
this region a direct relationship exists between T cell dose 
and 113 titre. This result indicates that the requirement 
for some form of T-T cooperation was not obligatory but 
simply reflects a need for cellular presentation of the 
mitogen. It is interesting also to note the distinction in T 
cell dose response curves generated by 0.5 and 5 µg/ml Con A 
(Figure 6.1). The higher lectin dose will trigger 113 at T 
cell concentrations where the lower dose had fallen off to 
produce a plateau. This result can be explained by 
considering the reversible nature of lectin binding. The 
more T cells (i.e. the more lectin binding sites) present 1n 
the well the less Con A will be bound per cell. Presumably 
with increasing T cell doses a level of bound lectin will be 
reached where the ability to trigger lymphokine release from 
a T cell will be diminished. 
It is also noteworthy that the 113 titre produced 
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following lectin stimulation for a given T cell dose was 
approximately 10-fold higher than that obtained for Naro 4 
stimulation, suggesting that either 10-fold less cells are 
triggered by Naro4 or that this mitogen triggers 113 release 
at a slower rate than lectin stimulation. 
The requirement for cellular cooperation for Naro4 
triggering suggests that cells which are mildly oxidized 
'appear' antigenic to syngeneic T cells. This response may 
be analogous to an alloreaction where small changes in the 
chemical structure of the MHC antigens are capable of being 
recognized by a large number of T cells (Blanden et al, 
1976). This result is consistent with a previous 
observation that y-irradiated Naro 4 treated spleen cells 
could activate a high proportion of syngeneic untreated 
spleen cells (Greineder and Rosenthal, 1975; McLain et al, 
1975). 
The requirement for cellular presentation of lectins is 
more surprising. One possibility is that the lectins bind 
directly to the T cell receptor and that some form of 
receptor cross-linking is required before the antigen signal 
is triggered. This hypothesis is supported by the work of 
Chilson et al (1984) who have provided direct evidence for 
binding of rnitogenic lectins to the T cell receptor. 
In section 6.3.2 no evidence could be found that cross-
linking through a solid support is capable of triggering 113 
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release. The unusual dose response obtained for Con A-
Sepharose stimulation could be explained if Con A is removed 
from the beads at a rate dependent on the T cell number and 
that the soluble Con A and T cells then cooperate to effect 
lymphokine release. These observations are interesting if 
considered in terms of the drug receptor theory used in the 
study of phamacology. Calling the T cell receptor, R, 
yields the following reaction, 
R + Con A 
where Sis the antigen signal, k 1 and k 2 are rate constants 
and k 3 is the intrinsic activity term which indicates the 
efficiency with which the R-Con A complex mediates the 
antigen signal. Three experimental conditions have been used 
which could generate R-Con A complexes on the T cell 
surface; Con A presented in a soluble form, Con A presented 
on the surface of a cell and Con A attached to a solid 
matrix. Only when Con A is bound to a cell is the T cell 
signal generated. Equating Con A with the specific case of 
antigen stimulation suggests that soluble antigen or antigen 
bound to a solid matrix, such as might occur on the tegument 
of a nematode parasite, cannot trigger the T cell antigen 
signal even if they could bind to the receptor. Thus the 
intrinsic activity requirements of signal generation, could 
confine T cell reactivity to cell-associated antigens. 
The above discussion applies only if lectins act by 
binding to the T cell receptor. It is also possible that 
6.13 
they act 1n the manner already suggested for Naro4 and 
alter in some way the cell surface. Thus, triggering by 
lectins would involve 'specific' recognition via the T cell 
receptor and not bridging between receptor and ligand. This 
model has been proposed previously by Kimura and Ersson 
(1981) to account for their finding that all mitogenic and 
no non-mitogenic lectins bind to MHC glycoproteins. However, 
it is difficult to imagine how nearly 100% of all T cells 
could be stimulated by Con A (Chen et al, 1982) if it acted 
simply by altering the antigenic appearance of the cell. It 
seems more likely that Con A triggers the T cell by its 
capacity to non-specifically bind to sugars carried by the T 
cell receptor (Chilson et al, 1984; Kanellopoulis et al, 
1975) and that the observed correlation of mitogenic lectins 
with MHC binding (Kimura and Ersson, 1984) indicates some 
other activation requirement. One possibility is the release 
of I11 from accessory cells in culture. Lafferty has 
suggested that the MHC products on these cells control 
release of I11 from s+ accessory cells (Lafferty et al, 
1983). Thus, for a lectin to be mitogenic for resting T 
cells, which require both antigen and 111 signals (Larsson 
et al, 1979), it must be capable of binding to the T cell 
receptor and to the MHC. If this were true, triggering of 
lyrnphokine release from activated T cells, a reaction which 
has no accessory cell requirement, would not require the 
lectin to bind to the MHC. Evidence in support of this 
hypothesis was presented in section 6.3.3 which showed that 
the human cell line K562, which does not possess detectable 
MHC antigens (Klein et al, 1980) can 
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present Con A in a stimulatory form for lymphokine release. 
A contradiction however, is that mitogenic lectins do not 
trigger I11 release from purified s+ cells (Andrus, 1981). 
This could be explained by assuming that the MHC products on 
the s+ cell must be cross-linked in a manner most 
efficiently performed by the T lymphocyte. 
To summarize this view, lectin stimulation actually 
occurs by a mechanism which is similar to the steps required 
for alloantigen stimulation. In the first reaction, the 
activation step, the resting T cell has its antigen 
receptors cross-linked after contact with lectin coated 
cells (not necessarily s+ cells). Lectin-coated s+ cells 
are triggered through their cell surface MHC to release I11 
following interaction with T lymphocytes. This product 
completes the activation requirements for the lectin 
triggered lymphocytes. The activated T cells then interact 
with other lectin-coated cells in culture (any cell) and are 
triggered to release lymphokines which include I12. The 
activated T cells then proliferate in response to this 
factor. 
TABLE 6.1 
The K562 cell line can stimulate I13 release when coated 
with Con A 
Treatment 
T onlya 
T + Con Ab 
EL4 onlyc 
K562 only 
T + EL4 
T + K562 
T + EL4 + Con A 
T + K562 + Con A 
I13 activity 
(Log 10 endpoint titre) 
<0.3 
~ 0. 3 
~ 0. 3 
~0 .3 
~0.3 
<0 .3 
1.90 + 0.1d 
2.36 ± 0.09 
a) 10 4 seven day-activated B6 anti-BALB/c T cells in 
200 µl EMEM + 10- 4 M 2-ME. Assays performed as described 
1n section 6.2.1. 
b) 5 µg/ml Con A 
C) Each well received 2 x 10s EL4 or K562. 
d) Mean+ 95% confidence interval. 
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Figure 6.1. The T cell dose response curve generated using 
two concentrations of Con A. Seven day-activated B6 anti-
BALB/c T cells (T') were incubated at varying numbers with 5 
or 0 .5 µg/ml Con A. At the end of 6 hours t h e supern atants 
were collected and assayed for 113 activity. Each point is 
the mean plus 95% confidence intervals calculated from four 
replicates. The thin line 1s included as a reference and 
represents a slope of 2 . 
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Figure 6.2. T cell dose response after stimulation with 
leucoagglutinin (LC) or Naro4 . Seven day-activated B6 anti-
BALB/c T cells (T') were incubated with 5 µg/ml 
leucoagglutinin for 6 hours, or were treated with 10- 4 M 
Naro 4 prior to being placed in culture. Each point is the 
mean and 95% confidence interval calculated from four 
replicates. The thin line represents a slope of 2. 
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Figure 6.3. T cell dose response curves. Varying doses of 
seven day-activated T cells were incubated with 5 µg/rnl 
Con A, 2.5 x 10 5 UV-irradiated EL4 or 2.5 x 10s UV-
irradiated EL4 which had been previously incubated for 15 
min with 15 µg/ml Con A (EL4-Con A). Supernatants were 
collected after 6 hours and assayed for 113. Each point is 
the mean± 95% confidence intervals calculated from four 
replicates. The thin lines are included for reference and 
represent slopes of 1 and 2. 
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Figure 6.4. T cell dose response curves. Varying doses of 
activated T cells were incubated with either; 2.5 x 10s UV-
ir.ra<liated EL4 or 2.5 x 10s UV-EL4 which had been treated 
previously with 10- 4 M Naro4 for 10 min (NaI04 -EL4). Also 
shown is the response obtained for NaI0 4-treated T cells 
only. Supernatants were harvested after 6 hours and assayed 
for IL3 activity. Each point is the mean and 95% confidence 
intervals based on four replicates. The thin lines are 
included for reference, and depict slopes of 1 and 2. 
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Figure 6.5. Con A-Sepharose stimulation of lymphokine 
release. Varying numbers of activated T cells were incubated 
with 0.2 mg/ml gel sediment of a commercial preparation of 
Con A-Sepharose (Pharmacia). The IL3 titres obtained after 6 
hours incubation are represented by the open squares. The 
closed circles are the response obtained from incubating the 
same T cell numbers with Con A pretreated EL4 (from figure 
6.3). Each point is the mean and 95% confidence limits 
based on 4 replicates. 
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Figure 6.6. The ability of plastic-bound Con A to trigger 
IL3 release. 104 seven day activated B6 anti-BALB/c T cells 
were incubated for 6 hours in wells of a 96 well microtitre 
tray. In the control wells shown in panel A, T cells were 
incubated either alone, with 5 µg/ml Con A, with 2.5 x 10 5 
UV-irradiated EL4 or with both Con A and EL4. In panel B the 
wells were preincubated for 1 hour at 37°C with the 
concentrations of Con A shown, before 10 4 T cells were added 
and incubated a further 6 hours. The level of T cell 
binding to these Con A coated wells was determined in a 
group of control wells as described in section 6.2.4. 
CHAPTER 7 
A QUANTITATIVE ANALYSIS OF CELL DOSE RESPONSE CURVES 
FOR LYMPHOKINE RELEASE 
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7.1 INTRODUCTION 
In chapter 3 it was concluded from an analysis of T cell 
dose response curves, that the triggering of 113 release 
from activated T cells is dependent solely upon T cell-
target cell interaction. In this chapter a more complete 
examination of the relationship between cell dose and 
lymphokine titre was attempted. It was found that the dose 
response curves of lymphokine titre versus cell number 
(either T cell or antigenic cell) behave in quite complex 
ways which are not readily explained by simple one to one 
binding between the T cell and the target cell. A 
mathematical analysis of this system was attempted by first 
determining what set of basic assumptions about T cell 
responsiveness and in vitro cell interaction can adequately 
account for the observed experimental results. 
Two points were of particular interest. Firstly, whether 
T cell triggering is an all or none response, or a graded 
response. That is, does a single T cell, when triggered, 
release a constant amount of lymphokine characteristic of 
that particular T cell and independent of the strength of 
the triggering signal or, alternatively, is the amount of 
lyrnphokine released by an individual cell dependent on the 
nature of the triggering stimulus. The second point is 
whether or not a single T cell-target cell interaction 1s a 
sufficient stimulus to initiate lymphokine release or 
whether multiple cellular interactions are necessary. The 
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results reported in this chapter are consistent with the 
hypothesis that T cell triggering is an all or none 
event and that binding of at least two antigenic cells to a 
single T cell is necessary to trigger lymphokine production 
in that cell. 
7.3 
7.2 MATERIALS AND METHODS 
7.2.1 113 release assay 
Seven day-activated B6 anti-BALB/c T cells were used in 
all experiments. Suspensions of T cells and of UV-irradiated 
P815 tumour cells were prepared in EMEM containing 10-4M 2-
ME. An aliquot of 100 µl of T cell suspension was mixed with 
100 µl of P815 cells in individual wells of a 96 well 
microtitre culture tray (NUNC) and incubated at 37°c in a 
humidified atmosphere of 10% co2 in air for 5 hours unless 
otherwise indicated. After culture the supernatant was 
removed and stored at -zooc prior to assay for 113 
activity. 
7.2.2113 assay 
Each 113 assay was performed using the FD 113 indicator 
cell line in the assay procedure described in section 2.12B 
7.2.3 51 cr-labelling P815 
Live and UV-irradiated P815 were labelled with 51 cr 
using the procedure described in section 2.13. 
7.4 
7.3 RESULTS 
7.3.1 Experimentally derived cell dose response curves for 
lymphokine release 
In Figure 7.1 the basic relationships between 113 
release and T cell or P815 number are shown. Figure 7.1A is 
the dose response curve obtained by varying P815 cell number 
while holding the total T cell number constant. The 
relationship is linear with an approximate slope of two in 
the region of T cell excess with a plateau in the region 
where T cell and P815 cell numbers are comparable. In Figure 
7.1B the T cell dose response curve is shown for a constant 
P815 cell number. The slope of lyrnphokine titre versus T 
cell number is close to unity throughout the region of 
antigenic cell excess. Figure 7.1C shows the dose response 
curve obtained when both T cell and P815 cell numbers are 
varied together. The slope of the relationship lies between 
two and three over the main region of the graph showing a 
very gradual roll-off at the highest total cell number. 
These simple relationships between cell number and 
lymphokine release effectively delimit the possible 
characteristics of any model of lymphokine release. The fact 
that the relationship between antigenic cell number and 
lyrnphokine titre has a slope greater than unity indicates 
that the order of the reaction between T cells and antigenic 
cells is greater that one, i.e. more than one antigenic cell 
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must bind to the T cell before lymphokine release can be 
triggered. That the slope is approximately equal to two 
suggests that a minimum requirement for triggering of a 
single T cell is the binding of at least two antigenic 
cells. That the slope of 113 titre versus T cell number is 
approximately equal to one indicates that under the specific 
conditions of this experiment there is little or no 
effective cooperation between T cells. The form of the 
relationship in Figure 7.1A, a linear region at low 
antigenic cell number asymptoting to a fixed value in the 
region of antigen excess, is analogous to classical binding 
curves suggesting that as a first approximation T cell-
antigen cell interactions may be treated as simple steady 
state binding reactions. 
7.3.2 A model of T cell-target cell interaction 
A basic model relating T cell and antigenic cell number 
to lymphokine release can now be derived with the use of two 
assumptions. It is assumed that the rate limiting step of 
lymphokine production is the intra-cellular process of 
lymphokine synthesis and release, not the initial inter-
cellular triggering events. That is to say, the processes 
of T cell-antigenic cell recognition, binding and triggering 
are considered to be fast, compared to the time necessary 
for a triggered T cell to manufacture and release detectable 
lymphokine. The second assumption made is that the amount 
of lymphokine released is directly proportional to the 
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number of T cells which have bound to at least two P815. The 
amount of lymphokine produced can therefore be expressed by 
the following equation. 
[LK] ( 1 ) 
2 
where, [LK] is the concentration of lymphokine in the 
supernatant, NTA is the total number of T cells bound to 
2 
two antigenic cells and a is a proportionality constant. 
With these two assumptions the simplest binding model 
which is consistent with the results of Figure 1. is as 
follows. 
K K a 
T + A +---+ TA+ A +---+ TA 2 --+ [LK] 
where, Tis a T cell unbound to any antigenic cells, TA is a 
T cell bound to a single antigenic cell, TA2 is a T cell 
bound to two antigenic cells and a is the proportion of T 
cells bound to two antigen cells which are triggered to 
produce lymphokine. This model predicts that the amount of 
lymphokine released by a given number of T and antigen cells 
can be described by the following equation. 
[LK] - a NTA 
2 
- N I ( 1 + 
T(tot) 
+ (K)2) ~ 
where, NT is the total T cell number per well and N 
(2) 
A 1S 
the number of antigenic cells unbound to any T cell. 
Derivation of this equation is given in Appendix 7.1 
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Figure 7.2A shows the family of curves predicted by the 
steady state binding model relating antigen cell number to 
lymphokine release for different values of total T cell 
number. The main predictions of the model are that the 
linear region of the dose response relationship will have a 
slope of two and that this region of the curve will 
gradually merge in assays at high T cell concentrations. 
The model also predicts that the difference between 
asymptote values of lymphokine production should remain 
directly proportional to the total T cell number per well. 
Figures 7.2B and 7.2C show experimental results with fitted 
curves. There is clearly good agreement between the 
predictions of the theory and the experimental results. 
Figures 7.1B and 7.3 show T cell titration results 
with curves fitted using the steady state binding model. 
The model predicts an initial linear region of slope 
approximately equal to one, a short plateau region and then 
a decline in lymphokine production with increasing T cell 
number. The explanation for the decline of lymphokine 
production at high T cell numbers is that at the highest T 
cell concentrations competition between T cells for binding 
of target cells becomes significant and the number of T 
cells bound to two cells actually falls. 
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The prediction of the steady state binding model for the 
case when T cell and antigen cell numbers are increased 
simultaneously is quite complicated. The model predicts an 
initial region with a slope of three, then a transitional 
region with slope gradually changing from three to one and a 
final region of slope equal to one. The practical 
experimental range is relatively restricted and in this 
region the slope of lymphokine titre versus total cell 
number is less than three and greater than one as is shown 
in Figure 7.1C. 
7.3.3 The antigen dose response curve generated at 
different incubation times 
Figure 7.4 shows the behaviour of the P815 dose 
response curve at a number of different times after the 
initiation of culture. A feature of these curves is that 
the linear section does not alter between 8 and 16 hours 
whereas the plateau section continues to increase. This 
suggests that T cells can only release a certain quantity 
of IL3 before they must be retriggered by another target 
cell interaction. In the linear section, retriggering is 
unlikely as most target cells will have been bound. In 
target cell excess retriggering can occur. This phenomenon 
could be due to the lysis of the target cells following 
contact with T cells. As the target cells were UV-
irradiated it was of interest to test their stability with 
and without added T cells. 
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Figure 7.5 shows that the rate of 51 cr release from 
live and UV-irradiated P815 was similar for approximately 4 
hours. However, by 16 hours most irradiated cells had 
released their radio-label. When incubated with an excess 
of T cells, both live and UV-irradiated P815 released most 
of the available 51 cr within 3 hours. Thus, in the 
lymphokine release cultures with T cells in excess, most 
target cells will have lysed within 3 hours. 
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7.4 DISCUSSION 
The rationale for attempting to mathematically model 
lymphokine production is that it necessarily forces an 
explicit statement of the basic assumptions about events 
occurring at the cellular level. It is possible to explain 
our experimentally derived cell dose response curves using 
two assumptions. The first assumption is that cell 
recognition and binding is a relatively fast process in 
comparison to the overall time course of the experiment and 
that these processes are in equilibrium. The assumption is 
supported by Figure 7.4 which shows that the slope of the 
linear section of the antigen dose response curve is similar 
at 4, 8 or 16 hours. The second assumption is that T cell 
triggering is an all or none process. In terms of the steady 
state binding model this means that T cells which have bound 
only a single antigen cell simply do not receive sufficient 
stimulation to trigger lymphokine release, whereas T cells 
binding two or more antigen cells do receive a threshold 
stimulus which is necessary to trigger lymphokine 
production. In this model there is no partial triggering or 
graded reponse; a T cell can only be triggered or quiescent. 
This is not to say that all triggered T cells produce the 
same amount of lymphokine, simply that further stimulation 
by, for example, the binding of more antigenic cells, does 
not result in an increase in lymphokine production over that 
produced by the threshold amount of stimulation. 
Figure 7.6 shows the predictions of the steady state 
7 • 11 
binding model if it is assumed that some proportion of T 
cells bound to only one antigen cell can also be triggered. 
For curve a. all T cells bound to only one antigenic cell as 
well as those bound to two antigen cells were considered to 
be triggered. The slope of the linear region of the curve 
is now equal to unity. For curve b. only 10% of the T cells 
bound to a single antigen cell were triggered. It 1s clear 
that even in this limited case, where only a small fraction 
of T cells bound to a single target cell are triggered, that 
there is a significant deviation from curve c. the case, 
where only T cells bound to two target cells are triggered. 
The system appears to be quite sensitive to variations 1n 
the threshold for triggering. While it remains obvious that 
a T cell can bind to more than two target cells it appears 
that this is a minimum requirement for triggering in our 
system. 
The finding that the linear region of the dose response 
curve for P815 cells is equal to two is in one sense simply 
fortuitous. Other systems which have been studied have 
slopes closer to unity for antigen cell dose response curves 
(Sinickas et al, submitted for publication; Lafferty 
personal communication). This suggests that in these systems 
the binding of only one antigen cell to the T cell is 
sufficient stimulus to trigger. A simple explanation of 
these observations is possible when triggering is discussed 
at a single cell level. In classical pharmacology the 
7.12 
relationship between receptor, ligand (antigen) and signal 
is given by the scheme: 
R + L s 
k 
2 
k 1 and k 2 determine the affinity of binding while k 3 relates 
the efficiency with which the number of R-L complexes is 
translated into the signal. For lymphokine triggering it is 
assumed that the strength of S must reach a threshold level 
before any reaction occurs. As the T cell can only get 
discrete quantities of ligand depending on the number of 
target cells bound, then the threshold signal level must be 
reached after binding a 'threshold' number of target cells. 
The observation that anti-viral T cells (Sinickas et al, 
submitted for publication) or other alloreactive T cells 
(Lafferty personal communication) reach a target cell 
threshold at one, whereas for B6 anti-BALB/c plus P815 the 
threshold is reached at two, can be explained in one of 
three ways. Either: 
1) the number of receptors per T cell is significantly 
higher in these reactions, 
2) The density or total number of antigenic ligand on the 
target cell is higher, or, 
3) k 3 (efficacy or intrinsic activity) is greater for 
some ligands or some target cells. 
7.13 
It seems unlikely that the T cell receptor number will v ary 
with specificity. Thus, the latter two explanations probably 
account for the differences in triggering systems. 
The modelling approach used is not without limitations. 
The model does not hold over the extreme range of cell 
numbers. At the very highest T cell or P815 cell 
concentrations the amount of lymphokine produced was lower 
than predicted by the model. This may simply be a result of 
some relatively non-specific metabolic effect due to cell 
crowding or it could be due to non-specific binding between 
like cells. For example, at high P815 concentrations if 
there was any significant binding between P815 cells this 
would effectively reduce the number of P815 cells available 
to bind to T cells and result in a concomitant reduction in 
lymphokine titre. It is also true that the assumptions upon 
which the model is based are not the only ones which could 
be used to build a model. As is true of any binding or 
kinetic study, other than the most simple case, a number of 
different models will give predictions which are 
indistinguishable within experimental error. It is to be 
hoped however, that by attempting to quantify the 
relationships controlling lymphokine production a more 
accurate description of the processes occurring at the 
cellular level will ultimately result. 
Figure 7. 1 
A) Antigenic cell dose response curve. Varying numbers 
of UV-irradiated P815 were incubated with 2 x 105 B6 
anti-BALB/c seven day-activated T cells for 5 hours in 
a final volume of 200 µl EMEM containing 10-4M 2-ME. 
Four replicate supernatants for each data point were 
assayed for IL3 activity. 
B) T cell dose response curve. Varying numbers of B6 
anti-BALB/c seven day-activated T cells were incubated 
with 106 UV-irradiated P815 for 5 hours in a final 
volume of 200µ1. Each data point is the mean IL3 
titre of four replicates. 
C) Combined T cell and P815 cell dose response curve. 
Equal numbers of UV-irradiated P815 and B6 anti-BALB/c 
seven day-activated T cells were incubated at different 
total cell numbers in 200 µl medium for 5 hours. 
Data points for these curves were fitted using equation 
A.9 and substituting for: A, K = 5 x 104, tf = 0.6; B, 
K = 105, tf = 0.5; C, K = 105, tf = 0.4. 
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Figure 7.2 
A) Simulated family of antigen dose response curves 
with T cell number equal to 10 5 , 10 4 · 5 , 10 4 · 0 and 
10
3
·
5
, usi ng equation A.9 with K = 8 x 104 and tf = 
0. 5. 
B) Family of experimental P815 dose response curves 
(1). Varying numbers of UV-irradiated P815 were 
incubated with (top curve) 10 4 · 7 , 10 4 · 2 , and (bottom 
curve) 10 3 · 7 , B6 anti-BALB/c activated T cells in a 
fixed volume of 200 µl. The data points were fitted 
using equation A.9 with K = 5 x 10 4 and tf = 0.25. 
C) Family of experimental P815 dose response 
curves (2). 
5 bottom) 10 , 
were K = 9 x 
Same as (B) using T cell numbers (top to 
10 4 · 5 , 10 4 , and 10 3 · 5 . Fitted parameters 
4 10 and tf = 0.75. 
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Figure 7.3. T cell dose response curve. Varying numbers of 
B6 anti-BALB/c seven-day activated T cells were incubated 
with 10 5 · 5 (top curve) or 10 5 UV-irradiated P815 for 5 hours 
1n a final volume of 200 µ 1. Each point lS the mean IL3 
titre of four replicates. The data points were fitted using 
equation A.9 with K = 4 X 10 4 and tf = 0.55. 
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Figure 7.4. P815 dose response curves generated at different 
times. Varying numbers of UV-irradiated P815 were incubated 
with 10 5 B6 anti-BALB/c seven day activated T cells for 2 
( • ) , 4 ( O ) , 8 ( b ) or 16 hours ( • ) . Each point is the 
mean and 95 % confidence interval of IL3 titres determined 
from four replicates. 
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Figure 7.5. 51 cr release from UV-irradiated P815. 2 x 10 4 
live (open symbols) or UV-irradiated (closed symbols) P815 
were incubated either alone (squares) or with 105 seven 
day-activated B6 anti-BALB/c T cells in 200 µl. At various 
times supernatants were removed from triplicate cultures and 
the level of T-irradiation measured. 100% release was 
measured from distilled water treated target cells obtained 
after a four hour incubation. 
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Figure 7.6. Simulated antigenic cell dose response curve 
with T cell number equal to 10 5 , K = 8 x 10 4 , and tf = 0.5. 
Curve (a) represents the situation if T cells release IL3 
following binding to 1 or 2 target cells. Curve (b) is 
obtained if 10% of reactive T cells are triggered following 
binding to 1 target cell and the other 90% are triggered by 
binding to 2 targets. Curve (c) is generated if all T cells 
must bind 2 target cells to trigger IL3 release. 
APPENDIX 7. 1 
For the following binding reaction, 
kl 
T+A+-- TA+ A 
assuming that binding between cells is in equilibrium, 
then; 
dt 
dt 
Rearranging A.2 gives; 
2K 
7. 14 
(A. 1) 
(A. 2) 
(A. 3) 
Rearranging A.1 and substituting into equation A.3 gives; 
(A. 4) 
7. 1 5 
Since it is expected that the total number of T cells and 
antigenic cells will remain constant during the initial 
binding and triggering period the following relationships 
will also hold true; 
+ + 2NTA 
2 
N 
T(tot) 
N 
A(tot) 
(A. 5) 
(A. 6) 
where, NT is the total number of T cells per well and 
(tot) 
N is the total number of antigenic cells per well. 
A(tot) 
Substituting equations (A.3) and (A.4) into (A.5) 
gives, 
2K 
N I 
T(tot) 
( 1 + + ) . (A. 7) 
Combining equations (A.3), (A.4), (A.5) and (A.6) gives, 
(2K (NTA - NT ) - K2 ) NTA 
2 (tot) 2 (A. 8) • 
2KNTA - ( 2NTA - NA )(NTA - NT ) 
2 2 (tot) 2 (tot) 
-7. 1 6 
Substituting equation (A.8) into (A.6) and reducing gives; 
4N • ( N ) 2 - ( K 2 + 4 ( N ) 2 + 4 KN T + 
T ( tot ) TA 2 T ( tot) ( tot ) 
2KN 
A(tot) + (NA ) 2 ) • N TA + (tot) 2 
(NA )2 • NT - 0. 
(tot) (tot) 
(A. 9) 
To evaluate NTA it is necessary to solve the quadratic 
2 
equation A.9. 
To fit the data points it was necessary to take account 
of the fact that not all of the T cells were primed against 
the P815 antigen cell. This was achieved by scaling the 
number of T cells per well by a constant factor 'tf' which 
was taken to be the proportion of T cells primed against 
the antigen cell P815. The effective number of T cells per 
well is then given by, 
(A. 1 0) 
The other free parameters for fitting were K, the 
apparent dissociation constant and a the scale factor for 
the average amount of lymphokine released per T cell. 
CHAPTER 8 
GENERAL DISCUSSION AND CONCLUSIONS 
8. 1 
In this final chapter I propose to discuss some of the more 
general implications of the work already described. 
A 'universal' T cell assay 
A variety of procedures and signals have been found 
to influence lymphokine release. Early work with primary 
bulk cultures found that release of lymphokines from T cells 
required accessory cells or 111 and that peak titres 
occurred after approximately 16 hours in culture (Andersson 
et al, 1979; Thoman and Weigle, 1980; Swain and Dutton, 
1980). Work with 112-dependent T cells or T cell hybridomas 
have revealed a different pattern usually release 1s non -
111 dependent and peak titres occur within 10 hours (Ely et 
al, 1981; Kelso et al, 1982; Prystowsky et al, 1982; Kelso 
and Glasebrook, 1984; Andrus et al, 1984). Shimonkevitz et 
al (1983) showed that release of 112 from an ovalbumin-
specific T cell hybridoma required an accessory cell, 
however, the function of this cell was solely to present 
antigen since fixation with glutaraldehyde did not inhibit 
the stimulating function of the cell. Class 2 MHC-bearing 
'accessory cells' are an obvious requirement for class 2-MHC 
resticted T cell responses. The different requirements for 
triggering lymphokine release from resting and activated T 
cells could simply be due to the need for activation of the 
resting cell, with subsequent lymphokine triggering being 
mediated by the same reaction as occurs for 112 dependent-T 
cells. This would explain the requirement for 111 and the 
longer time required to achieve maximal lyrnphokine release. 
8.2 
As there are many different lymphokines with diverse 
functions it is clear that the role a T cell will play 1n an 
immune reaction is to a large degree determined by the 
lymphokines it will produce. An important question then is 
what controls the release of lymphokines and what influences 
the type made by a particular cell. 
In chapter 3 a study of the reproducibility, dose 
response, and time course behaviour of both IL2 and IL3 
release from in vitro activated T cells reached the 
following conclusions: the release of both lymphokines 1s 
linked, exposure to antigen alone is a sufficient stimulus 
to induce the release of both lymphokines and the triggering 
process requires synthesis of lymphokine-encoding mRNA. 
Kelso and Glasebrook (1984) examined the behaviour of a 
large number of T cell clones and found that most cells 
release some lymphokine activity although the amount and the 
range produced by a given cell is unpredictable. Individual 
clones, however, make the same lymphokines in approximately 
equivalent amounts after each antigen exposure. A general 
conclusion from this work and the work described in chapter 
3 is that activated T cells have a 'repertoire' of 
lymphokines whose release is dependent on the antigen 
signal. Each individual cell has a characteristic 
repertoire but the signal which controls the release of 
lymphokines is common to all T cells. This implies that 
measurement of lymphokine release can be related to 
triggering of the antigen signal and that the release 
characteristics of a single lymphokine will be 
representative of the entire lymphokine repertoire. 
8.3 
This discussion illustates the rationale for the use, in 
this thesis, of a single lymphokine release assay (113 
release) to draw general conclusions about the T cell 
antigen signal. 
Other experimental procedures have shown an effect of 
non-antigen signals on lymphokine release. Howard et al 
(1983) and Inaba et al (1983) found that release of B cell 
stimulating lymphokines could be induced from an activated T 
cell by 112. Kelso et al (1984) have also reported that 112 
can enhance the rate of MAF release from T cell clones. 
These results suggest that not all lymphokine release is 
antigen controlled or that alternative pathways may exist 
for triggering. For the study of the antigen signal, it is 
useful to define conditions whereby this signal is the sole 
requirement for triggering lymphokine release. As a general 
rule, two necessary and sufficient conditions are: (i) non -
cooperation between T cells (which can be simply achieved by 
showing that the T cell dose response curve is first order) 
and (ii) the use of target cells incapable of contributing 
to the reaction. 
The behaviour of lymphokine releasing cells in relation 
to cell dose and time were examined in chapter 7 and were 
found to be complex. However, the complexity could be 
explained by assuming that triggering of lymphokine release 
8.4 
was an all or none event. Analysis of antigen dose response 
curves obtained at different times after antigen exposure 
also suggested that T cells recycle and require new target 
cells after about 5 hours. This is probably due to the 
killing of target cells following T cell interaction. Thus, 
dose response curves determined within 5 hours of antigen 
exposure can be interpreted as being simply a function of 
the number of triggered T cells. Two immediate applications 
of this conclusion are suggested. First, in a heterogeneous 
population of T cells it is possible to calculate the 
proportion of cells reactive to different target cells by 
directly comparing the titre obtained in target cell excess. 
For example, the linear section of figures 6.3 and 6.4 are 
produced in target cell excess and can be interpreted as 
showing that 100-fold more T cells are triggered by Con A 
than by Naro4 . Conversely a cloned T cell population could 
be used to detect the number of antigenic cells in separate 
heterogeneous populations of target cells. They could also 
be used to examine the parameters which control the 
effectiveness of target cell-T cell interaction, i.e. why do 
some T cells require two target cells and others one before 
lymphokine triggering is started? 
A number of steps can be defined which would allow the 
application of these quantitative methods to the detection 
of any lymphokine releasing T cell. These include: 
8.5 
1) Choice of a lymphokine whose activity is relevant to 
the reaction of interest, 
2) Choice of triggering conditions whereby 
lymphokine release is solely antigen dependent, 
3) Use of assay conditions whereby the background 
release of lymphokine is negligible. For in vivo 
generated cells this may require a short in vitro 
culture (For example if cells were triggered to 
release lymphokine just prior to cell preparation, 
then incubation of the cells for a few hours at a 
high dilution, to prevent further cell interaction, 
would reduce this release). 
An assay with these characteristics would then be subject 
to the rules of quantitation established with experimental 
model systems. Such an assay could therefore be used to 
estimate activated T cell numbers, measure antigen 
specificity and also the antigen triggering 'efficacy' of 
different target cells. 
The importance of CsA as an immunological tool 
Lyrnphokine release was used to study the immuno-
suppressive properties of the drug CsA. This work found that 
CsA acts selectively and reversibly on the lymphokine 
release reaction at a site after antigen binding and before 
transcription of lymphokine encoding mRNA. CsA does not 
affect other T cell activities such as cytotoxicity and 112 
dependent proliferation. This specific site of action 
offers a wide range of potential uses in dissecting the role 
8.6 
of the antigen signal in immune reactions. Using this drug 
the antigen signal was shown to be required continuously to 
maintain lymphokine release from the cell. When added at 
any time after antigen stimulation, the rate of lymphokine 
release remained steady for two hours and then rapidly 
decreased. This finding suggests that the lymphokine 
release machinery must continually receive antigen signals 
in order to to operate. 
CsA is non-toxic for cells and appears to selectively 
act on lymphocytes. These properties allow its use in vivo 
to examine signal-dependent T cell reactions. One such 
study was described in chapter 5. The finding that acute 
rejection of pancreatic islet grafts by lyt 2+ T cells is 
lymphokine dependent, is perhaps surprising and emphasises 
the importance of analysing reactions in vivo rather than 
simply assuming a function from in vitro analysis. 
Identifying which particular lymphokines are important for 
this reaction can be approached using the technique of 
incorporating T cell clones along with the graft (in the 
manner seven day-activated T cells were used in chapter 5). 
As clones release a distinct repertoire of lymphokines, 
different cells could be selected for the release of 
different activities and tested for there ability to reject 
tissue allografts. Other T cell dependent reactions which 
could be analysed using this drug include: the role of the 
antigen signal in maintaining T cell memory and the relative 
contribution of lymphokine release (CsA sensitive) and 
8.7 
cognate signalling (which is unlikely to be CsA sensitive) 
in T-B cell collaboration in immunoglobulin class switching. 
The T cell antigen signal 
The lymphocyte antigen signal must be triggered before 
an adaptive immune response can be generated. Clearly the 
triggering characteristics of this signal will play an 
important role in the development of immunity. In this 
thesis a number of new methods were employed to explore the 
T cell antigen signal. 
An antigen signalling mechanism is comprised of at least 
two separate reaction steps. These can be represented by 
receptor binding and by the ability of the bound antigen to 
trigger the signal. A suggested term for the property of the 
antigen which allows it to confer the second reaction 1s the 
intrinsic activity (section 1 .12). The importance of the 
intrinsic activity in T cell receptor triggering was shown 
by experiments described in chapter 6 where it was found 
that the T cell mitogenic lectin Con A will not trigger the 
antigen signal unless bound to another cell. This occured 
despite the observation of Chilson et al (1984) that this 
mitogen will bind to the T cell receptor. 
In chapter 7 the conclusion was reached that the antigen 
signal is all or none, while in chapter 4 CsA treatment 
revealed that the signal must be transferred continuously to 
8.8 
maintain a cell in the lymphokine release 'mode'. In 
summary, the findings which relate to the characteristics of 
the T cell antigen signal are: 
1) the signal is all or none, 
2) triggering depends on the physical properties of the 
antigen, and 
3) the signal must be continuously maintained to trigger 
the release of a fixed set of lymphokine activities. 
Such a fixed behaviour pattern is reminiscent of B 
lymphocytes which will only produce one immunoglobulin 
isotype at any time. Together these observations suggest a 
modification to the clonal selection theory which would make 
a provision for describing and predicting the development of 
a particular class of immune response. The original rule 
"one cell, one specificity" (Burnet, 1957) could be changed 
to read: 
One cell, one specificity, one triggering mechanism and 
one pattern of effector activity. 
According to this rule immune response heterogeneity 
would be set by the prior programming status of the 
lymphocytes involved. For T lymphocytes this heterogeneity 
will be determined by the lymphokine repertoire. In 
discussing the application of the cellular paradigm to the 
problem of response heterogeneity (chapter 1) the importance 
of 3 mechanisms for the generation of lymphocyte diversity 
were described. It is interesting to reiterate them here 
8.9 
using the T cell lymphokine repertoire as the specific 
example of lymphocyte heterogeneity. Writing the T cell 
activation reaction in the manner of Lafferty et al (1983) 
yields; 
T(x) + s X 
1 
-+ 
where T(x)is an antigen reactive T cell, Sx is the antigen 
bearings+ cell, T' is the activated T cell, 1 is the 
antigen signal, 2 represents the second or costimulation 
signal and z represents the lymphokine repertoire. It can be 
seen that a different T cell response could be selected by 
antigen if clonally distributed T cells existed which 
possessed different triggering mechanisms (and consequently 
perceived intrinsic differences between antigen classes). 
The resulting activated T cell population could then express 
different "z". Alternatively the selected T cell could 
express a different response because a history of prior 
activation events has led to an altered program (assuming 
that activated T cells return to the resting state). Another 
area of potential heterogeneity would be the nature of the 
second signal. Although IL1 is the best known costirnulator 
there is no evidence to suggest it is the only one. There 
are a number of cell types which can act ass+ cells such as 
splenic dendritic cells (Witmer and Steinman, 1978; Steinman 
et al, 1983) epidermal Langerhans cells (Stingl et al, 1978) 
and macrophages from different sites (Minami et al, 1980; 
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Sunshine et al, 1982). Information regarding the site of 
antigen exposure could be transferred to the T cell through 
tissue specific accessory cell costimulators. This 
mechanism could also pattern responses to different antigen 
classes. Assuming that manifold accessory cells possess 
different antigen processing capabilities (depending, for 
example, on the physical properties of the antigen or on 
associated opsonins) the information could be transferred to 
the T cell by accessory cell-specific costimulators. 
According to this view, T cells express a number of 
different potential 'second signal receptors' following 
antigen exposure. Costimulation through different receptors 
ultimately affects the lymphokine repertoire of the 
activated T cell. Another means by which information about 
site of antigen exposure could be mediated is via 
environmental or site-specific hormones and/or by resident 
cell types capable of initiating non-antigen signals to the 
cell. Either mechanism could alter the T cell program. 
In the introduction to this thesis it was observed that 
different response patterns probably evolved to counter 
different classes of infectious disease or antigen 
challenge. Although undoubtedly useful to the survival of 
the species, the heterogeneity in response is a problem for 
the design of new vaccines. For example, a vaccine may 
present viral antigen in a form which stimulates an immune 
response more appropriate for eliminating a soluble protein 
than fighting a viral infection. The ability to control the 
8 . 11 
class of immune response is an important component of the 
"central problem" assigned to immunologists (see section 
1 .1). One step towards the solution of any problem is to 
define it in a solvable form and to develop procedures 
suitable for its analysis. The lymphokine release assay, 
described in the previous section, should prove useful for 
examining the lymphokine repertoire generated by T cells 
from different sites and following stimulation with 
different s+ cells or costimulators. This assay also has the 
ability to detect the intrinsic activity requirements for 
antigen signalling of T cells activated following a 
particular priming protocol. A projected technical problem 
is that T cells isolated from peripheral lymphoid organs 
represent a diverse collection of different programs due to 
their different histories of stimulation. To counter this 
problem it would be necessary to work with 'virgin' 
lymphocytes. Possible sources of these cells would be the 
thymus or foetal lymphoid tissue. 
8.13 
A THEORETICAL APPENDIX 
This appendix is included in support of a deductive 
method of describing immune phenomena and to illustrate how 
quantitative arguments can be found to explain so called 
helper effects in in vitro T cell culture. 
A note on method 
The immune response in some sense can be viewed as a 
semi-autonomous organism. The different receptor and 
programmed response properties of its cellular components 
confer on this 'organism' a number of potential behaviour 
patterns. The stochastic nature of cellular interaction 1n 
vivo and the influence of the structured lymphoid organs on 
the ability of cells to interact and signal one another 
will probably ensure that no accurate quantitative theory 
will soon be provided which could be used to predict the 
speed and level of an immune response. However, the 
observed response of isolated immune cell types to various 
signals can be used as the foundation for the application of 
a deductive scientific method to predict the qualitative 
outcome of an immune response. Evidence for this assertion 
is the work of Lafferty, et al (1983) who showed that from a 
small number of fundamental empirical observations a number 
of properties of graft rejection can be predicted. A further 
example is supplied by Bevan and Matzinger (1977) who showed 
that the empirically derived rules of T cell specificity can 
be adapted to predict the very high proportion of cells 
reactive to foreign MHC. 
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Ideally this scientific method of deducing complex behaviour 
from the fundamental properties of the constitutive cells 
could be formalized. The consistent application of this 
method would yield a deductive theory (expressed in terms of 
elements and rules governing their behaviour) which would 
(hopefully) define the parameters involved in stimulation of 
all classes of immune response. 
When applying this method, if a deduced behaviour is 
found not to correspond to the observed in vivo behaviour, 
one of two problems would be indicated. Either, some premise 
of the theory is incorrect or an element not accounted for 
in the theory is exerting some influence. Unfortunately for 
cellular immunology, the latter explanation is usually 
chosen and takes the form of a new cell type with just the 
right properties to balance the phenomenon with the original 
theory (for example, a suppressor T cell). Any science has 
as its domain, elements for description. The complexity of 
any theory developed within that domain will be an 
exponential function of the number of elements it seeks to 
describe. As cells are a prominent part of an immunologists 
work, new ones should only be postulated when all other 
avenues of explanation are exhausted. Another problem with 
assuming new elements for description is the increasing 
difficulty for any theory to be predictive. When considering 
a theory to predict the qualitative behaviour of an immune 
response it 1s not necessary to admit supposed cell types 
which modulate or alter the quantitative outcome of a 
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reaction. In fact, when considering lymphocytes it should 
not be necessary to assume many more lymphocytes than there 
are classes of adaptive immune reaction. 
Steps toward a deductive theory of immunology 
The Lafferty theory depends upon two postulates. The 
first is a statement of a number of experimental 
characteristics of T cell activation. That is: two signals 
antigen and costimulator (CoS), are required for initiation 
of T cell activation. This is expressed: 
T 
1 
2 T' 
where Tis the resting T cell, T' the activated T cell and 1 
and 2 represent the antigen and costimulation signals 
respectively. A corollary of this postulate is that a cell 
capable of providing Cos (ans+ cell) is required for T cell 
activation. 
The second postulate is that a control structure on the 
s+ cell surface regulates the release of Cos activity. 
Although there is no direct evidence for this postulate, it 
can be seen as a r e asonable assumption based on a number o f 
experimental findings. They are; 1) thats+ cells do no t 
constitutively produce Cos, 2) that CoS is found in the 
supernatant following interaction of T cells with antigenic 
s+ cells and 3) that some mitogens can stimulate the release 
of Cos from s+ cells. 
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From these two simple rules Lafferty _et al {1983) show that 
the control stucture of Cos release will behave precisely 
like the MHC of the species. 
This theory however, makes no provision for a 
distinction between the activation of class 1 and class 2 
restricted T cells. Thus, it cannot explain the findings of 
Ertl (1981) regarding the development of class 1 restricted 
T cell reponses to viruses {described in section, 1.8). 
When the empirical conclusion derived from the work with the 
response to different viruses is included in the formulation 
of Lafferty a theory results which is more generally 
applicable than that of Lafferty. 
The conclusion to be drawn from examination of T cell 
responses to viruses is that a class 1 MHC-restricted T cell 
response cannot be generated unless the antigen has some 
mechanism for incorporation into a cell membrane. The 
sentiment expressed in this experimental observation will be 
referred to as the "law of class distinction". 
The requirement for ans+ cell to present t he antigen 
to effect T cell activation allows the law of class 
distinction and the Lafferty theory to be combined i n the 
following way. 
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Postulate A: Antigens which form part of the s+ cell surface 
will generate class 1 MHC restricted responses following 
interaction with a receptive T cell repertoire. i.e. 
1 
---+ 
2 T(Ky) 
where y represents the antigen while its position -
superscripted in front of the S cell - indicates that it 1s 
an integral part of the cell surface, T indicates the T cell 
population. The subscripted brackets r e present the T cell 
receptor and the enclosed 2-letter expression gives the 
specificity. In this case "K" represents the class 1 MHC 
antigens. This process will be referred to as passive 
presentation of antigen. 
Postulate B: Antigens which cannot become part of the 
cell membrane must be actively processed by the s+ 
cell. Antigens presented in this way will stimulate class 2 
restricted T cell responses. The processing step can be 
expressed: 
s + y ~ s , y 
and the reaction referred to as active processing. The 
distinction between active and passive a n tige ns is give n by 
the position of the antigen symbol 
The reaction with T cells 1s written: 
S + T 
y 
T' 
( Iy) 
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where I represents the class 2 MHC antigens. 
These reactions encapsulate the law of class distinction 
into the Lafferty theory. Most of the predictions made by 
Lafferty which relate to alloreactivity and the rejection of 
grafts still apply although the modification does differ in 
some details regarding grafts which differ at minor 
histocompatibiltiy antigens. These differences are currently 
being tested and will not be discussed here. From the 
discussion so far a number of conclusions can be deduced. 
One implication of these reactions 1s that to produce a 
class 1 restricted T cell response to a virus then a 
stimulating cell must be infected (unless it is enveloped 
and can fuse with the s+ cell membrane). Viral antigen 
products produced in other cell types or introduced as a 
killed vaccine or purified protein product must be processed 
and hence will generate a class 2 MHC restricted T cell 
response but no class 1 response. As class 1 MHC antigens 
are expressed on all cells then the response restricted by 
this antigen is likely to be the most effective in 
eliminating viruses. This has in fact been demonstrated for 
immunity to influenza virus (Leung and Ada, 1982). Clearly, 
if a virus were to always kill or compromise in some way the 
s+ cell, then a class 1 resticted response would be 
impossible. In this case class 2 restricted responses would 
occur as these do not require the cell to be infected. The 
immune response to the herpes group of viruses displays 
these characteristics. Class 1 MHC restricted T cells are 
very difficult to demonstrate following infection with these 
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viruses despite the fact that virus specific antibody is 
detected (Pfizenmaier et al, 1977). Whether this 
characteristic is due to the mechanism provided above 1s 
amenable to experiment. 
The theory also encompasses alloreactivity following a 
similar argument to that used by Matzinger and Bevan (1977). 
The T cell specificity repertoire is normally randomly 
expressed and tolerant of self antigens. This tolerance must 
include all 'processed' self products (assuming for the 
moment that processing is indiscriminate) as well as 
antigenic components of the cell membrane. The 'rules' of T 
cell specificity (deduced from this theory because MHC must 
be involved in antigen recognition before the T cell can 
receive the second activation signal) can be stated; 
The interaction antigen (My) t (M 1y) 1.e. Restriction 
The interaction antigen (My) t (My 1 ) i.e. Specificity 
M represents the restricting MHC allele and y represents 
the antigen. The "l'' subscript distinguishes different 
allelic forms. 
Considering the case of passive presentation of antigen 
bys+ cells, an alteration in K, the class 1 MHC antigen, 
will mean that all normal and self cell surface products 
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will by rule 1 above (restriction), appear foreign to the T 
cell repertoire. It is not known how many different non-MHC 
antigens appear on a cell surface but it is probably over 
one hundred. This figure represents the proportional 
increase of new antigens created by changing a single MHC 
allele compared to the incorporation of a new foreign 
antigen into the cell surface membrane. 
be expressed as: 
1 
2 
This reaction can 
In these reactions the Kand Kl superscripts are used to 
distinguish cells carrying separate class one MHC alleles. 
The symbol yin this reaction represents all cell surface 
molecules and is therefore made up of individual molecules 
y 1 , y 2 , y 3 ... yn' where n is the number of different 
cell surface molecules. Clearly, incorporation of a single 
new molecule such as might occur following a virus 
infection, will provide 'n'-fold less new antigens than will 
the alteration of the class 1 MHC antigen. 
A similar argument can be used to explain Class 2 MHC 
alloreactivity. In the case where a new class 2 antigen 1s 
included in the stimulating cell then all processed 
molecules, self or not, will appear foreign. Once again the 
number of reactive T cells will be a function of the number 
of molecules potentially processed by the s+ cell. This 
number will again be the factor by which a class 2 MHC 
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allogeneic s+ cell will be stimulatory over the processing 
of one foreign antigen. These conclusions depend on the 
assumption that antigen processing cells process 
indiscriminately any protein. It is difficult to imagine how 
alternative options such as selective processing only of 
foreign antigen could be mediated by a phagocyte without the 
power of discrimation borne by the entire lymphocyte 
repertoire. As the question of how antigen presenting cells 
select antigen for processing is still an open one, the 
above theory of class 2 alloreactivity remains. 
Thus, by this theory, alloreactivity can be shown to be 
a direct consequence of T cell stimulation by two classes of 
antigen. This theory also explains why allogeneic cells 
reactive to class 1 MHC antigens express the lyt 2 antigen 
typical of class 1-MHC restricted T cells (by this theory 
they are class 1 MHC-restricted T cells) whereas class 2 MHC 
alloreactive T cells display the cell surface phenotype of T 
cells restricted by the same antigen. 
Precisely the same mechanism can be invoked to explain 
the large number of T cells responsive to oxidized 
(Novogrodsky and Katchalski 1971) or haptenated cells 
(Shearer 1974). Chemical treatment of the MHC would be 
(immunologically) equivalent to a foreign MHC allele, and 
induce both class 1 and class 2 'alloreactions'. This 
prediction is borne out by the finding in chapter 6 that 
Naro4 does not act directly on the T cell but that cells 
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must interact to detect the alterations on the cell surface. 
The fact that the alloreactive T cells used for analysis of 
mitogen behaviour recognize oxidized cells could be due to 
cross-reactivity of a number of interaction antigens. That 
is, foreign MHC and some minor histocompatibility antigen 
would cross-react with oxidized MHC and a minor antigen (not 
necessarily the same antigen). This redundancy in 
allospecificity runs counter to the observation that 
cytotoxic T cells are sensitive to small antigenic changes. 
However, the large number of antigens predicted for cells 
carrying altered MHC provides a much greater chance of cross 
reactivity for a given restricted T cell with a particular 
alloantigen. Hunig and Bevan (1982) have demonstrated that a 
d T cell clone reactive to H-2 plus a BALB/c minor antigen 
will also recognize a cell carrying H-2kand a different 
BALB/c background antigen. 
The method by which lectins fit into this scheme has 
already been discussed (section 6.4). 
Quality versus quantity 1n interpeting data 
The addition of two more empirical rules leads to a 
number of important observations relating to lymphocyte 
behaviour in vitro. These two rules are: 
That antigen alone triggers lymphokine release 
(including IL2). 1.e. 
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T' l • IL2 
That activated T cells proliferate in response to IL2. 
1.e. 
T' + IL2 ---+ nT' 
The set of reactions we have do not allow any 
quantitative statements to be made of the reaction 1n vivo. 
However, when the cells are isolated and devoid of structure 
they will behave in a fashion dependent on the interactive 
behaviour of the individual components. 
The model predicts a number of reactions which will take 
place in an MLR. For instance in an MLR between strains 
differing at a class 1 MHC allele only, the following 
reactions apply: 
(1) Release of CoS: 
(2) Antigen signalling of T cells: 
y K + y K1 p T 
-
cos 
Tl/2 
(Ky) 
where pis an antigen bearing cell (not necessarily ans+ 
cell-type but including them) and T 1/ 2 is an antigen 
triggered T cell before costimulation. 
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( 3 ) Activation: 
Tl/2 + cos • T(Ky) (Ky) 
( 4 ) IL2 release: 
T(Ky) + yp 
K IL2 -+ 
( 5 ) Proliferation: 
T(Ky) + IL2 ---+ nT' 
( 6) reactions 4 and 5 repeated. 
I have no formal model of this reaction as many of the 
putative steps have no experimentally defined dose response 
function, however, it is interesting to observe the 
behaviour of this reaction assuming the simplest possible 
model, that is, all antigen requirements are fulfilled for 
each step and that linear relationships apply at each dose 
response. In this case, consider the distinction between a 
minor histocompatibility antigen versus a major antigen 
disparity between the two cultured cell types. This theory 
has already shown how many more cells will be reactive to 
the maJor antigen. Taking the conservative estimate that 10-
fold less T cells recognize the minor antigen leads to the 
following deduction. 
Reaction 1. Release of CoS; 10-fold less T cells will 
trigger the release of 10-fold less Cos. 
Reaction 2. Antigen signalling. I have assumed all 
antigen components are fulfilled therefore, 10 fold less 
112 · 11 f . h . . T wi orm in response tote minor antigen. 
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Reaction 3. Activation. In the culture with the minor 
difference 1/10 the Cos concentration with 1/10 the T 
cell number yields 1/100 the number of T' compared to the 
culture with the major difference. 
Reaction 4. IL2 release. Again antigen requirements are 
fulfilled, therefore the difference in the IL2 
concentration between the two cultures will be one 
hundred fold. 
Reaction 5. Proliferation 1/100 the [IL2] plus 1/100 the 
number of T' generates 1/10000 the number of T' in the 
minor culture compared to the major. 
Already this is a massive difference, if we took another IL2 
release and proliferation step into account the figure would 
become; 1/10 000 the T' plus 1/10 000 the IL2 concentration 
gives 1/108 difference in the number of T'. All this 
results from a 10-fold difference in starting concentration 
of reactive T cells and assuming the simple linear relation 
at each step and perfect antigen stimualtion. Quite 
obviously the actual functions are not straight lines, 
however the point 1s made that the number of reactions 
involved multiply differences profoundly at each step. This 
quantitative argument can account for the observation that 
reactions to minor angtigens and other antigens are much 
weaker in vitro than those which occur in a MLR. The above 
argument holds equally for active and passive antigens. 
Although when both occur in the culture it is interesting to 
note the possible cooperative effects which can occur due to 
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the fact that no distinction has been made concerning the 
action of the soluble mediators IL2 and Cos. 
In an MLR for instance between cells bearing both class 
1 and class 2 differences adopting a protocol similar to 
that described by Cantor and Boyse (1975) treating with anti 
ly 1 and C' (assuming this is a marker for class 2 MHC 
reactive T cells) effectively halves the number of reactive 
cells in culture. Therefore when assaying cytotoxic cell 
generation {assuming the targets are only Class 1 MHC 
positive) produces a 25-fold decrease in T' number or a 1/32 
reduction in the number of 'cytotoxic' cells. Such a 
dramatic effect would conventionally be used to argue for 
the existence of a helper cell type obligatory for 
generation of cytotoxic cells. Clearly, however, assuming no 
more than 2 classes of T cell with different phenotype can 
explain very large in vitro helper effects without assuming 
any qualitative change to the behaviour of the constituent 
cell population*. 
The complexity of these 1n vitro reactions . lS, 1n fact, 
almost certainly greater than I have indicated here. 
Consider for example reaction 3, IL2 release. This is the 
reaction studied in chapters 3 and 7 of this thesis. In 
* It is interesting to note that in the paper by Cantor 
and Boyse which showed T-T cooperation the authors make no 
claim for obligatory help. They found that treatment with 
anti-ly 1 and C' reduced the cytotoxic response only if they 
did not reconstitute viable cell numbers. Reconstitution 
following antisera treatment resulted in a 2-fold increase 
in the number of cytotoxic T cells. The concept of 
obligatory T-T help appears to have come later with the 
erroneous concept that only ly 1+ T cells can produce IL2. 
8.27 
chapter 7 it was demonstrated that, depending on the T cell 
number and the antigen cell dose, an increase 1n T cell 
number could produce more, less, or the same amount of IL2. 
This occurs because of the requirement for the binding of 2 
target cells. Incorporating this into the above argument, 
it is clear that the effect of changing any cell number in 
an in vitro T cell culture can have profound influences 
either positive or negative. Most importantly, changes in 
the outcome of a reaction due to changes to cell populations 
are not necessarily due to qualitative changes in behaviour 
of the interacting cell types. The conclusion? Either 1n 
vitro T cell behaviour should be carefully modelled by 
studying it's component parts 1n order to anticipate 
possible quantitative effects, or, the reaction should not 
be used at all to study cell interactions. 
Conclusions 
The above discussion illustrates how a large number of 
diverse immune phenomena, not obviously related, can be 
deduced from simple rules of T cell behaviour. The 
reactions used; 
"Control structure" 
"Costimulation" 
"Class distinction" 
"Lymphokine release" 
"Proliferation" 
SK + 
X 
T~ 2 
s + 
X 
Ys + 
T' 1 
T' + 
T(Kx)-+ cos 
T' 
--+ T(Ix) 
-+ T(Ky) 
--+ i 
IL2 -+nT' 
• 
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all have an empirical basis. Some of the reactions assumed 
are poorly understood and certainly need to be more 
adequately demonstrated under a number of different test 
conditions. The success of the deduced conclusions from 
these rules perhaps serve as an illustration of how advances 
could be made by studying the fundamental units of cell 
behaviour and not the myriad possible permutations of their 
higher level interaction. 
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